

CITATION REPORT

List of articles citing

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

DOI: 10.1016/s0195-668x(03)00114-3
European Heart Journal, 2003, 24, 987-1003.

Source: <https://exaly.com/paper-pdf/35766705/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2313	A computer decision aid for medical prevention: a pilot qualitative study of the Personalized Estimate of Risks (EsPeR) system. 2003 , 3, 13		9
2312	[Clinical practice guidelines for hypertension 2003. Do they clarify or confuse?]. 2003 , 56, 940-3		2
2311	[Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions]. 2003 , 121, 521-6		28
2310	[Evaluation of cardiovascular risk. What table to use?]. 2003 , 32, 586-9		8
2309	[From Framingham's equation to cardiovascular prevention]. 2003 , 121, 334-6		1
2308	[Coronary risk in Spain and its treatment with lipid-lowering drugs]. 2003 , 32, 420-2		4
2307	The rudimentary phase of personalised medicine: coronary risk scores. 2003 , 362, 1776-7		30
2306	¿Podemos aplicar la ecuaci3n de Framingham para el c3lculo del riesgo coronario en otras poblaciones?. 2003 , 10, 581-582		
2305	Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. 2003 , 327, 1267		328
2304	Methods to identify increased risk of coronary disease in the general population: conclusion is oversimplification. 2003 , 327, 619; author reply 619		
2303	Risk factor scoring for coronary heart disease. 2003 , 327, 1238-9		19
2302	The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. 2004 , 20, 1625-31		30
2301	Cardiovascular risk intervention in patients with type 2 diabetes. 2004 , 4, 414-416		
2300	Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. 2004 , 109, 3112-21		274
2299	Systolic blood pressure during recovery from exercise and the risk of acute myocardial infarction in middle-aged men. 2004 , 44, 820-5		81
2298	Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. 2004 , 110, 1579-85		113
2297	Measures of global risk: old versus new methods. 2004 , 26, 653-62		0

2296	New European, American and International guidelines for hypertension management: agreement and disagreement. 2004 , 2, 359-68	34
2295	Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. 2004 , 255, 494-502	55
2294	Risk of coronary events by baseline factors during 28 years follow-up and three periods in a random population sample of men. 2004 , 256, 298-307	22
2293	Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. 2004 , 18, 139-85	868
2292	When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). 2004 , 19, 1982-93	65
2291	Primaire preventie van hart- en vaatziekten in de huisartsenpraktijk: geen tijd voor grote veranderingen. 2004 , 47, 274-279	2
2290	Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. 2004 , 47, 2118-28	131
2289	Combined antihypertensive and lipid-lowering treatment. 2004 , 6, 300-6	4
2288	Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. 2004 , 255, 188-205	260
2287	Screening asymptomatic low-risk individuals for coronary heart disease: issues and controversies. 2004 , 11, 382-7	13
2286	Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. 2004 , 4, 299-314	22
2285	Analyse des nouvelles recommandations européennes dans lâhypertension artfielle. 2004 , 4, 1-6	
2284	Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. 2004 , 20, 811-8	22
2283	Lipoproteïna(a): del genotipo al riesgo cardiovascular, pasando por el fenotipo. 2004 , 16, 151-153	2
2282	[Advanced age, lipoproteic profile and cardiovascular risk]. 2004 , 122, 620-2	
2281	Perfil clïnico de una poblaciï hipercolesterolïmica espaïla y diferencias entre sexos. Estudio LIPYCare. 2004 , 21, 395-402	0
2280	Utilizaciï del cïculo del riesgo cardiovascular para el control y tratamiento de las dislipemias en atenciï primaria. 2004 , 16, 240-246	0
2279	Adaptaciï Espaïla de la Guï Europea de Prevenciï Cardiovascular. 2004 , 30, 449-462	

2278	[Risk percentiles: a new adapted method for evaluating vascular risk. ERVPA study]. 2004 , 123, 121-6	3
2277	Efectividad de una intervenci3n de mejora de calidad en la reducci3n del riesgo cardiovascular en pacientes hipertensos. 2004 , 57, 644-651	0
2276	[About cardiovascular risk assessment in the new clinical trials with statins]. 2004 , 122, 559	
2275	Importancia del colesterol ligado a lipoprote3nas de alta densidad (cHDL) en la prevenci3n del riesgo cardiovascular. Recomendaciones del Foro HDL. 2004 , 16, 262-280	
2274	Adaptaci3n espa3ola de la Gu3a Europea de Prevenci3n Cardiovascular. 2004 , 21, 403-405	1
2273	R3plica de los autores. 2004 , 33, 409-411	0
2272	S3ndrome metab3lico y enfermedad cardiovascular en poblaci3n diab3tica asistida en Atenci3n Primaria. 2004 , 21, 339-346	
2271	Gu3as para el tratamiento de las dislipemias en el adulto: Adult Treatment Panel III (ATP-III). 2004 , 51, 254-265	5
2270	[Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European Societies]. 2004 , 123, 681-5	15
2269	[Looking for the cardiovascular risk]. 2004 , 123, 134-5	
2268	Effectiveness of a Quality Improvement Intervention in Reducing Cardiovascular Risk in Hypertensive Patients. 2004 , 57, 644-651	1
2267	The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. 2004 , 42, 1355-63	178
2266	[Spanish adaptation of the European Guide to Cardiovascular Prevention (I)]. 2004 , 34, 427-32	10
2265	[Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study]. 2004 , 123, 686-91	29
2264	[Coronary risk differences in hypertensive patients of different autonomous communities. CORONARY study]. 2004 , 204, 614-25	3
2263	[Cardiovascular risk in the Spanish population. Geographical heterogeneity?]. 2004 , 204, 611-3	6
2262	Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. 2004 , 33, 467-81, v	42
2261	Risk assessment of myocardial infarction and stroke. 2004 , 1262, 30-38	0

2260	Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). 2004 , 148, 596-601	49
2259	Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. 2004 , 117, 528-30	11
2258	[The dawn of a new era in cardiovascular prevention]. 2004 , 33, 1126-8	
2257	[Hypercholesterolemia, the future of drug associations]. 2004 , 33, 1141-2	
2256	Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommendations. 2004 , 30, 353-18	44
2255	Protocolo de valoración del riesgo vascular metabólico. 2004 , 9, 1157-1161	
2254	Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. 2004 , 363, 157-63	6911
2253	The Use of Computerized Decision Support Systems in Preventive Cardiology—Principal Results from the National Precard Survey in Denmark. 2005 , 12, 52-55	1
2252	Differences between coronary disease and stroke in incidence, case fatality, and risk factors, but few differences in risk factors for fatal and non-fatal events. <i>European Heart Journal</i> , 2005 , 26, 1916-22	9.5 31
2251	Association of Dyslipidemia and Concomitant Risk Factors with In-Hospital Mortality in Acute Coronary Syndrome in Switzerland. 2005 , 5, 131-139	1
2250	Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. 2005 , 23, 1575-81	69
2249	Age and time need not and should not be eliminated from the coronary risk prediction models. 2005 , 111, 542-5	13
2248	Role of modifiable risk factors in life expectancy in the elderly. 2005 , 23, 1803-8	37
2247	Guidelines on cardiovascular disease prevention in clinical practice: the European perspective. 2005 , 20, 430-9	18
2246	Guidelines on cardiovascular risk assessment and management. 2005 , 7, L5-L10	3
2245	Cardiovascular risk calculators: understanding differences and realising economic implications. 2005 , 74, 191-9	14
2244	Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. 2005 , 95, 29-35	267
2243	[Multislice computed tomography to detect coronary stenosis among asymptomatic patients with cardiovascular risk factors and equivocal prior stress test: preliminary study]. 2005 , 54, 227-32	0

2242	Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?. 2005 , 61, 595-601	10
2241	[Cardiovascular high-risk constellations in primary care. DETECT Study 2003]. 2005 , 48, 1374-82	9
2240	[Possible ways of managing cardiovascular prevention: polypharmacy, additional payment or application of evidence based medicine?]. 2005 , 46, 698-705	1
2239	[New guidelines for treatment of hypertension]. 2005 , 46, 538-47	3
2238	Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when?. 2005 , 62, 739-50	105
2237	Value of exercise capacity and physical activity in the prevention of cardiovascular diseasesâBrief review of the current literature. 2005 , 13, 313-317	3
2236	[Comparison of international recommendations for the recognition of asymptomatic high risk patients for a heart attack in Germany]. 2005 , 94, 52-60	7
2235	[Total risk for cardiovascular disease. At what point is medical prophylactic medication useful?]. 2005 , 94 Suppl 3, III/6-10	1
2234	[Use of risk factors in determining individual coronary risk]. 2005 , 94 Suppl 4, IV/65-69	
2233	[Impact of both cardiac-CT and cardiac-MR on the assessment of coronary risk]. 2005 , 94 Suppl 4, IV/70-80	0
2232	Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. 2005 , 112, 666-73	445
2231	Whither cardiovascular risk prediction?. 2005 , 12, 421-3	1
2230	Estimating the risk for atherothrombosis: are current approaches sufficient?. 2005 , 12, 427-32	2
2229	Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease. 2005 , 21, 1091-7	11
2228	Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women. 2005 , 12, 433-41	48
2227	Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. 2005 , 34, 413-21	160
2226	Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. 2005 , 42, 393-452	4
2225	Does blood pressure control contribute to a more successful aging?. 2005 , 46, 261-2	9

2224	Why are we getting myocardial infarction? Because our genes date from the last Ice Age. The global cardiovascular risk. 2005 , 60, 285-91		
2223	Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. 2005 , 331, 551		66
2222	Heart rate: a strong predictor of mortality in subjects with coronary artery disease. <i>European Heart Journal</i> , 2005 , 26, 943-5	9.5	48
2221	Control of hypertension in patients at high risk of cardiovascular disease. 2005 , 98, 581-8		11
2220	Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. <i>European Heart Journal</i> , 2005 , 26, 2673-80	9.5	40
2219	The metabolic syndrome. 2005 , 365, 1415-28		4380
2218	Obesity. 2005 , 366, 1197-209		3045
2217	Protocolo de evaluación clínica del riesgo cardiovascular. 2005 , 9, 2543-2547		
2216	Factores metabólicos de riesgo cardiovascular. Relevancia epidemiológica. Tratamiento farmacológico. Situaciones de especial relevancia. 2005 , 9, 3032-3043		
2215	[Was the second edition of the semFYC guide to lipaemia necessary?]. 2005 , 36, 477-9		
2214	Epidemiología de las dislipemias y del riesgo cardiovascular relacionado. 2005 , 36, 2-9		0
2213	Diagnóstico de las dislipemias en atención primaria: detección de la dislipemia y estimación del riesgo cardiovascular. 2005 , 36, 19-23		
2212	Bases de la evidencia científica del tratamiento hipolipemiante. Factores que condicionan su efectividad e indicaciones en prevención cardiovascular. 2005 , 36, 31-39		
2211	Factores de riesgo cardiovascular en la mujer. 2005 , 22, 45-47		
2210	Evaluación del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. 2005 , 22, 195-203		2
2209	Concordancia de dos métodos para el cálculo del riesgo cardiovascular: Framingham calibrado por REGICOR y SCORE. 2005 , 22, 306-310		4
2208	Adaptación española de la Guía Europea de Prevención Cardiovascular. 2005 , 17, 19-20		1
2207	Epidemiology of the metabolic syndrome in 2045 French military personnel (EPIMIL study). 2005 , 31, 353-9		30

2206 [Cardiovascular risk calculation in Spanish population according to of DORICA study]. **2005**, 125, 678-9

2205 [Common and specific methodological features of checklists]. **2005**, 125 Suppl 1, 14-20

3

2204 LDL cholesterol and global risk stratification in referred hypertensive patients. **2005**, 180, 137-43

12

2203 Tracking atherosclerosis regression: a clinical tool in preventive cardiology. **2005**, 180, 1-10

34

2202 A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. **2005**, 181, 93-100

83

2201 Enfermedad cerebrovascular (I): prevención primaria y diagnóstico. **2005**, 12, 11-28

2200 Concordancia de dos métodos para el cálculo del riesgo cardiovascular: Framingham calibrado por REGICOR y SCORE. **2005**, 22, 306-310

2199 Factores de riesgo cardiovascular en la mujer. **2005**, 22, 45-47

2198 Evaluación del riesgo cardiovascular y nuevos factores de riesgo de aterosclerosis. **2005**, 22, 195-203

2197 Telemedicine: the determination of fatal cardiovascular risk in internet users population. **2005**,

1

2196 Swiss Hypertension and Risk Factor Program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. **2005**, 14, 337-44

28

2195 Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. **2005**, 111, 682-94

366

2194 Fluvastatin: efficacy and safety in reducing cardiac events. **2005**, 6, 1883-95

2

2193 Treating Hypertension with Angiotensin II Receptor Blockers. **2005**, 12, 9-15

2

2192 Adverse effects of statins : how should cardiologists and general physicians manage them in clinical practice?. **2005**, 12, 141-8

1

2191 What Should We Expect from the Next Guidelines on Hypertension?. **2005**, 12, 199-202

2190 How to Manage Metabolic Syndrome. **2005**, 12, 231-238

2

2189 JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. **2005**, 91 Suppl 5, v1-52

523

2188	The metabolic syndrome. 2005 , 240, 3-13	16
2187	A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. 2005 , 12, 442-50	50
2186	Point: uses of carotid plaque measurement as a predictor of cardiovascular events. 2005 , 8, 118-21; discussion 126	17
2185	Expanding the definition and classification of hypertension. 2005 , 7, 505-12	123
2184	The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. 2005 , 101, 231-5	7
2183	Identification of risk factors for prevention and early diagnosis of a-symptomatic post-menopausal women. 2005 , 52 Suppl 1, S7-22	14
2182	Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. 2005 , 27, 1658-68	1
2181	Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases. 2005 , 15, 79-85	34
2180	Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. 2005 , 15, 426-40	36
2179	[Is mild hyperhomocysteinemia an additional risk factor of the metabolic syndrome?]. 2005 , 26, 695-702	4
2178	[The application of the SCORE charts to advanced age males triple the number of high-risk subjects compared to the Framingham function]. 2005 , 124, 487-90	26
2177	[Framingham is in Massachusetts]. 2005 , 35, 399-401	
2176	[Primary prevention with statins, consensus and risk tables]. 2005 , 36, 31-8	9
2175	[Evaluation of stroke risk in patients with hypertension]. 2005 , 125, 254-6	
2174	Indicadores clínicos de progresión de la miocarditis chagásica crónica. 2005 , 58, 1037-1044	40
2173	[Use of tables for cardiovascular risk assessment in elderly people]. 2005 , 125, 438; author reply 438-9	
2172	Respuesta del autor. 2005 , 125, 438-439	
2171	[Objective-oriented planification in the treatment of hypercholesterolemia]. 2005 , 124, 108-10	7

2170	[The DISEHTAC II study: diagnosis and follow-up of hypertension in Catalonia. comparison with 1996 data]. 2005 , 35, 7-12	16
2169	[Variability in the calculation of coronary risk in type-2 diabetes mellitus]. 2005 , 35, 30-6	20
2168	Clinical Predictors of Chronic Chagasic Myocarditis Progression. 2005 , 58, 1037-1044	
2167	Risk factors for atherosclerotic vascular disease. 2005 , 71-105	18
2166	Biomarkers of cardiovascular disease: molecular basis and practical considerations. 2006 , 113, 2335-62	862
2165	Riesgo cardiovascular global en hipertensos. 2006 , 23, 205-206	
2164	Cardiovascular risks associated with smoking: a review for clinicians. 2006 , 13, 507-14	62
2163	High blood pressure despite treatment: results from a cross-sectional primary healthcare-based study in southern Sweden. 2006 , 24, 224-30	22
2162	[Assessment of cardiovascular risk in population groups. Comparison of Score system and Framingham in hypertensive patients]. 2006 , 206, 182-7	1
2161	[Tables for cardiovascular risk estimation: many questions remain]. 2006 , 126, 535-6	5
2160	La contribuci3n de la medicina del trabajo a la medicina cardiovascular. 2006 , 59, 409-413	2
2159	The impact of cardiovascular risk factors on subclinical left main coronary artery disease: an intravascular ultrasound study. 2006 , 152, 693.e7-12	10
2158	Riesgo cardiovascular en la poblaci3n mediterr3nea. 2006 , 13, 571-573	
2157	Normas t3cnicas sobre tratamiento farmacol3gico en la cartera de servicios de atenci3n primaria. 2006 , 21, 264-270	0
2156	Comparaci3n de las gu3as de pr3ctica cl3nica de riesgo vascular. 2006 , 32, 273-285	1
2155	[Management of hypertension in patients with diabetes]. 2006 , 35, 1041-6	0
2154	[Medical guidelines and medical practices: The example of lipid lowering therapy]. 2006 , 35, 1427-33	1
2153	[How to evaluate the cardiovascular and renal risk at the individual level?]. 2006 , 35 Suppl 1, 35-40	

2152	[How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk?]. 2006 , 35 Suppl 1, 41-6	3
2151	[What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?]. 2006 , 35 Suppl 1, 61-8	
2150	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. 2006 , 22, 573-81	53
2149	The role of global risk assessment in hypertension therapy. 2006 , 22, 606-13	24
2148	Framingham-Grundy, REGICOR y SCORE en la estimaci3n del riesgo cardiovascular del paciente hipertenso. Concordancias y discrepancias (CICLO-RISK). 2006 , 23, 111-117	2
2147	Riesgo cardiovascular global en hipertensos. 2006 , 23, 205-206	0
2146	Índice tobillo-brazo y riesgo cardiovascular estimado mediante la funci3n SCORE en sujetos no diab3ticos en prevenci3n primaria. 2006 , 18, 45-50	2
2145	Percentiles de riesgo coronario: una nueva forma de adaptar las escalas de riesgo. Estudio ERVPA. 2006 , 18, 218-225	1
2144	[Comparison of the Score and Framingham-DORICA models to estimate the cardiovascular risk in a cohort of hypertensive patients from southern Spain]. 2006 , 127, 314-5	5
2143	The evolution of European guidelines: changing the management of cholesterol levels. 2006 , 185, 12-20	19
2142	Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the SMART study. 2006 , 43, 525-32	47
2141	Framingham-Grundy, REGICOR y SCORE en la estimaci3n del riesgo cardiovascular del paciente hipertenso. Concordancias y discrepancias (CICLO-RISK). 2006 , 23, 111-117	1
2140	Contribution of Occupational Medicine to Cardiovascular Medicine. 2006 , 59, 409-413	1
2139	Health Economic Evaluation of Low-Dose Acetylsalicylic Acid in the Primary Prevention of Cardiovascular Disease. 2006 , 59, 807-815	
2138	Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. 2006 , 66, 1971-87	42
2137	Adaptaci3n espa3ola de la Gu3a Europea de Prevenci3n Cardiovascular. 2006 , 206, 17-18	
2136	[Validation of 3 equations of coronary risk in diabetic population of a primary care center]. 2006 , 126, 485-90	8
2135	[Cardiovascular risk by Framingham and SCORE in patients 40-65 years old]. 2006 , 126, 527-31	11

2134	[Effectiveness of an intervention to improve quality care in reducing cardiovascular risk in hypertense patients]. 2006 , 37, 498-503	9
2133	[Estimation of overall cardiovascular risk from coronary risk. A cohort study]. 2006 , 127, 8-10	3
2132	[Cardiovascular risk in diabetes mellitus and hypertension in Spain. The CORONARIA study]. 2006 , 127, 126-32	1
2131	[Information on cardiovascular risk in hypertense patients monitored in primary care. Does it improve our efficacy?]. 2006 , 38, 102-6	4
2130	Evaluaci3n econ3mica del tratamiento con 3ido acetilsalic3lico en dosis bajas en la prevenci3n primaria de enfermedades cardiovasculares. 2006 , 59, 807-815	6
2129	[Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up]. 2006 , 127, 368-73	12
2128	[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. 2006 , 59, 1026-32	3
2127	[Overview of cardiovascular risk factors]. 2006 , 127, 774-5	
2126	Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. 2006 , 13, 555-61	70
2125	Intensive cardiovascular examination regarding blood pressure levels: evaluation of risk groups. ICEBERG study. 2006 , 15, 291-301	1
2124	Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. 2006 , 92, 1752-9	296
2123	Risk factors for photodynamic therapy of predominantly classic choroidal neovascularization in age-related macular degeneration. 2006 , 142, 441-7	5
2122	Sex and classic risk factors after myocardial infarction: a community study. 2006 , 152, 461-8	25
2121	The metabolic syndrome revisited: "cardiometabolic risk" emerges as common ground between differing views of the ADA and AHA. 2006 , 1, 362-3	10
2120	Predicting readmissions and cardiovascular events in heart failure patients. 2006 , 109, 108-13	36
2119	The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. 2006 , 110, 217-23	22
2118	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). 2006 , 110, 242-50	23
2117	Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study. 2006 , 120, 1140-8	20

2116	Aspirin overprescription in primary cardiovascular prevention. 2006 , 118, 471-7	16
2115	The association of job strain with coronary heart disease and metabolic syndrome in municipal workers in Turkey. 2006 , 48, 332-8	18
2114	Cardiovascular Disorders. 2006 , 317-543	
2113	Hypertension artfielle essentielle et rein. 2006 , 1, 1-17	
2112	Estimated risk of a first stroke and conditioning factors in Spanish hypertensive women. The RIMH study. 2006 , 15, 237-44	7
2111	Risk prediction and finding new independent prognostic factors. 2006 , 24, 643-5	12
2110	A total cardiovascular risk estimate should not be used dichotomously. 2006 , 24, 1697-8	2
2109	Trends in hypertension care in eastern and south-western Finland during 1982-2002. 2006 , 24, 829-36	22
2108	Risk scoring in the assessment of cardiovascular risk. 2006 , 17, 375-86	37
2107	Statin-induced myositis: a commonly encountered or rare side effect?. 2005 , 16, 640-7	15
2106	Gender-specific prediction of cardiac disease: importance of risk factors and exercise variables. 2006 , 14, 281-5	14
2105	Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. 2006 , 24, 603-10	148
2104	Barriers and remaining questions on assessment of absolute cardiovascular risk as a starting point for interventions to reduce cardiovascular risk. 2006 , 24, 1683-5	9
2103	Diagnosis and management of hypertension in obesity. 2006 , 7, 155-62	27
2102	Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. 2006 , 60, 1129-37	8
2101	A simple linear model for the effect of changes in metabolic risk factors on coronary heart disease. 2006 , 259, 561-8	3
2100	Impact of follow-up time and re-measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction. 2006 , 260, 22-30	15
2099	Population-attributable risk of coronary heart disease risk factors during long-term follow-up: the Malm�Preventive Project. 2006 , 260, 134-41	65

2098	C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients. 2006 , 20, 587-92	3
2097	Review of gated SPECT imaging in women with suspected coronary heart disease. 2006 , 13, 474-9	3
2096	Concomitant detection of systemic atherosclerotic disease while screening for abdominal aortic aneurysm. 2006 , 30, 1350-9	7
2095	Arzneimitteltherapie zur Primärprävention kardiovaskulärer Erkrankungen bei adipösen Patienten. 2006 , 1, 57-63	
2094	Risikostratifizierung mit unterschiedlichen Score-Systemen. 2006 , 1, 139-148	1
2093	Role of noninvasive imaging in asymptomatic high-risk patients. 2006 , 13, 156-62	5
2092	Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. 2006 , 73, 379-87	64
2091	Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. 2006 , 50, 721-31	166
2090	Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?. 2006 , 97, 33A-41A	156
2089	Cardiovascular health in men attending for abdominal aortic aneurysm screening. 2006 , 97, 1123-4	2
2088	Managing cardiovascular risk in patients with metabolic syndrome. 2006 , 8 Suppl 1, S7-14	6
2087	Tratamiento de la hipercolesterolemia: los nuevos ensayos con estatinas. ¿Se deben revisar las guías de tratamiento?. 2006 , 6, 46G-51G	
2086	Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. 2006 , 5, 735-41	633
2085	The "Americanisation" of migrants: evidence for the contribution of ethnicity, social deprivation, lifestyle and life-course processes to the mid-20th century Coronary Heart Disease epidemic in the US. 2006 , 63, 465-84	20
2084	How artificial intelligence tools can be used to assess individual patient risk in cardiovascular disease: problems with the current methods. 2006 , 6, 20	17
2083	Risk of ischaemic heart disease and acute myocardial infarction in a Spanish population: observational prospective study in a primary-care setting. 2006 , 6, 38	34
2082	The metabolic syndrome as a risk factor for diabetes and cardiovascular diseases. 2006 , 3, 126-130	
2081	Long-term cardiovascular risk in the orthotopic liver transplant population. 2006 , 12, 352-5	22

2080	Validation of cardiovascular risk scores in a liver transplant population. 2006 , 12, 394-401		58
2079	Myocardial perfusion. 2006 , 24, 953-63		23
2078	Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. <i>European Heart Journal</i> , 2006 , 27, 316-22	9.5	37
2077	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. <i>European Heart Journal</i> , 2006 , 27, 796-801	9.5	49
2076	Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. 2006 , 332, 1419		64
2075	Future strategies in the management of coronary artery disease. 2006 , 2, 555-66		4
2074	Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. 2006 , 13, 839-45		78
2073	How to improve screening in first-degree relatives of patients with premature coronary heart disease. 2006 , 13, 711-7		1
2072	The value of risk scores. 2006 , 92, 1713-4		8
2071	Consequences of using different methods to assess cardiovascular risk in primary care. 2006 , 23, 28-33		24
2070	Evidence-based prescribing of statins: a developing world perspective. 2006 , 3, e50		10
2069	Chapter 5.1: major public health problems - cardiovascular diseases. 2006 , 67, 51-8		6
2068	The SCORE risk model applied to recent population surveys in Norway compared to observed mortality in the general population. 2006 , 13, 731-7		11
2067	Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. 2006 , 114, 2217-25		160
2066	Cardiovascular risk prediction systems have to be adapted and updated to current national conditions. 2006 , 13, 674-5		4
2065	Cardiovascular risk estimation by professionally active cardiovascular nurses: results from the Basel 2005 Nurses Cohort. 2006 , 5, 258-63		18
2064	Attempt to eliminate health inequalities in Poland arising at the time of political and economic transformation: Polish 400 Cities Project. 2006 , 13, 832-8		6
2063	Management of dyslipidaemias. 2006 , 92, 1529-34		4

2062	Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. 2006 , 15, 675-82	105
2061	Determinants of carotid plaque occurrence. A long-term prospective population study: the San Daniele Project. 2006 , 22, 416-22	38
2060	How overcome some pitfalls of present methods to assess the individual absolute risk for major cardiovascular events thanks to artificial intelligence tools. 2006 ,	
2059	The importance of total cardiovascular risk assessment in clinical practice. 2006 , 12, 148-55	18
2058	Assessing the ability of cardiovascular disease risk calculators to evaluate effectiveness of trials and interventions. 2006 , 6, 417-24	4
2057	Is hyperhomocysteinemia an additional risk factor of the metabolic syndrome?. 2006 , 4, 185-95	14
2056	An examination of the relationship between normal range thyrotropin and cardiovascular risk parameters: a study in healthy women. 2007 , 17, 243-8	16
2055	Comparison of Two Different Methods for Cardiovascular Risk Assessment: Framingham Risk Score and Score System. 2007 , 26, 94-97	
2054	Rationale, design, methods and baseline characteristics of the Asklepios Study. 2007 , 14, 179-91	124
2053	Can non-physician health-care workers assess and manage cardiovascular risk in primary care?. 2007 , 85, 432-40	68
2052	Attitudes to and application of the concept of overall cardiovascular risk: comparison of male and female primary care providers. 2007 , 21, 359-65	1
2051	Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. 2007 , 21, 925-33	7
2050	The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. 2007 , 14, 501-7	35
2049	Primary prevention of cardiovascular diseases in general practice: mismatch between cardiovascular risk and patients' risk perceptions. 2007 , 27, 754-61	62
2048	Screening Apparently Healthy Individuals. 2007 , 261-299	
2047	CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. 2007 , 14, 141-8	20
2046	Beyond conventional stroke guidelines: setting priorities. 2007 , 38, 2185-90	19
2045	Effects of haemodialysis on circulating endothelial progenitor cell count. 2007 , 25, 242-51	22

2044	Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases. 2007 , 14, 815-24	17
2043	Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. 2007 , 21, 183-211	94
2042	Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators. 2007 , 13, 27-34	19
2041	Chapter 1: Introduction. 2007 , 14, S2-S113	
2040	Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future. 2007 , 59, 40-53	53
2039	Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. 2007 , 14, 761-8	29
2038	New Concepts for Early Diagnosis of Coronary Artery Disease. 2007 , 52-64	
2037	Persistent ischaemic ECG abnormalities on repeated ECG examination have important prognostic value for cardiovascular disease beyond established risk factors: a population-based study in middle-aged men with up to 32 years of follow-up. 2007 , 93, 1104-10	13
2036	Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. 2007 , 10, 508-26	47
2035	Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. 2007 , 14, 192-9	23
2034	Cardiovascular disease risk profiles among 'healthy' siblings of patients with early-onset cardiovascular disease: application of the new SCORE system. 2007 , 14, 521-5	3
2033	Cardiovascular risk prediction tools for populations in Asia. 2007 , 61, 115-21	119
2032	Patients at high risk for ischemic stroke: identification and actions. 2007 , 24 Suppl 1, 49-63	12
2031	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). 2007 , 115, 402-26	399
2030	EUROACTION: A demonstration project in preventive cardiology. 2007 , 2, 41-47	
2029	Ambulatory blood pressure monitoring: a mean to stratify cardiovascular risk. 2007 , 12, 263-5	0
2028	The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. 2007 , 12, 255-62	111
2027	Small artery structure is an independent predictor of cardiovascular events in essential hypertension. 2007 , 25, 1021-6	141

2026	Dyslipidmies de la personne trè gè. 2007 , 2, 1-10	
2025	World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. 2007 , 25, 1578-82	196
2024	Cardiovascular risk assessment in hypertensive patients: major discrepancy according to ESH and SCORE strategies. 2007 , 25, 757-62	10
2023	The concept of doctor targets based on quality guidelines: focus on blood pressure. 2007 , 9, B29-B36	1
2022	CVD risk in South Asians: the importance of defining adiposity and influence of dietary polyunsaturated fat. 2007 , 66, 286-98	13
2021	Distinguer la dysfonction fectile (DE) : utopie ou devoir ?. 2007 , 16, 75-79	2
2020	Screening for erectile dysfunction (ED): wishful thinking or dire necessity?. 2007 , 16, 80-84	2
2019	Carotid endarterectomy in the elderly: are the patient characteristics, the early outcome, and the predictors the same as those in younger patients?. 2007 , 67, 467-71; discussion 471	19
2018	Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts. 2007 , 17, 311-8	7
2017	Jnc 7.5. 2007 , 9, 901-4	1
2016	Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. 2007 , 9, 324-9	37
2015	Rationale, design, and methods for the risk evaluation and communication health outcomes and utilization trial (REACH OUT). 2007 , 28, 662-73	11
2014	A review of the metabolic syndrome. 2007 , 33, 405-13	86
2013	Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. 2007 , 76, 436-44	23
2012	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. 2007 , 194, 1-45	190
2011	Essential hypertension. 2007 , 370, 591-603	435
2010	Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. 2007 , 370, 1829-39	1539
2009	Nuevos instrumentos y los riesgos de siempre. 2007 , 60, 464-467	12

2008	Calibraci3n de la tabla SCORE de riesgo cardiovascular para Espaã. 2007 , 60, 476-485	110
2007	Guas de prãtica clãnica sobre diabetes, prediabetes y enfermedades cardiovasculares: versi3n resumida. 2007 , 60, 525.e1-525.e64	7
2006	Hipertensi3n arterial (2). 2007 , 9, 5255-5265	
2005	Aportaciones cientficas mãs relevantes del XVII Congreso de la Sociedad Europea de Hipertensi3n. Milã, 15-19 de junio de 2007. 2007 , 24, 247-255	
2004	Epidemiologã del riesgo cardiovascular del hipertenso. 2007 , 24, 3-9	
2003	Mammographic screening from age 40 years. 2007 , 369, 737	3
2002	Anãlisis de la concordancia y validaci3n de las ecuaciones de Framingham-REGICOR y DORICA en la poblaci3n diabãtica de un Centro de Salud seguida durante 10 aãs. 2007 , 33, 50-57	
2001	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. 2007 , 23, 529-38	49
2000	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232	247
1999	Rosuvastatin in elderly patients. 2007 , 24, 933-44	6
1998	Future Developments in Preventive Cardiology: The EUROACTION Project. 2007 , 476-488	
1997	Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines. 2007 , 4, 151-62	20
1996	Proportion of isolated clinical hypertension in primary care settings. Comparison of target organ damage in patients with isolated clinical hypertension and patients with sustained arterial hypertension. 2007 , 16, 354-61	
1995	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). 2007 , 14 Suppl 2, E1-46	309
1994	The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need. 2007 , 23 Suppl 5, S19-24	4
1993	Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?. 2007 , 39, 805-12	34
1992	Normal S-cholesterol indicates unchanged S-LDL, S-HDL and S-triglycerides in patients with previously acceptable blood lipids. 2007 , 67, 498-506	1
1991	Risk factor control in treated hypertensives from Estonia and Sweden. Why the difference?. 2007 , 16, 301-4	5

1990	Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. 2007 , 23, 1821-7	5
1989	Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK). 2007 , 25, 105-11	12
1988	Assessment of the Patient With Diabetes for Coronary Heart Disease Risk: Review and Personal Reflection. 2007 , 31, 153-163	1
1987	Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. 2007 , 4 Suppl B, S162-77	138
1986	Cholestfol et sujets gñs. 2007 , 7, 7-17	
1985	Aportaciones científicas más relevantes del XVII Congreso de la Sociedad Europea de Hipertensión. Milà, 15-19 de junio de 2007. 2007 , 24, 247-255	
1984	Comparación de las tablas REGICOR y SCORE para la clasificación del riesgo cardiovascular y la identificación de pacientes candidatos a tratamiento hipolipemiante o antihipertensivo. 2007 , 60, 139-147	30
1983	La Aterosclerosis como enfermedad sistémica. 2007 , 60, 184-195	42
1982	[Cardiovascular disease prevention and cardiac rehabilitation]. 2007 , 60 Suppl 1, 68-78	3
1981	[New perspectives in the measurement of cardiovascular risk: explorations to detect subclinical atherosclerosis and inflammation markers]. 2007 , 128, 344-51	5
1980	La determinación de calcio coronario con tomografía computarizada en la evaluación del riesgo cardiovascular: un estudio descriptivo. 2007 , 60, 268-275	7
1979	[Identification, diagnosis and control of patients with abdominal obesity and cardiovascular and metabolic risk factors]. 2007 , 128, 429-37	6
1978	[Validation of cardiovascular risk tables: are we more or less confused?]. 2007 , 128, 558	
1977	[Blood pressure and lipid control and coronary risk in the hypertensive population attended in Primary Care setting in Spain. The PRESCOT study]. 2007 , 207, 172-8	14
1976	[Clinical factors associated with inappropriate prescription of statins]. 2007 , 129, 86-90	2
1975	Rendimiento de la estimación del riesgo cardiovascular en España mediante la utilización de distintas funciones. 2007 , 60, 693-702	31
1974	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94	29
1973	Réplica. 2007 , 39, 579-580	1

1972	[Agreement between REGICOR and SCORE scales in identifying high cardiovascular risk in the Spanish population]. 2007 , 60, 1042-50	22
1971	[Variability in coronary risk assessment in HIV-infected patients]. 2007 , 129, 521-4	4
1970	[Cardiovascular risk assessment]. 2007 , 129, 534-41	1
1969	[Diagnosis and treatment of patients with cardiometabolic risk]. 2007 , 129, 588-96	2
1968	[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. 2007 , 129, 641-5	4
1967	Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs. 2007 , 27, 707-17	2
1966	Clinical guidelines for cardiovascular disease prevention: Should they differ by gender?. 2007 , 1, 148-152	
1965	Comparison of the REGICOR and SCORE Function Charts for Classifying Cardiovascular Risk and for Selecting Patients for Hypolipidemic or Antihypertensive Treatment. 2007 , 60, 139-147	
1964	Atherosclerosis As a Systemic Disease. 2007 , 60, 184-195	5
1963	Computed Tomographic Measurement of Coronary Artery Calcification in the Assessment of Cardiovascular Risk: A Descriptive Study. 2007 , 60, 268-275	
1962	New Instruments, Same Risks. 2007 , 60, 464-467	
1961	Calibrating the SCORE Cardiovascular Risk Chart for Use in Spain. 2007 , 60, 476-485	4
1960	Estimating Cardiovascular Risk in Spain Using Different Algorithms. 2007 , 60, 693-702	0
1959	Erectile dysfunction as a predictor of cardiovascular risk. 2007 , 1303, 60-64	1
1958	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on	753
1957	Resting heart rate in cardiovascular disease. 2007 , 50, 823-30 Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardio. 2007 , 49, 378-402	722
1956	Making a case for quantitative assessment of cardiovascular risk. 2007 , 1, 234-41	16
1955	Silent myocardial ischemia screening in patients with diabetes mellitus. 2007 , 51, 285-93	16

1954	Generation of knowledge for clinical decision support. 2007 , 227-248	4
1953	An application of the patient rule-induction method for evaluating the contribution of the Apolipoprotein E and Lipoprotein Lipase genes to predicting ischemic heart disease. 2007 , 31, 515-27	11
1952	Error propagation in calculated ratios. 2007 , 40, 728-34	23
1951	Choice of time scale and its effect on significance of predictors in longitudinal studies. 2007 , 26, 1343-59	115
1950	Identifying obese women most at risk from cardiovascular disease. 2007 , 31 Suppl 2, S19-25; discussion S31-2	3
1949	Waist circumference and BMI cut-off based on 10-year cardiovascular risk: evidence for "central pre-obesity". 2007 , 15, 2832-9	37
1948	Are definitions of adiposity appropriate for identification of cardiovascular disease risk in South Asian populations?. 2007 , 32, 129-137	2
1947	Cardiovascular risk profile of subjects with known diabetes from the middle- and high-income group population of Delhi: the DEDICOM survey. 2008 , 25, 27-36	6
1946	The predictive value of cardiorespiratory fitness combined with coronary risk evaluation and the risk of cardiovascular and all-cause death. 2007 , 262, 263-72	56
1945	Introduction: Symposium on diabetes, inflammation and cardiovascular disease. 2007 , 262, 142-4	3
1944	How can we prevent cardiovascular disease in diabetes. 2007 , 262, 199-207	8
1943	Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Mñster (PROCAM) study. 2007 , 37, 925-32	135
1942	Prediction of coronary atherosclerotic disease with liver transaminase level. 2007 , 27, 895-900	34
1941	Heart rate variability is related to disease activity and smoking in rheumatoid arthritis patients. 2007 , 61, 777-83	23
1940	Coronary risk stratification in patients with ischemic stroke or transient ischemic stroke attack. 2007 , 2, 177-83	24
1939	A coronary heart disease risk score based on patient-reported information. 2007 , 99, 1236-41	44
1938	Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease. 2007 , 100, 217-21	19
1937	Comprehensive management of cardiometabolic risk factors. 2007 , 8, 69-80	2

1936	Cardiovascular risk in the metabolic syndrome: fact or fiction?. 2007 , 9, 479-85	11
1935	Iedere patiënt met diabetes mellitus type 2 een statine, tenzij? 2007 , 50, 246-249	
1934	Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound. 2007 , 18, 629-39	64
1933	Primaire Atherosklerose. 2007 , 12, 401-412	
1932	Subsets of SNPs define rare genotype classes that predict ischemic heart disease. 2007 , 120, 865-77	17
1931	Perceived psychosocial stress and cardiovascular risk factors in obese and non-obese patients. 2007 , 96, 365-74	23
1930	Kardio- und zerebrovasculäres Risiko bei PAVK. 2007 , 2, IV22-IV29	
1929	Integration von funktioneller und morphologischer nichtinvasiver Bildgebung in die Evaluation von Patienten mit intermediärer Vortestwahrscheinlichkeit für eine koronare Herzkrankheit. 2007 , 2, V57-V67	
1928	von Willebrand Factor in CHD and stroke: relationships and therapeutic implications. 2007 , 9, 180-90	12
1927	Cost-effectiveness analysis in diagnosis of coronary artery disease: choice of laboratory markers. 2007 , 40, 1180-7	3
1926	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. 2008 , 24, 645-71	75
1925	FRAX and the assessment of fracture probability in men and women from the UK. 2008 , 19, 385-97	1591
1924	[Prevention of coronary artery disease]. 2008 , 49, 154-61	
1923	Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. 2008 , 2, 128-37	31
1922	Makroangiopathie bei Diabetes mellitus. 2008 , 3, 29-34	
1921	Coronary artery calcium scoring in the age of CT angiography: what is its role?. 2008 , 10, 438-43	8
1920	Nutritional status and physical activity of a selected sample of elderly healthy Italian people. 2008 , 1, 43-48	1
1919	Visceral obesity predicts surgical outcomes after laparoscopic colectomy for sigmoid colon cancer. 2008 , 51, 1757-65; discussion 1765-7	163

1918	Assessment of global cardiovascular risk and risk factors in Portugal according to the SCORE ² model. 2008 , 16, 361-367	3
1917	The correlation between waist circumference and ESC cardiovascular risk score: data from the German metabolic and cardiovascular risk project (GEMCAS). 2008 , 97, 827-35	13
1916	Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior program aimed at lifestyle changes in people at risk: Design of a randomized controlled trial. 2008 , 8, 6	33
1915	First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. 2008 , 7, 22	13
1914	Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). 2008 , 7, 31	40
1913	Diet and cardiovascular risk in university marching band, dance team and cheer squad members: a cross-sectional study. 2008 , 5, 9	4
1912	Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. 2008 , 27, 157-72; discussion 207-12	4524
1911	Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. 2008 , 57, 33-40	41
1910	Screening for coronary atherosclerosis with coronary calcium scoring: the "shape" of things to come?. 2008 , 15, 162-9	3
1909	Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. 2008 , 18, 2785-807	78
1908	Managing hypertension in cardiology practice according to risk profile. 2008 , 62, 1403-12	7
1907	A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile. 2008 , 62, 1484-98	41
1906	C reactive protein and its determinants in healthy men and women from European regions at different risk of coronary disease: the IMMIDIET Project. 2008 , 6, 436-43	21
1905	Cardiovascular risk assessment through target organ damage: role of carotid to femoral pulse wave velocity. 2008 , 35, 530-3	18
1904	Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models. 2008 , 263, 636-43	42
1903	C-reactive protein and coronary heart disease: a critical review. 2008 , 264, 295-314	269
1902	Application of the SCORE and Wilson-Grundy methods for the assessment of cardiovascular risk in community pharmacies. 2008 , 33, 475-81	4
1901	Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. 2008 , 8, 30	7

1900	Identification of patients for clinical risk assessment by prediction of cardiovascular risk using default risk factor values. 2008 , 8, 25	17
1899	Predicting the onset and persistence of episodes of depression in primary health care. The predictD-Spain study: methodology. 2008 , 8, 256	17
1898	Prevalence of obesity in primary care using different anthropometric measures--results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). 2008 , 8, 282	30
1897	Construction of an odds model of coronary heart disease using published information: the Cardiovascular Health Improvement Model (CHIME). 2008 , 8, 49	3
1896	Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services study. 2008 , 8, 148	10
1895	Improving patient adherence to lifestyle advice (IMPALA): a cluster-randomised controlled trial on the implementation of a nurse-led intervention for cardiovascular risk management in primary care (protocol). 2008 , 8, 9	35
1894	Cardiovascular risk after bariatric surgery for obesity. 2008 , 102, 930-7	78
1893	"First-hit" heart attack risk calculators on the world wide web: implications for laypersons and healthcare practitioners. 2008 , 77, 405-12	5
1892	Diabetes mellitus tipo 2 y enfermedad cardiovascular en Espa�a: una revisi�n descriptiva. 2008 , 8, 53C-61C	
1891	Implicaciones del estudio ONTARGET en hipertensi�n arterial y diabetes tipo 2. 2008 , 8, 56E-62E	
1890	The metabolic syndrome and cardiovascular disease: part 2. 2008 , 11, 223-9	17
1889	Cardiovascular risk assessment--where are we going?. 2008 , 11, 183-4	3
1888	Identifying early cardiovascular disease to target candidates for treatment. 2008 , 10, 226-31	20
1887	Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. 2008 , 10, 377-81	30
1886	Comment on: statin therapy does not seem to benefit giant cell arteritis. 2008 , 38, 63-4; 64-5	2
1885	A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. 2008 , 104, 1-12	62
1884	Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers). 2008 , 28, 211-20	5
1883	Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. 2008 , 28, 281-9	11

- 1882 [Reflections on the updating of 2005 cardiovascular PAPPs]. **2008**, 40, 50; author reply 50-1
- 1881 Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. **2008**, 61, 82.e1-82.e49 14
- 1880 [Definition and current situation of cardiometabolic risk]. **2008**, 208, 63-5 3
- 1879 Prevención cardiovascular: ¿siempre demasiado tarde?. **2008**, 61, 291-298 23
- 1878 [Ankle-brachial index testing is particularly indicated in patients with metabolic syndrome but without known arterial disease]. **2008**, 208, 175-81 6
- 1877 [Role of pulse pressure, systolic blood pressure, and diastolic blood pressure in the prediction of cardiovascular risk. Cohort study]. **2008**, 130, 361-5 5
- 1876 Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. **2008**, 61, 404-416 33
- 1875 [Cardiovascular risk factors in HIV-infected patients on effective antiretroviral therapy]. **2008**, 130, 797 1
- 1874 [Evaluation and management of hypertension in Spain. A consensus guide]. **2008**, 131, 104-16 49
- 1873 Políticas preventivas globales. Estrategias a escala europea y mundial. **2008**, 61, 960-970 6
- 1872 [Cardiovascular risk in subjects with high probability of metabolic syndrome and insulin resistance. DESIRE study]. **2008**, 208, 377-85 13
- 1871 [Influence of morbidity, metabolic control, and use of resources in subjects with cardiovascular risk in the primary care setting]. **2008**, 40, 447-54 1
- 1870 [Quality of life and cardiovascular risk]. **2008**, 40, 475-6 0
- 1869 Factors affecting relevance of tele-ECG systems application to high risk for future ischemic heart disease events patients group. **2008**, 14, 345-9 8
- 1868 Cardiovascular Prevention: Always Too Late?. **2008**, 61, 291-298
- 1867 Risk Functions and the Primary Prevention of Cardiovascular Disease. **2008**, 61, 404-416
- 1866 Global Preventive Policies. Strategies at European and Worldwide Level. **2008**, 61, 960-970
- 1865 Comparison of cardiovascular risk factors in young Spanish men between the 1980s and after the year 2000. Data from the AGEMZA study. **2008**, 61, 1260-6

1864	Coronary artery calcium to predict all-cause mortality in elderly men and women. 2008 , 52, 17-23	195
1863	An Italian Chart for Cardiovascular Risk Estimate Including High-Density Lipoprotein-Cholesterol. 2008 , 16, 183-197	2
1862	Blood pressure control in the year following coronary events. 2008 , 130, 205-10	3
1861	Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. 2008 , 155, 154-60	107
1860	The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes. 2008 , 155, 534-40	11
1859	Association of premature ventricular complexes with central aortic pressure indices and pulse wave velocity. 2008 , 155, 500.e1-6	4
1858	Simple adaptation of current abdominal aortic aneurysm screening programs may address all-cause cardiovascular mortality: prospective observational cohort study. 2008 , 155, 938-45	2
1857	Ten-year risk prediction in French men using the Framingham coronary score: results from the national SU.VI.MAX cohort. 2008 , 47, 61-5	13
1856	Prognostication--the lost skill of medicine. 2008 , 19, 155-64	29
1855	Antihypertensive effect of zofenopril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension according to their cardiovascular risk level: A post hoc analysis. 2008 , 69, 232-42	6
1854	Dislipidemias en pacientes muy ancianos. 2008 , 12, 1-10	
1853	[Impact of the presence of cardiovascular disease on blood pressure and lipid control in the hypertense population attended in primary care]. 2008 , 40, 21-7	5
1852	[Are mortality or morbidity risks appropriate endpoints for interventional studies in primary or secondary prevention with shared decision-making?]. 2008 , 102, 391-6	
1851	Clinical implications of white-coat effect among patients attending at a lipid clinic. 2008 , 197, 904-9	8
1850	Manejo terapéutico general y extrahospitalario del paciente con hiperlipidemia. Medidas generales y farmacológicas. Criterios clínicos y analíticos de seguimiento. Modificaciones posológicas y farmacológicas. Cumplimiento terapéutico. 2008 , 10, 1272-1278	
1849	Protocolo de tratamiento preventivo de la trombosis arterial. 2008 , 10, 1515-1518	
1848	Dislipemias. Metodología en atención primaria. Implicando a los pacientes en su plan de salud cardiovascular. 2008 , 20, 30-34	
1847	Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. 2008 , 371, 923-31	237

1846	Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. 2008 , 371, 1999-2012	401
1845	Comparaci3n de los factores de riesgo cardiovascular de j3venes espa3oles de los a3os ochenta y tras el 2000. Datos del estudio AGEMZA. 2008 , 61, 1260-1266	4
1844	Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. 2008 , 22, 845-55	16
1843	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. 2008 , 24, 455-63	36
1842	Dislipidemie del soggetto molto anziano. 2008 , 10, 1-10	
1841	Cardiovascular Risk Management in Clinical Practice. 2008 , 15, 9-16	3
1840	Global cardiovascular disease risk management in italian patients with metabolic syndrome in the clinical practice setting. 2008 , 15, 37-45	2
1839	2008 white paper for implementing strategies and interventions for cardiovascular prevention in Italy. 2008 , 15, 63-73	3
1838	Molecular signatures of cardiovascular disease risk: potential for test development and clinical application. 2008 , 12, 281-7	4
1837	Novel Cardiac Risk Factor Stratification Using Neuro-fuzzy Tool. 2008 ,	
1836	General cardiovascular risk profile for use in primary care: the Framingham Heart Study. 2008 , 117, 743-53	4273
1835	Cardiovascular risk engines can help in selecting patients to be evaluated by dynamic penile color doppler ultrasound. 2008 , 31, 1058-62	6
1834	Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. 2008 , 15, 402-8	31
1833	Adherence to a Mediterranean-type diet and reduced prevalence of clustered cardiovascular risk factors in a cohort of 3,204 high-risk patients. 2008 , 15, 589-93	105
1832	Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. 2008 , 46, 748-63	35
1831	Comparative prognostic value of glomerular filtration rate estimating formulas in ischaemic heart disease. 2008 , 15, 423-7	8
1830	Predicting 6-year mortality risk in patients with type 2 diabetes. 2008 , 31, 2301-6	37
1829	Cardiovascular risk tables. 2008 , 336, 1445-6	9

1828	Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction. 2008 , 10, F7-F10	4
1827	Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. 2008 , 24, 1823-32	22
1826	BMI, lipid profile, physical fitness and smoking habits of young male adults and the association with parental education. 2009 , 19, 46-51	9
1825	Risk factors and target organ damage: is there a special case for prehypertension?. 2008 , 26, 2268-70	0
1824	Effect of persistent use of antihypertensives on blood pressure goal attainment. 2008 , 24, 1025-31	21
1823	Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. 2008 , 24, 2703-9	4
1822	Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. 2008 , 15, 562-6	28
1821	Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care. 2008 , 24, 1659-68	5
1820	Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. 2008 , 31, 2038-43	119
1819	General practitioners' coronary risk assessments and lipid-lowering treatment decisions in primary prevention: comparison between two European areas with different cardiovascular risk levels. 2008 , 9, 248	2
1818	Prediction of first events of coronary heart disease and stroke with consideration of adiposity. 2008 , 118, 124-30	119
1817	Hierarchical analysis of cardiovascular risk factors in relation to the development of acute coronary syndromes, in different parts of Greece: the CARDIO2000 study. 2008 , 59, 156-65	4
1816	Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. 2008 , 20, 92-9	117
1815	Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study. 2008 , 15, 719-25	23
1814	The impact of occult renal failure on the cardiovascular risk stratification in an elderly population: the PREV-ICTUS study. 2008 , 17, 212-9	3
1813	Physical health--a cluster randomized controlled lifestyle intervention among persons with a psychiatric disability and their staff. 2008 , 62, 486-95	50
1812	Evaluation of a recalibrated Systematic Coronary Risk Evaluation cardiovascular risk chart: results from Systematic Coronary Risk Evaluation Germany. 2008 , 15, 409-15	24
1811	Exercise workload, coronary risk evaluation and the risk of cardiovascular and all-cause death in middle-aged men. 2008 , 15, 285-92	8

1810	Measurement of stiffness index by digital volume pulse analysis technique: clinical utility in cardiovascular disease risk stratification. 2008 , 21, 866-72	38
1809	Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. 2008 , 28, 1039-49	1009
1808	HeartScore calculated in individuals younger than 40 years is related to vascular markers of early atherosclerosis. 2008 , 15, 619-24	3
1807	Targeted versus global approaches to the management of hypercholesterolaemia. 2008 , 128, 248-54	3
1806	Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. 2008 , 117, 2875-83	75
1805	Cardiac multidetector CT: technical and diagnostic evaluation with evidence-based practice techniques. 2008 , 248, 366-77	11
1804	Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. 2008 , 93, 3671-89	128
1803	Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?. 2008 , 5 Suppl 1, S10-4	17
1802	Renal disease: a common and a silent killer. 2008 , 5 Suppl 1, S27-35	7
1801	Prevention strategies for hypertension: who should be targeted?. 2008 , 4, 211-3	
1800	Serum lipids, blood pressure and body weight around the age of the menopause. 2008 , 15, 83-8	23
1799	Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data. 2008 , 72, 1569-75	17
1798	Risk scoring for the primary prevention of cardiovascular disease. 2008 ,	13
1797	European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces. 2008 , 26, 157-60	3
1796	Ethnicity and cardiovascular disease prevention: practical clinical considerations. 2008 , 23, 465-70	4
1795	Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. 2008 , 26, 26-34	32
1794	Systematic review of implementation strategies for risk tables in the prevention of cardiovascular diseases. 2008 , 4, 535-45	13
1793	Cardiovascular co-morbidity in rheumatic diseases. 2008 , 4, 605-14	79

1792	[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. 2008 , 149, 1827-37	1
1791	Cardiovascular Disease Prevention. 2008 , 538-549	
1790	Cardiovascular risk assessment of Bulgarian urban population: cross-sectional study. 2008 , 49, 783-91	10
1789	Periodontitis and Calculated Risk of Cardiovascular Mortality. 2008 , 2, CMC.S573	0
1788	Health measurement scales: methodological issues. 2009 , 3, 160-5	26
1787	Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients. 2009 , 6, 2800-11	1
1786	Agent-based process-critiquing decision support system. 2009 ,	3
1785	Ethnic differences in SCORE cardiovascular risk in Oslo, Norway. 2009 , 16, 229-34	33
1784	Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention. 2009 , 54, 3-10	231
1783	Oral health care professionals' identification of cardiovascular disease risk among patients in private dental offices in Sweden. 2009 , 140, 1385-91	27
1782	Long term cardiovascular risk models' combination - a new approach. 2009 , 2009, 4711-4	2
1781	How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. 2009 , 16, 304-14	92
1780	Fewer deaths from cardiovascular disease than expected from the Systematic Coronary Risk Evaluation chart in a Swedish population. 2009 , 16, 321-4	10
1779	Homocysteine increases the risk associated with hyperlipidaemia. 2009 , 16, 150-5	20
1778	Ankle-brachial index and extent of atherosclerosis in patients from the Middle East (the AGATHA-ME study): a cross-sectional multicenter study. 2009 , 60, 329-34	20
1777	New European guidelines for cardiovascular disease prevention in clinical practice. 2009 , 47, 138-42	9
1776	Artificial neural network versus multiple logistic function to predict 25-year coronary heart disease mortality in the Seven Countries Study. 2009 , 16, 583-91	19
1775	C-reactive protein and coronary heart disease: predictive test or therapeutic target?. 2009 , 55, 239-55	55

1774	Development and validation of a cardiovascular risk prediction model for Japanese: the Hisayama study. 2009 , 32, 1119-22	39
1773	Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. 2009 , 24, 1528-33	15
1772	Prevalence of cardiovascular risk factors in older people with intellectual disability. 2009 , 114, 427-36	43
1771	AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the Australian Academy of Family Physicians, American Association of Colleges and Universities, and Pulmonary Rehabilitation Association. 2009 , 20, 125-32	92
1770	Challenges of designing trials for the primary prevention of stroke. 2009 , 40, S82-4	7
1769	Comparing methods for assessing cardiovascular risk. 2009 , 27, 2342-3	3
1768	New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. 2009 , 23, 105-12	8
1767	The contribution of six polymorphisms to cardiovascular risk in a Dutch high-risk primary care population: the HIPPOCRATES project. 2009 , 23, 659-67	11
1766	Evaluation of Coronary Risk Score Applications in 10-Year Coronary Heart Risk Estimation. 2009 , 28, 145-151	2
1765	Effect of heart rate on the risk of developing metabolic syndrome. 2009 , 32, 801-6	19
1764	Impact of body composition on very-low-density lipoprotein-triglycerides kinetics. 2009 , 296, E165-73	25
1763	Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID study. 2009 , 16, 660-8	10
1762	Resistance exercise plus to aerobic activities is associated with better lipids' profile among healthy individuals: the ATTICA study. 2009 , 102, 609-16	23
1761	Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. 2009 , 16, 562-70	28
1760	Self-reported cognitive and emotional effects and lifestyle changes shortly after preventive cardiovascular consultations in general practice. 2009 , 27, 104-10	4
1759	Cardiovascular disease risk in a semirural community in Malaysia. 2009 , 21, 410-20	22
1758	Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. 2009 , 32, 2094-8	76
1757	Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. 2009 , 18, 348-61	13

1756	Involving patients in cardiovascular risk management with nurse-led clinics: a cluster randomized controlled trial. 2009 , 181, E267-74	51
1755	The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands. 2009 , 16, 371-6	9
1754	Practical organisation of preventive cardiology programmes: integrating prevention and rehabilitation. 2009 , 16 Suppl 2, S37-42	3
1753	What is my risk of developing cardiovascular disease?. 2009 , 16 Suppl 2, S2-7	3
1752	Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study). 2009 , 43, 849-61	14
1751	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. 2009 , 27, 2121-58	1004
1750	Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. 2009 , 16, 541-9	77
1749	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. 2009 , 48, 1114-21	173
1748	Individual socioeconomic factors conditioning cardiovascular disease risk. 2009 , 22, 1085-95	7
1747	HeartScore predicts surrogate markers of cardiovascular disease in individuals aged below 40 years. 2009 , 16, 513	1
1746	Risk factor management: a practice guide. 2009 , 16 Suppl 2, S24-8	3
1745	Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20,000 Dutch men and women aged 20-65 years. 2009 , 16, 729-34	57
1744	Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients. 2009 , 9, 17	5
1743	Design of the Balance@Work project: systematic development, evaluation and implementation of an occupational health guideline aimed at the prevention of weight gain among employees. 2009 , 9, 461	22
1742	How to identify the asymptomatic high-risk patient?. 2009 , 34, 539-77	3
1741	Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies. 2009 , 103, 1089-95	8
1740	[Framingham function estimates the risk of cardio vascular mortality more effectively than SCORE function in the population of the Canary Islands (Spain)]. 2009 , 23, 216-21	5
1739	Cardiovascular risk in patients with bipolar disorder. 2009 , 115, 302-8	59

1738	Development of a diet index for older adults and its relation to cardiovascular disease risk factors: the Elderly Dietary Index. 2009 , 109, 1022-30	35
1737	Capacidad predictiva de las funciones de riesgo cardiovascular: limitaciones y oportunidades. 2009 , 9, 4-13	1
1736	Long-term medical comorbidities and their management: hypertension/cardiovascular disease. 2009 , 15 Suppl 2, S75-8	21
1735	Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. 2009 , 61, 1571-9	271
1734	Screening bei peripherer arterieller Verschlusskrankheit. 2009 , 14, 370-375	1
1733	Cardiovascular risk status and primary prevention in postmenopausal women: the MENOCARD study. 2009 , 121, 202-8	6
1732	Agreement of Swiss-adapted international and European guidelines for the assessment of global vascular risk and for lipid lowering interventions. 2009 , 23, 249-54	5
1731	Short-term versus lifetime risk assessment for cardiovascular disease: Pros, cons, and clinical implications. 2009 , 3, 144-149	4
1730	An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population. 2009 , 178, 161-6	12
1729	Mania and mortality: why the excess cardiovascular risk in bipolar disorder?. 2009 , 11, 475-80	61
1728	Dyslipidemia therapy update: the importance of full lipid profile assessment. 2009 , 26, 711-8	10
1727	Prevalence of coronary artery disease across the Framingham risk categories: coronary artery calcium scoring and MSCT coronary angiography. 2009 , 16, 368-75	22
1726	Cardiovascular risk assessment scores for people with diabetes: a systematic review. 2009 , 52, 2001-14	113
1725	Current European guidelines for management of arterial hypertension: are they adequate for use in primary care? Modelling study based on the Norwegian HUNT 2 population. 2009 , 10, 70	16
1724	Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. 2009 , 30, 834-42	10
1723	Brachial artery diameter is related to cardiovascular risk factors and intima-media thickness. 2009 , 39, 554-60	27
1722	Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population. 2009 , 15, 103-9	12
1721	Exercise workload, cardiovascular risk factor evaluation and the risk of stroke in middle-aged men. 2009 , 265, 229-37	6

1720	Fitness and abdominal obesity are independently associated with cardiovascular risk. 2009 , 266, 547-57	14
1719	Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. 2009 , 85, 45-50	106
1718	Tobacco use in relation to socioeconomic factors and dental care habits among Swedish individuals 15-70 years of age, 1983-2003. 2009 , 7, 62-70	10
1717	Impact of substance use on the physical health of patients with bipolar disorder. 2010 , 121, 437-45	23
1716	Vascular risk screening: possible or too much, too soon?. 2009 , 63, 989-96	5
1715	Inclusion of dietary evaluation in cardiovascular disease risk prediction models increases accuracy and reduces bias of the estimations. 2009 , 29, 176-86	10
1714	Ecuadorian stingless bee (Meliponinae) honey: A chemical and functional profile of an ancient health product. 2009 , 114, 1413-1420	83
1713	Circulating sTWEAK improves the prediction of coronary artery disease. 2009 , 42, 1381-6	32
1712	Women's health in menopause with a focus on hypertension. 2009 , 17, 68-72	66
1711	Development of life-expectancy tables for people with type 2 diabetes. <i>European Heart Journal</i> , 2009 , 30, 834-9	9.5 94
1710	Hypercholesterolaemia and risk of coronary heart disease in the elderly: impact of age: the Copenhagen City Heart Study. 2009 , 20, 139-44	22
1709	Thigh and buttock exertional pain for the diagnosis of peripheral arterial disease. 2009 , 20, 429-34	4
1708	Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: comparison between general practitioners, internists, and cardiologists. 2009 , 20, 601-6	2
1707	[Differences between women and men: even through cardiovascular risk factors... role of the gynecologist]. 2009 , 37, 186-93	1
1706	Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. 2009 , 41, 2339-44	2
1705	Obesity markers and estimated 10-year fatal cardiovascular risk in Switzerland. 2009 , 19, 462-8	19
1704	Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study. 2009 , 19, 532-41	36
1703	Obstructive sleep apnoea/hypopnea influences high-density lipoprotein cholesterol in the elderly. 2009 , 10, 882-6	51

1702	Effects of a global health and risk assessment tool for prevention of ischemic heart disease in an individual health dialogue compared with a community health strategy only results from the Live for Life health promotion programme. 2009 , 48, 20-4	8
1701	Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. 2009 , 133, 346-53	20
1700	Early detection of coronary artery disease by 64-slice multidetector computed tomography in asymptomatic hypertensive high-risk patients. 2009 , 135, 280-6	17
1699	Coronary heart disease benefits from blood pressure and lipid-lowering. 2009 , 135, 218-22	6
1698	Assessing coronary heart disease in women. 2009 , 62, 243-7	12
1697	Risk factors for cardiovascular disease in women. 2009 , 63, 186-90	53
1696	[Usefulness of the ankle-arm index for detection of peripheral arterial disease in a working population of Junta de Andalucía at Málaga]. 2009 , 132, 7-11	5
1695	[Primary and secondary prevention of stroke: a guideline]. 2009 , 133, 754-62	8
1694	Preventing weight gain: one-year results of a randomized lifestyle intervention. 2009 , 37, 270-7	71
1693	Overview of risk prediction models in cardiovascular disease research. 2009 , 19, 711-7	28
1692	[Durability of the effects of a quality improvement intervention in hypertensive patients on long-term follow-up (CICLO-RISK study)]. 2009 , 41, 371-8	2
1691	[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation]. 2009 , 41, 463.e1-463.e24	1
1690	Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). 2009 , 54, 1154-61	54
1689	Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. 2009 , 54, 1209-27	267
1688	ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of	66
1687	Relación del modelo conductual con el riesgo cardiovascular en una población mediterránea de bajo riesgo. 2009 , 26, 241-242ses Association: en. 2009 , 54, 1364-405	
1686	Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality—an update on patient populations with a wide range of cardiovascular risk. 2009 , 60, 481-7	168
1685	Impact of peripheral arterial disease on health status: a comparison with chronic heart failure. 2009 , 50, 1391-8	17

1684	[Evaluation of cardiovascular risk in the longitudinal phase of the Mediterranean study]. 2009 , 209, 118-30	5
1683	[Evaluation of cardiovascular risk in the cross-sectional phase of the Mediterranean Study]. 2009 , 209, 211-20	5
1682	Guà Europea de Prevencià Cardiovascular en la Pràctica Clànica. Adaptacià espaàla del CEIPC 2008. 2009 , 209, 279-302	11
1681	Aportaciones de las tènicas de imagen cardàca en la valoracià del paciente de alto riesgo cardiovascular. 2009 , 209, 9-17	
1680	Clinical Effect of Lifestyle Modification on Cardiovascular Risk in Prehypertensives: PREHIPER I Study. 2009 , 62, 86-90	1
1679	Adaptation of the Framingham-Wilson coronary risk equation for the population of Navarra (RICORNA). 2009 , 62, 875-85	2
1678	The REGICOR-calibrated function provides a better classification of high-risk patients on statin treatment in the Spanish population than the Framingham or SCORE classifications. 2009 , 62, 1134-40	6
1677	Eficacia y seguridad de la atorvastatina en pacientes con insuficiencia renal y dislipemia. 2009 , 30, 46-49	
1676	Guà Europea de Prevencià Cardiovascular en la Pràctica Clànica. Adaptacià espaàla del CEIPC 2008. 2009 , 26, 157-180	2
1675	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. 2009 , 18, 308-47	186
1674	Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. 2009 , 25, 421-30	13
1673	Carotid intima-media thickness measurement in cardiovascular screening programmes. 2009 , 16, 639-44	28
1672	SCORE should be preferred to Framingham to predict cardiovascular death in French population. 2009 , 16, 609-15	12
1671	Canadian Association of Radiologists: Consensus Guidelines and Standards for Cardiac CT. 2009 , 60, 19-34	8
1670	Cardiovascular risk assessment in postmenopausal women: the role of the gynecologist. 2009 , 12 Suppl 1, 58-61	2
1669	Correlations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: are there differences between male populations from primary healthcare and urology clinics? A review of the current knowledge. 2009 , 15, 128-35	10
1668	[Implications of the REACH registry for cardiologists]. 2009 , 132 Suppl 2, 15-20	
1667	Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study. 2009 , 203, 587-92	94

1666	Cigarette smoking: an undertreated risk factor for cardiovascular disease. 2009 , 205, 23-32	182
1665	HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. 2009 , 206, 611-6	155
1664	Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. 2009 , 206, 546-50	43
1663	Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study. 2009 , 207, 573-8	31
1662	Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. 2009 , 24, 431-41	41
1661	Paradigm of pretest risk stratification before coronary computed tomography. 2009 , 3, 386-91	10
1660	Barriers to multiple risk factor management in cardiovascular disease. 2009 , 10, 1-2	6
1659	International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. 2009 , 16, 472-80	12
1658	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. 2009 , 25, 279-86	57
1657	Guà Europea de Prevenciã Cardiovascular en la Prãtica Clãnica. Adaptaciã espaõla del CEIPC 2008. 2009 , 35, 66-85	1
1656	[Controversies and future of the approach to cardiovascular disease in HIV patients]. 2009 , 27 Suppl 1, 48-53	
1655	Guà Europea de Prevenciã Cardiovascular en la Prãtica Clãnica. Adaptaciã espaõla del CEIPC 2008. 2009 , 21, 124-150	3
1654	Anãlisis de la calidad de vida y su relaciã con el riesgo cardiovascular en una poblaciã mediterrãnea con bajo riesgo. 2009 , 21, 268-272	
1653	Manejo general y extrahospitalario del paciente con factores de riesgo vascular. 2009 , 10, 2708-2717	
1652	Eficacia clãnica de la modificaciã del estilo de vida en el riesgo cardiovascular en prehipertensos: estudio PREHIPER I. 2009 , 62, 86-90	17
1651	Adaptaciã de la funciã de riesgo coronario de Framingham-Wilson para la poblaciã de Navarra (RICORNA). 2009 , 62, 875-885	5
1650	La funciã calibrada REGICOR mejora la clasificaciã de los pacientes de alto riesgo tratados con estatinas respecto a Framingham y SCORE en la poblaciã espaõla. 2009 , 62, 1134-1140	10
1649	Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. 2009 , 27, 275-88	11

1648 Cardiac Risk Prevention Strategies. **2009**, 133-147

1647 Echocardiography in Identifying Subclinical Disease. **2009**, 201-217

1646 Risk scores for prediction of coronary heart disease: an update. **2009**, 38, 33-44 16

1645 Predicting the 30-year risk of cardiovascular disease: the framingham heart study. **2009**, 119, 3078-84 553

1644 Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence. **2009**, 60, 614-32 130

1643 New and emerging biomarkers of heart failure. **2009**, 46, 107-28 11

1642 Prevalence, awareness and treatment of hypertension in Finland during 1982-2007. **2009**, 27, 1552-9 59

1641 Ankle-brachial index is lower in hypertensive than in normotensive individuals in a cardiovascular risk population. **2009**, 27, 2036-43 20

1640 Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. **2009**, 27, 2351-7 29

1639 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. **2009**, 27, S3-11 26

1638 Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. **2009**, 27, 744-52 47

1637 Lifestyle and stroke risk: a review. **2009**, 22, 60-8 63

1636 Postmenopausal hormone therapy and the risk of cardiovascular disease. **2009**, 10, 303-9 8

1635 Prognostic models with competing risks: methods and application to coronary risk prediction. **2009**, 20, 555-61 376

1634 Assessment of risk for developing coronary heart disease in asymptomatic individuals. **2009**, 29, 207-19 5

1633 The metabolic syndrome and risk of myocardial infarction in familial hypertension (hypertension heredity in Malmö evaluation study). **2009**, 27, 109-17 2

1632 Heart rate management in coronary artery disease: the CLARIFY registry. **2009**, 11, D13-D18 28

1631 Obtaining arterial stiffness indices from simple arm cuff measurements: the holy grail?. **2009**, 27, 2159-61 20

1630	Risk charts illustrating the 10-year risk of myocardial infarction among residents of Japanese rural communities: the JMS Cohort Study. 2009 , 19, 94-100	16
1629	Risk charts illustrating the 10-year risk of stroke among residents of Japanese rural communities: the JMS Cohort Study. 2009 , 19, 101-6	14
1628	Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication. 2009 , 73, 27-34	69
1627	Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study. 2009 , 19, 634-40	9
1626	Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. 2009 , 40, 2319-26	80
1625	The myocardial infarction associated CDKN2A/CDKN2B locus on chromosome 9p21 is associated with stroke independently of coronary events in patients with hypertension. 2009 , 27, 769-73	40
1624	The potential yield of ECG screening of hypertensive patients: the Utrecht Health Project. 2010 , 28, 1527-33	14
1623	Evaluation of patients with suspected coronary artery disease. 2010 , 21, 386-90	8
1622	Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. 2010 , 28, 2016-25	13
1621	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. 2010 , 28, 251-8	21
1620	Discrepancy between European Society of Hypertension and SCORE risk assessment methods in hypertensive patients: still a matter of concern--answer to Sehestedt et al. 2010 , 28, 2171-3; author reply 2173-5	1
1619	Impact of metabolic syndrome on the short-term outcomes of colorectal cancer surgery. 2010 , 53, 186-91	32
1618	Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. 2010 , 170, 470-7	33
1617	High cardiovascular risk and poor adherence to guidelines in 11,069 patients of middle age and older in primary care centres. 2010 , 17, 593-8	10
1616	Asymptomatic carotid lesions add to cardiovascular risk prediction. 2010 , 17, 514-8	18
1615	Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial. 2010 , 60, 40-6	76
1614	Coronary score adds prognostic information for patients with acute coronary syndrome. 2010 , 74, 490-5	39
1613	Dyslipidemia and cardiovascular disease: a series of epidemiologic studies in Japanese populations. 2010 , 20, 259-65	27

1612	Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. 2010 , 341, c3966	82
1611	Evaluation of selected lipid parameters and blood pressure in ethnically-homogenous population of middle-aged persons, depending on gender, age and body mass. 2010 , 5, 486-494	0
1610	Hoe ervaren hoogrisicopatiënten CVRM door een praktijkondersteuner?. 2010 , 5, 136-143	1
1609	The rise and fall of the metabolic syndrome. 2010 , 53, 597-9	33
1608	Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. 2010 , 99, 723-33	29
1607	A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. 2010 , 11, 195-203	31
1606	Impact of change in high-density lipoprotein cholesterol from baseline on risk for major cardiovascular events. 2010 , 27, 233-44	8
1605	Statines verhogen risico op diabetes een beetje. 2010 , 53, 354-354	
1604	CVRM door een praktijkverpleegkundige is effectief. 2010 , 53, 362-367	
1603	A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. 2010 , 4, 256-65	6
1602	Assessment of cardiovascular risk. 2010 , 12, 384-93	11
1601	The Framingham Heart Study's impact on global risk assessment. 2010 , 53, 68-78	88
1600	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). 2010 , 10, 382	21
1599	EDUCORE project: a clinical trial, randomised by clusters, to assess the effect of a visual learning method on blood pressure control in the primary healthcare setting. 2010 , 10, 449	4
1598	Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia. 2010 , 10, 717	14
1597	Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). 2010 , 10, 737	8
1596	Cardiovascular risk assessment--from individual risk prediction to estimation of global risk and change in risk in the population. 2010 , 8, 29	46
1595	Cardiovascular disease risk factors: epidemiology and risk assessment. 2010 , 105, 3A-9A	171

1594	Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. 2010 , 106, 911-6	65
1593	[Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?]. 2010 , 42, 470-81	
1592	[Effectiveness of a preventive intervention strategy based on structured telephone interviews in a working population with a moderate to high cardiovascular risk]. 2010 , 42, 498-505	6
1591	Growing epidemic of coronary heart disease in low- and middle-income countries. 2010 , 35, 72-115	571
1590	[Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10mg and atorvastatin 10mg]. 2010 , 34, 170-80	1
1589	Patient perceptions of nurse-delivered cardiovascular prevention: cross-sectional survey within a randomised trial. 2010 , 47, 1237-44	13
1588	[What has changed in the current management of hypertension from the renal point of view?]. 2010 , 210 Suppl 1, 12-7	0
1587	[Diabetes mellitus and cardiovascular risk. Is integrated therapy of type 2 diabetes and cardiovascular risk factors necessary?]. 2010 , 42 Suppl 1, 16-23	1
1586	Subclinical atherosclerosis: evolving role of carotid intima-media thickness. 2010 , 13, 186-97	23
1585	Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? Point. 2010 , 13, 152-9	7
1584	The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. 2010 , 19, 195-210	21
1583	The effect of different cardiovascular risk presentation formats on intentions, understanding and emotional affect: a randomised controlled trial using a web-based risk formatter (protocol). 2010 , 10, 41	6
1582	Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study. 2010 , 9, 34	40
1581	The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. 2010 , 64, 1440-3	43
1580	Management of patients with peripheral arterial disease in primary care: a cross-sectional study in Germany. 2010 , 64, 875-84	6
1579	Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. 2010 , 64, 1252-9	41
1578	Is cataract associated with cardiovascular morbidity?. 2010 , 24, 1352-8	26
1577	Tracking of noninvasive ultrasound measurements of subclinical atherosclerosis in adulthood: findings from the Cardiovascular Risk in Young Finns Study. 2010 , 36, 1237-44	9

1576	Does geographical location influence the phenotype of Fabry disease in women in Europe?. 2010 , 77, 131-40	11
1575	Coronary Artery Calcification: Pathogenesis, Imaging, and Risk Stratification. 2010 , 332-355	
1574	Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine. 2010 , 6, 387-97	12
1573	Cardiac risk stratification: role of the coronary calcium score. 2010 , 6, 603-11	21
1572	Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. 2010 , 5, e9065	71
1571	COSEHC global vascular risk management quality improvement program: rationale and design. 2010 , 6, 1135-45	3
1570	"Later, lazier, and unluckier": a heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study). 2010 , 3, 163-6	5
1569	Risk assessment and aspirin use in Asian and Western populations. 2010 , 6, 943-56	18
1568	Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. 2010 , 17, 549-55	13
1567	Validaõ de conteõo das atuais e de novas caracterõsticas definidoras do diagnõstico de enfermagem dõbito cardõaco diminuõdo. 2010 , 23, 764-768	10
1566	Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. 2010 , 55, 785-91	55
1565	Measures of overweight and obesity and risk of cardiovascular disease: a population-based study. 2010 , 17, 486-90	23
1564	Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. 2010 , 17, 244-9	43
1563	Providing patients with global cardiovascular risk information: is knowledge power?. 2010 , 170, 227-8	8
1562	Risk factor profiles for atherosclerotic cardiovascular disease in black and other Africans with established rheumatoid arthritis. 2010 , 37, 953-60	14
1561	Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. 2010 , 61, 49-57	13
1560	Cardiovascular Health in the Irish Traveller Community. 2010 , 10, 305-307	5
1559	Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. 2010 , 122, 7-15	11

1558	Aortic augmentation index: reference values in a large unselected population by means of the SphygmoCor device. 2010 , 23, 180-5	77
1557	Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study. 2010 , 21, 267-72	25
1556	Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. 2010 , 121, 2071-8	24
1555	Acromegaly per se does not increase the risk for coronary artery disease. 2010 , 162, 879-86	54
1554	Contemporary predictors of coronary artery disease in patients referred for angiography. 2010 , 17, 280-8	9
1553	Prevalence of modifiable cardiovascular risk factors in German adolescents. 2010 , 17, 204-10	18
1552	Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers. 2010 , 9, 156-9	2
1551	Addressing modifiable risk factors for coronary heart disease in primary care: an evidence-base lost in translation. 2010 , 27, 370-8	4
1550	Framingham risk prediction equations for incidence of cardiovascular disease using detailed measures for smoking. 2010 , 5, e11	23
1549	Italian cardiovascular mortality charts of the CUORE project: are they comparable with the SCORE charts?. 2010 , 17, 403-9	16
1548	Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. 2010 , 17, 18-23	26
1547	Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment. 2010 , 19, 240-8	24
1546	Menopause management: a cardiovascular risk-based approach. 2010 , 13, 328-39	8
1545	Masked, white coat and sustained hypertension: comparison of target organ damage and psychometric parameters. 2010 , 24, 151-7	27
1544	Assessing individual cardiac risk using extra-cardiac arterial imaging. 2010 , 8, 529-43	
1543	Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. 2010 , 26, 2833-9	8
1542	Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new zealand diabetes cohort study. 2010 , 33, 1347-52	54
1541	Characteristics of current smokers, former smokers, and second-hand exposure and evolution between 1985 and 2007. 2010 , 17, 730-6	17

1540	Clinical inertia in diagnosis and treatment of hypertension in primary care: quantification and associated factors. 2010 , 19, 3-10		41
1539	Cardiovascular risk and status assessment. 2010 , 2010, 2872-6		3
1538	Cardiovascular risk prediction: basic concepts, current status, and future directions. 2010 , 121, 1768-77		477
1537	Multiple marker approach to risk stratification in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2010 , 31, 3024-31	9.5	84
1536	Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study. 2010 , 28, 242-8		20
1535	Hyperglycemia in postmenopausal women screened for the metabolic syndrome is associated to increased sexual complaints. 2010 , 26, 86-92		11
1534	Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. 2010 , 11, 834-9		38
1533	Dietary supplementation with cis-9,trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults. 2010 , 91, 175-83		68
1532	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 , 122, e584-636		451
1531	Cross-sectional analysis of baseline data to identify the major determinants of carotid intima-media thickness in a European population: the IMPROVE study. <i>European Heart Journal</i> , 2010 , 31, 614-22	9.5	99
1530	Risk prediction is improved by adding markers of subclinical organ damage to SCORE. <i>European Heart Journal</i> , 2010 , 31, 883-91	9.5	195
1529	Simplifying cardiovascular risk estimation using resting heart rate. <i>European Heart Journal</i> , 2010 , 31, 2141-7	9.5	27
1528	Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). <i>European Heart Journal</i> , 2010 , 31, 2041-8	9.5	158
1527	Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart. <i>European Heart Journal</i> , 2010 , 31, 3040-5	9.5	47
1526	Evaluating risk for cardiovascular diseases--vain or value? How do different cardiovascular risk scores act in real life. 2010 , 20, 107-12		15
1525	Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. 2010 , 25, 3560-8		13
1524	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. 2010 , 103, 727-39		63
1523	Prediction of major vascular events in patients with transient ischemic attack or ischemic stroke: a comparison of 7 models. 2010 , 41, 2178-85		22

1522	Effect of rheumatoid factor on mortality and coronary heart disease. 2010 , 69, 1649-54		54
1521	Optimizing lipid-lowering therapy in the prevention of coronary heart disease. 2010 , 3, 649-61		
1520	How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. <i>European Heart Journal</i> , 2010 , 31, 2351-8	9.5	104
1519	Cardiovascular disease: prediction with ancillary aortic findings on chest CT scans in routine practice. 2010 , 257, 549-59		32
1518	The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. 2010 , 24, 631-8		5
1517	The conundrum of detecting stable angina pectoris in the community setting. 2010 , 7, 106-13		6
1516	What we have learned from risk charts?. 2010 , 6, 285-7		1
1515	An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. 2010 , 340, c2442		145
1514	Clinical evaluation of combined therapy for type 2 diabetes. 2010 , 26, 1171-83		8
1513	Respuesta del Dr. Jesŕ Medina Asensio. 2010 , 26, 361-365		
1512	Determination of unknown high-grade atherosclerotic lesions by whole-body cardiovascular imaging: assessment of patients with symptomatic atherosclerotic disease of peripheral arteries. 2010 , 17, 219-29		
1511	Cardiovascular risk factors in developing countries: A review of clinico-epidemiological evidence. 2010 , 5, 115-123		6
1510	Anŕlisis de potenciales factores protectores del riesgo cardiovascular en una poblaciŕn mediterrŕnea. 2010 , 27, 233-238		
1509	Estatinas y diabetes. 2010 , 27, 229-232		
1508	Screening for cardiovascular risk in asymptomatic patients. 2010 , 55, 1169-1177		139
1507	2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 , 56, e50-103		976
1506	First evaluation using a validated scale of the risk of congestive heart failure among hypertensive patients treated by general practitioners (O-PREDICT survey). 2010 , 103, 176-83		
1505	Cardiometabolic profile of people screened for high risk of type 2 diabetes in a national diabetes prevention programme (FIN-D2D). 2010 , 4, 231-9		22

1504	Long-term mortality prediction after operations for type A ascending aortic dissection. 2010 , 5, 42	10
1503	Praktijkondersteuning bij CVRM. 2010 , 53, 313-320	1
1502	Prevalence of chronic kidney disease in patients with or at a high risk of cardiovascular disease. 2010 , 63, 225-8	5
1501	Effect on cardiovascular risk of an intervention by family physicians to promote physical exercise among sedentary individuals. 2010 , 63, 1244-52	5
1500	Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10mg and atorvastatin 10mg. 2010 , 34, 170-180	
1499	Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?. 2010 , 122, 300-10	155
1498	Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. 2010 , 143, 385-90	27
1497	Cardiovascular risk of the general population assessed through SCORE and CUORE charts: an extensive survey by the General Practitioners from Abruzzo, Italy. 2010 , 144, 47-52	7
1496	Are there gender differences in impairment associated with high social anxiety? A community-based study. 2010 , 24, 487-93	5
1495	Heart rate predicts mortality in patients with heart failure and preserved systolic function. 2010 , 16, 806-11	24
1494	Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score. 2010 , 87, 267-74	29
1493	Genome-wide association studies in atherothrombosis. 2010 , 21, 74-8	24
1492	The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. 2010 , 21, 293-6	10
1491	Improving lifestyle and risk perception through patient involvement in nurse-led cardiovascular risk management: a cluster-randomized controlled trial in primary care. 2010 , 50, 35-44	72
1490	Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. 2010 , 159, 612-619.e3	274
1489	Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. 2010 , 121, 2388-97	257
1488	New cardiovascular risk factors and physical activity. 2010 , 45, 201-208	3
1487	Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. 2010 , 208, 305-16	68

1486	Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: the Suita study. 2010 , 209, 290-4	30
1485	The metabolic syndrome predicts carotid intima-media thickness no better than the sum of individual risk factors in a lipid clinic population. 2010 , 210, 214-9	13
1484	Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors. 2010 , 212, 292-8	63
1483	Predicting the risk of coronary heart disease I. The use of conventional risk markers. 2010 , 213, 345-51	31
1482	Common clinical practice versus new PRIM score in predicting coronary heart disease risk. 2010 , 213, 532-8	6
1481	[Utility of combined therapy in the prevention and treatment of the cardiovascular disease]. 2010 , 210, 230-6	1
1480	Prevalencia de insuficiencia renal crónica en pacientes de alto riesgo o con enfermedad cardiovascular. 2010 , 63, 225-228	12
1479	Efecto en el riesgo cardiovascular de una intervención para la promoción del ejercicio físico en sujetos sedentarios por el médico de familia. 2010 , 63, 1244-1252	17
1478	Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention. 2010 , 22, 48-51	
1477	Overall health assessment: a renal perspective. 2010 , 375, 2053-4	14
1476	JUPITER, rosuvastatin, and the European Medicines Agency. 2010 , 375, 2071	4
1475	Tratamiento integral individualizado de los factores de riesgo vascular. 2010 , 10, 4700-4707	
1474	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. 2010 , 26, 241-8	77
1473	Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. 2010 , 12, R218	42
1472	Cardiovascular risk estimation tailored to different clinical settings - the Tromsø study. 2010 , 44, 245-50	
1471	Statistical methods for assessment of added usefulness of new biomarkers. 2010 , 48, 1703-11	238
1470	The assessment of total cardiovascular risk in hypertensive subjects in primary care. 2010 , 42, 187-95	1
1469	Subclinical organ damage and cardiovascular risk prediction. 2010 , 19, 132-9	8

1468	Using ontologies and probabilistic networks to develop a preventive stroke diagnosis system (PSDS). 2010 ,	3
1467	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. 2010 , 17, 73-102	9
1466	2009 SIPREC Consensus Document – Executive Summary. 2010 , 17, 237-247	
1465	Distribution of cardiovascular risk factors in Belgian army men. 2010 , 65, 135-9	8
1464	Assessing fatal cardiovascular disease risk with the SCORE (Systematic Coronary Risk Evaluation) scale in post-menopausal women 10 years after different hormone treatment regimens. 2010 , 26, 533-8	4
1463	Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. 2011 , 27, 821-33	31
1462	Impact of new clinical trials on recent guidelines on hypertension management. 2011 , 43, 124-32	7
1461	Improving the efficiency of healthcare delivery system in underdeveloped rural areas. 2011 ,	6
1460	Chronic kidney disease in the hypertensive patient: an overview of the I-DEMAND study. 2011 , 18, 31-6	2
1459	Statins for cardiovascular prevention according to different strategies: a cost analysis. 2011 , 11, 33-44	6
1458	Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?. 2011 , 50, 1505-12	19
1457	Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. 2011 , 38, 567-71	22
1456	Hypertension artfielle et risque cardiovasculaire : bilan et perspectives. 2011 , 2011, 9-11	
1455	Prediction of cardiovascular disease events. 2011 , 29, 1-13	7
1454	Échelles de risque cardiovasculaire. 2011 , 5, 287-293	1
1453	Le risque cardiovasculaire. 2011 , 2011, 9-15	
1452	Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study). 2011 , 45, 727-39	14
1451	Imaging the vulnerable plaque. 2011 , 57, 1961-79	127

1450	Riesgo vascular. 2011 , 28, 121-125	0
1449	Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study. 2011 , 104, 428-34	6
1448	Assessment of cardiovascular risk in primary care patients in France. 2011 , 104, 381-7	7
1447	The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. 2011 , 80, 17-28	1305
1446	[Dyslipidemias: a pending challenge in cardiovascular prevention. Consensus document from CEIPC/SEA Committee]. 2011 , 137, 30.e1-30.e13	8
1445	[Self-perception of cardiovascular health in primary care physicians. CHABS study]. 2011 , 137, 262-8	2
1444	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. 2011 , 34, 714-21	21
1443	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. 2011 , 70, 896-904	681
1442	Can non-calcified coronary artery plaques be detected on non-contrast CT calcium scoring studies?. 2011 , 18, 858-65	1
1441	Análisis de la influencia de polimorfismos en APOE, APOA5, LPL, LIPC y CETP sobre los niveles de triglicéridos en población laboral malagueña. 2011 , 23, 62-71	0
1440	Riesgo cardiovascular en pacientes diabéticos tipo 2 con o sin síndrome metabólico asociado. 2011 , 23, 112-118	
1439	Framing cardiovascular disease event risk prediction. 2011 , 27, 171-3	7
1438	The challenges and benefits of cardiovascular risk assessment in clinical practice. 2011 , 27, 481-7	11
1437	Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). 2011 , 92, 19-25	18
1436	A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). 2011 , 93, 276-284	49
1435	[Non-alcoholic fatty liver disease. How and who to screen]. 2011 , 34, 278-88	
1434	Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. 2011 , 64, 1451-62	81
1433	Impact of coronary artery calcium on cardiovascular risk categorization and lipid-lowering drug eligibility in asymptomatic hypercholesterolemic men. 2011 , 151, 200-4	14

1432	Patients with premature cardiovascular disease and a positive family history for cardiovascular disease are prone to recurrent events. 2011 , 153, 64-7			16
1431	Correlation of cardiovascular risk scores with myocardial high-energy phosphate metabolism. 2011 , 150, 208-10			4
1430	[Intima-media thickness and its relation with the SCORE function in Spain]. 2011 , 136, 653-8			6
1429	Could clinical decision rules relying on cardiovascular risk models increase psychosocial inequalities in health? Results from the PRIME cohort study. 2011 , 52, 439-44			2
1428	Obesity in Castile and Leon, Spain: epidemiology and association with other cardiovascular risk factors. 2011 , 64, 63-6			22
1427	[In the identification of cardiovascular risk with the SCORE model, could we recommend its calculation interchangeably with total cholesterol or atherogenic index? Concordance between total cholesterol and atherogenic index in the SCORE table]. 2011 , 64, 421-3			3
1426	Ankle-brachial index improves the classification of cardiovascular risk: PERART/ARTPER Study. 2011 , 64, 186-92			22
1425	[Clinical applicability of the framingham 30-year risk score. Usefulness in cardiovascular risk stratification and the diagnosis of carotid atherosclerotic plaque]. 2011 , 64, 305-11			12
1424	[ESC/EAS Guidelines for the management of dyslipidaemias]. 2011 , 64, 1168.e1-1168.e60			37
1423	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011 , 32, 1769-818	9.5	2020	
1422	Coronary artery calcium scoring in cardiovascular risk assessment. 2011 , 29, e43-53			10
1421	Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. 2011 , 57, 1404-23			55 ²
1420	Obesity in Castile and Leon, Spain: Epidemiology and Association With Other Cardiovascular Risk Factors. 2011 , 64, 63-66			2
1419	In the Identification of Cardiovascular Risk With the SCORE Model, Could We Recommend Its Calculation Interchangeably With Total Cholesterol or Atherogenic Index? Concordance Between Total Cholesterol and Atherogenic Index in the SCORE Table. 2011 , 64, 421-423			
1418	Ankle-Brachial Index Improves the Classification of Cardiovascular Risk: PERART/ARTPER Study. 2011 , 64, 186-192			0
1417	Clinical Applicability of the Framingham 30-Year Risk Score. Usefulness in Cardiovascular Risk Stratification and the Diagnosis of Carotid Atherosclerotic Plaque. 2011 , 64, 305-311			
1416	New-onset diabetes and cardiovascular events in essential hypertensives: a 6-year follow-up study. 2011 , 153, 154-8			6
1415	[Health of family physicians: do we practice what we preach?]. 2011 , 43, 305-11			3

1414	Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. 2011 , 216, 237-43	66
1413	A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita study. 2011 , 217, 201-6	29
1412	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217 Suppl 1, S1-44	152
1411	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217, 3-46	459
1410	Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. 2011 , 21, 867-75	24
1409	Cardiovascular risk for pregnant women in childbirth Opatowsky AR, Siddiqi OK, D'Souza B Webb GD, Fernandes SM, Landzberg MJ (2011) Maternal cardiovascular events during childbirth among women with congenital heart disease. Heart doi:10.1136/heartjnl-2011-300828. 2011 , 6, 617-617	0
1408	The link between body mass index and cardiovascular disease Dudina A, Cooney MT, De Bacquer D on behalf of the SCORE investigators (2011) Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil 18(5): 731-732. 2011 , 6, 616-617	
1407	Factors associated with arterial hypertension in pharmacy users in Portugal. 2011 , 45, 136-44	6
1406	Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management. 2011 , 4, 55-71	5
1405	Cardiovascular Risk Assessment with Vascular Function, Carotid Atherosclerosis and the UKPDS Risk Engine in Korean Patients with Newly Diagnosed Type 2 Diabetes. 2011 , 35, 619-27	12
1404	Layperson-Oriented versus Clinical-Based Models for Assessing 10-Year Incidence of Coronary Heart Disease: National FINRISK Study. 2011 , 2011, 823782	
1403	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. 2011 , 5, 325-80	162
1402	Comparison of the Framingham Risk Score, UKPDS Risk Engine, and SCORE for Predicting Carotid Atherosclerosis and Peripheral Arterial Disease in Korean Type 2 Diabetic Patients. 2011 , 32, 189-96	10
1401	Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. 2011 , 7, 209-35	14
1400	The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies. 2011 , 6, e17508	14
1399	Paternal and maternal history of myocardial infarction and cardiovascular diseases incidence in a Dutch cohort of middle-aged persons. 2011 , 6, e28697	9
1398	Disproportionally impaired microvascular structure in essential hypertension. 2011 , 29, 896-905	34
1397	Total cardiovascular disease risk assessment: a review. 2011 , 26, 429-37	7

1396	Blood pressure class and carotid artery intima-media thickness in a population at the secondary epidemiological transition. 2011 , 29, 2194-200	7
1395	A life course approach to cardiovascular disease prevention. 2011 , 26, S22-34	22
1394	Nurse-based models for cardiovascular disease prevention: from research to clinical practice. 2011 , 26, S46-55	8
1393	Review on Non-Invasive Risk Stratification of Sudden Cardiac Death. 2011 , 20, 263-278	5
1392	Cardiovascular risk scores do not account for the effect of treatment: a review. 2011 , 97, 689-97	57
1391	Revised guidelines for cardiovascular risk management - time to stop medication? A practice-based intervention study. 2011 , 61, e347-52	19
1390	Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study. 2011 , 97, 923-30	28
1389	Social Determinants of Cardiovascular Diseases. 2011 , 33, 601-622	31
1388	Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. 2011 , 16, 85-92	3
1387	A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). 2011 , 28, 1213-20	49
1386	Experiences of doctors and nurses implementing nurse-delivered cardiovascular prevention in primary care: a qualitative study. 2011 , 67, 1758-66	14
1385	Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. 2011 , 75, 825-30	18
1384	Carotid intima-media thickness as a screening tool in cardiovascular primary prevention. 2011 , 41, 521-6	10
1383	How do prescribing doctors anticipate the effect of statins?. 2011 , 17, 420-8	6
1382	Predictive accuracy of the 'Framingham's general CVD algorithm' in a Middle Eastern population: Tehran Lipid and Glucose Study. 2011 , 65, 264-73	29
1381	Comparison of metabolic syndrome subjects with and without erectile dysfunction - levels of circulating oxidised LDL and arterial elasticity. 2011 , 65, 274-80	10
1380	Cardiovascular risk estimation--what is missing?. 2011 , 65, 111-3	
1379	Coronary risk assessment and arterial age calculation using coronary artery calcium scoring and the Framingham Risk Score. 2011 , 28, 686-93	8

- 1378 The relationship between diet and subclinical atherosclerosis: results from the Asklepios Study. **2011**, 65, 606-13 30
- 1377 [Vascular risk factors in HIV-infected patients in a penitentiary center]. **2011**, 211, 9-16 1
- 1376 [Cardiovascular prevention: more evidence]. **2011**, 211, 23-5
- 1375 Measuring pathways towards a healthier lifestyle in the Hoorn Prevention Study: the Determinants of Lifestyle Behavior Questionnaire (DLBQ). **2011**, 85, e53-8 14
- 1374 Nuevas herramientas en la estratificación del riesgo cardiovascular. **2011**, 11, 21-28
- 1373 Effects of a brief cardiovascular prevention program by a health advisor in primary care; the 'Hartslag Limburg' project, a cluster randomized trial. **2011**, 53, 395-401 5
- 1372 Small but important errors in cardiovascular risk calculation by practice nurses: a cross-sectional study in randomised trial setting. **2011**, 48, 285-91 4
- 1371 Adherence to a guideline on cardiovascular prevention: a comparison between general practitioners and practice nurses. **2011**, 48, 798-807 26
- 1370 Long term cardiovascular risk models' combination. **2011**, 101, 231-42 14
- 1369 Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular disease. **2011**, 668 Suppl 1, S91-100 9
- 1368 [Cardiovascular risk in Spanish smokers compared to non-smokers: RETRATOS study]. **2011**, 43, 595-603 1
- 1367 [Cardiovascular risk factors and Primary Care: evaluation and intervention]. **2011**, 43, 668-77 12
- 1366 National differences in screening programmes for cardiovascular risks could obstruct understanding of cardiovascular prevention studies in Europe. **2011**, 19, 458-63 1
- 1365 Unrequested information from routine diagnostic chest CT predicts future cardiovascular events. **2011**, 21, 1577-85 34
- 1364 Correlation between total cardiovascular risk and bone density in postmenopausal women. **2011**, 6, 795-803 2
- 1363 Ten-year risk of all-cause mortality: assessment of a risk prediction algorithm in a French general population. **2011**, 26, 359-68 14
- 1362 Using clinical cardiovascular risk scores to predict coronary artery plaque severity and stenosis detected by CT coronary angiography in asymptomatic Chinese subjects. **2011**, 27, 669-78 16
- 1361 The effect of work-time influence on health and well-being: a quasi-experimental intervention study among eldercare workers. **2011**, 84, 683-95 26

1360	External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. 2011 , 54, 264-70	59
1359	Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?. 2011 , 54, 230-2	5
1358	HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark. 2011 , 54, 1318-26	27
1357	Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. 2011 , 54, 2525-32	89
1356	Leisure sport activity as a trigger for acute coronary events in men without known coronary artery disease : a single-center case study. 2011 , 36, 637-42	5
1355	Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis. 2011 , 39, 451-8	12
1354	Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events. 2011 , 18, 904-11	70
1353	Een elektrocardiogram bij elke patiënt met hypertensie. 2011 , 54, 122-127	2
1352	Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. 2011 , 2, 15-26	11
1351	Protecting the public: is it time for a paradigm shift in expected practice standards?. 2011 , 26, 460-1	1
1350	Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: Cardiovascular PREvention Sacco Study (CAPRESS). 2011 , 6, 337-47	1
1349	The PANDORA study: peripheral arterial disease in patients with non-high cardiovascular risk. 2011 , 6, 509-19	25
1348	Agreement between Framingham-DORICA and SCORE scales in estimation of cardiovascular risk in the patients suffering from metabolic syndrome in Granada (Spain). 2011 , 180, 351-4	
1347	Role of coronary artery calcium score and coronary CT angiography in the diagnosis and risk stratification of individuals with suspected coronary artery disease. 2011 , 13, 271-9	16
1346	Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocol. 2011 , 11, 2	23
1345	Prevalence of peripheral arterial disease in subjects with moderate cardiovascular risk: Italian results from the PANDORA study Data from PANDORA (Prevalence of peripheral Arterial disease in subjects with moderate CVD risk, with No overt vascular Diseases nor Diabetes mellitus). 2011 , 11, 59	13
1344	Improving interMediate risk management. MARK study. 2011 , 11, 61	21
1343	Effectiveness of Motivational Interviewing in improving lipid level in patients with dyslipidemia assisted by general practitioners: Dislip-EM study protocol. 2011 , 12, 125	6

1342	Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observational study. 2011 , 11, 144	3
1341	Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. 2011 , 11, 704	21
1340	Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D Survey. 2011 , 11, 754	108
1339	Development and pilot of an internationally standardized measure of cardiovascular risk management in European primary care. 2011 , 11, 70	9
1338	Precision of a point of care testing device for lipid profiling. 2011 , 113, 1230-1234	2
1337	What are effective strategies to communicate cardiovascular risk information to patients? A systematic review. 2011 , 82, 169-81	89
1336	Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study. 2011 , 1, e000132	29
1335	The new Sheffield risk and benefit tables for the elderly. 2011 , 104, 3-12	6
1334	Biomarkers for predicting postmenopausal coronary heart disease. 2011 , 5, 485-95	3
1333	Surrogates of Large Artery versus Small Artery Stiffness and Ankle-Brachial Index. 2011 , 20, 167-72	2
1332	Stable angina pectoris: head-to-head comparison of prognostic value of cardiac CT and exercise testing. 2011 , 261, 428-36	28
1331	Sexual dysfunction in rheumatoid arthritis: a hot but sensitive issue. 2011 , 20, 1134-7	9
1330	High-sensitivity C-reactive protein and ankle brachial index in a finnish cardiovascular risk population. 2011 , 20, 43-8	4
1329	Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk $\geq 5\%$ or Framingham risk $>20\%$: post hoc analyses of the JUPITER trial requested by European health authorities. <i>European Heart Journal</i> , 2011 , 32, 75-83	9.5 27
1328	Carotid intima-media thickness determined vascular age and the Framingham Risk Score. 2011 , 10, 173-9	10
1327	Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. 2011 , 123, 1377-83	160
1326	Useful tests of usefulness of new risk factors: tools for assessing reclassification and discrimination. 2011 , 39, 439-41	41
1325	Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?. 2011 , 62, 167-75	48

1324	Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. 2011 , 28, 684-722		109
1323	Use of reclassification for assessment of improved prediction: an empirical evaluation. 2011 , 40, 1094-105		50
1322	Screening for cardiovascular disease: concerns with a Norwegian proposal. 2011 , 18, 165-6		0
1321	Sociopsychological correlates of smoking among male university students in Bangladesh. 2011 , 23, 555-67		10
1320	Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. 2011 , 123, 1243-62		1065
1319	Risk of sports: do we need a pre-participation screening for competitive and leisure athletes?. <i>European Heart Journal</i> , 2011 , 32, 934-44	9.5	140
1318	Belgian global implementation of cardiovascular and stroke risk assessment study: methods and baseline data of the BELGICA-STROKE STUDY. 2011 , 18, 635-41		2
1317	Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model. 2011 , 2011, 597163		4
1316	Predicting CHD risk in France: a pooled analysis of the D.E.S.I.R., Three City, PRIME, and SU.VI.MAX studies. 2011 , 18, 175-85		15
1315	Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. 2011 , 124, 741-5		29
1314	Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. 2011 , 70, 719-21		34
1313	Development of a cardiovascular risk score for use in low- and middle-income countries. 2011 , 141, 1375-80		7
1312	Estimating the proportion of Danes at high risk of fatal cardiovascular disease. 2011 , 39, 571-6		2
1311	Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. 2011 , 183, E1135-50		44
1310	An international risk prediction algorithm for the onset of generalized anxiety and panic syndromes in general practice attendees: predictA. 2011 , 41, 1625-39		22
1309	Predicting the onset of major depression in primary care: international validation of a risk prediction algorithm from Spain. 2011 , 41, 2075-88		33
1308	Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis. 2011 , 2011, 417813		4
1307	Oximeter-based autonomic state indicator algorithm for cardiovascular risk assessment. 2011 , 139, 253-259		20

1306	Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. 2011 , 33, 209-17		46
1305	Distribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results). 2011 , 1, e000068		27
1304	The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. 2011 , 1, e000363		25
1303	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , 2011 , 32, 581-9	9.5	153
1302	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. <i>European Heart Journal</i> , 2011 , 32, 2143-52	9.5	197
1301	Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. <i>European Heart Journal</i> , 2011 , 32, 2326-32	9.5	73
1300	The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. 2011 , 26, 2820-7		34
1299	Willingness to pay for a cardiovascular prevention program in highly educated adults: a randomized controlled trial. 2011 , 27, 283-9		5
1298	Relationships between body mass index, cardiovascular mortality, and risk factors: a report from the SCORE investigators. 2011 , 18, 731-42		85
1297	A tale of three labels: translating the JUPITER trial data into regulatory claims. 2011 , 8, 417-22		2
1296	Prediction of coronary heart disease risk by Framingham and SCORE risk assessments varies by socioeconomic position: results from a study in British men. 2011 , 18, 186-93		21
1295	Lipid parameters for measuring risk of cardiovascular disease. 2011 , 8, 197-206		144
1294	CUORE project: implementation of the 10-year risk score. 2011 , 18, 642-9		11
1293	SCORE model underestimates cardiovascular risk in hypertensive patients: results of the Polish Hypertension Registry. 2011 , 20, 342-7		2
1292	A novel approach to office blood pressure measurement: 30-minute office blood pressure vs daytime ambulatory blood pressure. 2011 , 9, 128-35		44
1291	An appropriate SCORE to assess cardiovascular risk in hypertension?. 2011 , 20, 320-1		
1290	Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. 2011 , 104, 13-26		60
1289	Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. 2011 , 89, 286-95		32

1288	Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. 2011 , 38, 1071-8	17
1287	Primary prevention of stroke: blood pressure, lipids, and heart failure. <i>European Heart Journal</i> , 2011 , 32, 545-52	9.5 52
1286	Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. 2011 , 4, 371-80	140
1285	Continental-Mediterranean and rural-urban differences in cardiovascular risk factors in Croatian population. 2011 , 52, 566-75	21
1284	Frequency and characteristics of myocardial ischemia recorded during stress echocardiography in patients with high coronary risk. 2011 , 68, 393-8	3
1283	Being at risk for cardiovascular disease: perceptions and preventive behavior in people with and without a known genetic predisposition. 2012 , 17, 511-21	30
1282	Blood pressure and global risk assessment in a Swedish population. 2012 , 2012, 835812	1
1281	Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. 2012 , 9, e1001361	26
1280	Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. 2012 , 39, 2118-26	47
1279	Every unhealthy population is unhealthy in its own way; population risk assessment: common and specific challenges. 2012 , 66, 857-8	1
1278	Predictive risk algorithms in a population setting: an overview. 2012 , 66, 859-65	28
1277	Distribution of short and lifetime risks for cardiovascular disease in Italians. 2012 , 19, 723-30	56
1276	Development, implementation and yield of a cardiometabolic health check. 2012 , 29, 174-81	5
1275	A systematic review on the application of cardiovascular risk prediction models in pharmacoconomics, with a focus on primary prevention. 2012 , 19, 42-53	4
1274	Risk estimation versus screening performance: a comparison of six risk algorithms for cardiovascular disease. 2012 , 19, 201-5	17
1273	Arterial ultrasound screening as a tool for coronary risk assessment in asymptomatic men and women. 2012 , 63, 282-8	9
1272	Population screening for coronary artery calcification does not increase mental distress and the use of psychoactive medication. 2012 , 27, 202-6	13
1271	Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. 2012 , 60, 1117-23	65

1270	Assessing fitness, predicting outcome, and the missing axis. 2012 , 109, 35-9	6
1269	Subclinical atherosclerosis imaging comes of age: coronary artery calcium in primary prevention. 2012 , 27, 508-14	5
1268	Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. 2012 , 19, 558-64	52
1267	Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 2012 , 43, 1998-2027	105
1266	Sudden cardiac death in athletes: what is the role of screening?. 2012 , 27, 41-8	26
1265	Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. 2012 , 19, 541-50	74
1264	Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function. 2012 , 19, 840-8	12
1263	Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study. 2012 , 19, 1074-81	9
1262	An evidence-based score to detect prevalent peripheral artery disease (PAD). 2012 , 17, 342-51	14
1261	Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. 2012 , 27, 1873-80	102
1260	Arterial elasticity and oxidized LDL among men with metabolic syndrome and different 10-year cardiovascular risk estimated by FINRISK and SCORE models. 2012 , 44, 503-12	5
1259	Panoptic total cardiovascular risk prediction using all predictors versus optimized risk assessment using variable subsets. 2012 , 8, 765-78	4
1258	Protocol for measuring carotid intima-media thickness that best correlates with cardiovascular risk and target organ damage. 2012 , 25, 955-61	34
1257	Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. <i>European Heart Journal</i> , 2012 , 33, 183-90	9.5 118
1256	Cardiovascular risk factor(s) prevalence in Greek hypertensives. Effect of gender and age. 2012 , 26, 443-51	8
1255	Comparison of photoplethysmographic and arterial tonometry-derived indices of arterial stiffness. 2012 , 35, 228-33	27
1254	Does aortic stiffness improve the prediction of coronary heart disease in elderly? The Rotterdam Study. 2012 , 26, 28-34	27
1253	Apolipoprotein E gene polymorphisms are strong predictors of inflammation and dyslipidemia in rheumatoid arthritis. 2012 , 39, 218-25	22

1252	Arterial stiffness as surrogate end point: needed clinical trials. 2012 , 60, 518-22	77
1251	Changes in medical treatment six months after risk stratification with HeartScore and coronary artery calcification scanning of healthy middle-aged subjects. 2012 , 19, 1496-502	5
1250	Ankle-brachial index and health-related quality of life. 2012 , 19, 901-7	16
1249	Estratificaci3n de riesgo cardiovascular en la poblaci3n chilena. 2012 , 23, 657-665	
1248	High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. 2012 , 6, 19-34	34
1247	Clinical validation of genetic markers for improved risk estimation. 2012 , 19, 25-32	7
1246	Carotid intima-media thickness and the prediction of vascular events. 2012 , 17, 239-48	36
1245	Do novel biomarkers add to existing scores of total cardiovascular risk?. 2012 , 19, 14-7	11
1244	Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. 2012 , 60, 898-905	86
1243	Process evaluation of a lifestyle intervention to prevent diabetes and cardiovascular diseases in primary care. 2012 , 13, 696-706	29
1242	Cardiovascular risk in patients with psoriatic arthritis. 2012 , 2012, 714321	37
1241	Cardiovascular disease risk factor patterns and their implications for intervention strategies in Vietnam. 2012 , 2012, 560397	26
1240	Framingham risk score and alternatives for prediction of coronary heart disease in older adults. 2012 , 7, e34287	68
1239	Cardiac imaging: does radiation matter?. <i>European Heart Journal</i> , 2012 , 33, 573-8	9.5 58
1238	Assessing the impact of chronic kidney disease on individuals and populations: use of relative and absolute measures. 2012 , 27 Suppl 3, iii39-42	6
1237	Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of estimated kidney function at population level: findings from the National FINRISK Study. 2012 , 27, 3210-7	11
1236	Development and validation of a coronary risk prediction model for older U.S. and European persons in the Cardiovascular Health Study and the Rotterdam Study. 2012 , 157, 389-97	48
1235	A cardiovascular risk calculator for renal transplant recipients. 2012 , 94, 57-62	51

1234	SYNTAX, STS and EuroSCORE - how good are they for risk estimation in atherosclerotic heart disease?. 2012 , 108, 1065-71	14
1233	The threat of ethnicity for cardiovascular disease risk. 2012 , 30, 269-70	
1232	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. 2012 , 30, 1056-64	63
1231	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. 2012 , 30, 513-21	7
1230	Impact of vascular aging on cardiovascular disease: the role of telomere biology. 2012 , 30 Suppl, S9-12	13
1229	Managing metabolic syndrome in women. 2012 , 37, 14-20; quiz 20-1	2
1228	A cost-utility analysis of hypertension treatment in Greece: assessing the impact of age, sex and smoking status, on outcomes. 2012 , 30, 227-34	5
1227	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. 2012 , 30, 1928-36	45
1226	Shooting beyond score: targeting organ disease to improve risk prediction in hypertension. 2012 , 30, 1909-10	1
1225	De Gruyter. 2012 , 18, 1-6	19
1224	The role of exercise testing in the interventional era: a shift of focus. 2012 , 4, 577-583	
1223	Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. 2012 , 14, 428-37	29
1222	Cardiovascular risk management after a hypertensive disorder of pregnancy. 2012 , 60, 1368-73	64
1221	Cardiovascular risk. 2012 , 74, 396-410	41
1220	Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. 2012 , 14, 721-31	18
1219	Atorvastatin calcium plus amlodipine for the treatment of hypertension. 2012 , 13, 2673-85	10
1218	Common carotid intima-media thickness in cardiovascular risk stratification of older people: the Rotterdam Study. 2012 , 19, 698-705	53
1217	Aspirin for primary prevention of cardiovascular disease events. 2012 , 32, 1020-35	26

1216 Protéine C réactive, homocystéine et risque cardiovasculaire. **2012**, 2012, 27-31

1215 A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. **2012**, 222, 564-6 6

1214 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). **2012**, 223, 1-68 286

1213 Patients with chronic gastrointestinal ischemia have a higher cardiovascular disease risk and mortality. **2012**, 224, 235-41 9

1212 Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. **2012**, 27, 267-74 15

1211 Psychological correlates in patients with different levels of hypertension. **2012**, 198, 154-60 19

1210 Age as a risk factor. **2012**, 96, 87-91 139

1209 Risques cardiovasculaires et médicaments. **2012**, 6, 11-13

1208 Riesgo cardiovascular en el lupus eritematoso sistémico: factores implicados y métodos para su valoración. **2012**, 13, 95-102 1

1207 [Cardiovascular risk in the 21st century: identifying risk in primary prevention. Controlling risk in secondary prevention]. **2012**, 65 Suppl 2, 3-9 11

1206 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *European Heart Journal*, **2012**, 33, 1635-701 9.5 2797

1205 Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. **2012**, 44 Suppl 1, S93-7 68

1204 Prevalence, awareness, treatment, and control of hypertension: rule of thirds in the Skaraborg project. **2012**, 30, 88-94 29

1203 Assessment of cardiovascular risk in primary health care. **2012**, 30, 101-6 6

1202 Non-invasive diagnostic testing for coronary artery disease in the hypertensive patient: potential advantages of a risk estimation-based algorithm. **2012**, 25, 1226-35 12

1201 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). **2012**, 19, 585-667 233

1200 Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. **2012**, 5, 467-73 131

1199 Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. **2012**, 26, 163-74 24

1198	An international model to predict recurrent cardiovascular disease. 2012 , 125, 695-703.e1	142
1197	[Multiplatform application to determine presence of metabolic syndrome and cardiovascular risk in patients with psoriasis]. 2012 , 103, 111-9	2
1196	Severe frailty and cognitive impairment are related to higher mortality in 12-month follow-up of nursing home residents. 2012 , 55, 22-4	60
1195	Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. 2012 , 155, 279-84	31
1194	Lipid core burden index and Framingham score: can a Systemic Risk Score predict lipid core burden in non-culprit coronary artery?. 2012 , 156, 211-3	4
1193	Constructing a point-based prediction model for the risk of coronary artery disease in a Chinese community: a report from a cohort study in Taiwan. 2012 , 157, 263-8	17
1192	A simple adaptation method improved the interpretability of prediction models for composite end points. 2012 , 65, 946-53	3
1191	Probability of fractures predicted by FRAX [®] and observed incidence in the Spanish ECOSAP Study cohort. 2012 , 50, 373-7	56
1190	Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. 2012 , 98, 83-90	16
1189	Aragon workers' health study--design and cohort description. 2012 , 12, 45	50
1188	Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland. 2012 , 12, 98	11
1187	Is the Scale for Measuring Motivational Interviewing Skills a valid and reliable instrument for measuring the primary care professionals motivational skills?: EVEM study protocol. 2012 , 13, 112	7
1186	Lack of adherence to hypertension treatment guidelines among GPs in southern Sweden-a case report-based survey. 2012 , 13, 34	8
1185	Randomized controlled trial on cardiovascular risk management by practice nurses supported by self-monitoring in primary care. 2012 , 13, 90	19
1184	Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study. 2012 , 12, 610	13
1183	Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial. 2012 , 12, 671	12
1182	Self-reported leisure time physical activity: a useful assessment tool in everyday health care. 2012 , 12, 693	82
1181	CARRS Surveillance study: design and methods to assess burdens from multiple perspectives. 2012 , 12, 701	85

1180	The effect of modifiable risk factors on geographic mortality differentials: a modelling study. 2012 , 12, 79	5
1179	Evaluation of risk equations for prediction of short-term coronary heart disease events in patients with long-standing type 2 diabetes: the Translating Research into Action for Diabetes (TRIAD) study. 2012 , 12, 12	10
1178	Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. 2012 , 11, 101	35
1177	Vulnerable atherosclerotic plaque: from the basic research laboratory to the clinic. 2012 , 123, 248-53	7
1176	Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study. 2012 , 8, 563-8	2
1175	Multiplatform Application to Determine Presence of Metabolic Syndrome and Cardiovascular Risk in Patients With Psoriasis. 2012 , 103, 111-119	
1174	Understanding the role of depression and anxiety on cardiovascular disease risk, using structural equation modeling; the mediating effect of the Mediterranean diet and physical activity: the ATTICA study. 2012 , 22, 630-7	34
1173	Avoidant personality problems--their association with somatic and mental health, lifestyle, and social network. A community-based study. 2012 , 53, 813-21	16
1172	[Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011]. 2012 , 30, 517-27	15
1171	Metabolic syndrome and vascular risk estimation in a Mediterranean non-diabetic population without cardiovascular disease. 2012 , 23, 558-63	9
1170	Assessment of cardiovascular risk in workers occupationally exposed to lead without clinical presentation of cardiac involvement. 2012 , 34, 351-357	5
1169	Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. 2012 , 108, 216-27	31
1168	Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden. 2012 , 108, 207-15	3
1167	Estimaci3n del riesgo cardiovascular global en pacientes diab3ticos. 2012 , 11, 1050-1054	
1166	Tratamiento de las hiperlipidemias. 2012 , 11, 1145-1152	
1165	All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. 2012 , 6, 193-200	13
1164	Participation, socioeconomic status and group or individual counselling intervention in individuals at high risk for type 2 diabetes: one-year follow-up study of the FIN-D2D-project. 2012 , 6, 277-83	10
1163	Rheumatoid arthritis is an independent risk factor for an increased augmentation index regardless of the coexistence of traditional cardiovascular risk factors. 2012 , 42, 17-22	14

1162	Comparison of the effect of the metabolic syndrome and multiple traditional cardiovascular risk factors on vascular function. 2012 , 87, 968-75	31
1161	[Diagnostic criteria for hypoalphalipoproteinemia and the threshold associated with cardiovascular protection in a Mexican Mestizo population]. 2012 , 138, 551-6	0
1160	Subclinical Atherosclerosis and Primary Prevention. 2012 , 15-28	
1159	Screening and High CV Risk Patients. 2012 , 289-292	
1158	The effects of angiotensin receptor blockers vs. calcium channel blockers on the acute exercise-induced inflammatory and thrombotic response. 2012 , 35, 1193-200	8
1157	Dietary strategy for prevention and management of dyslipidemia: international guidelines. 2012 , 5, 187-193	
1156	Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach. 2012 , 20, 320-5	14
1155	European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). 2012 , 13, 403-88	196
1154	Estratificaci3n del riesgo cardiovascular: importancia y aplicaciones. 2012 , 12, 8-11	
1153	Treatment targets in the management of dyslipidemias: which targets in whom?. 2012 , 14, 692-700	3
1152	The International Database of HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO): moving from baseline characteristics to research perspectives. 2012 , 35, 1072-9	26
1151	Clinical utility of novel biomarkers for cardiovascular disease risk stratification. 2012 , 7 Suppl 3, S263-70	4
1150	Prediction models for risk classification in cardiovascular disease. 2012 , 39, 1959-69	8
1149	Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model. 2012 , 32, 3741-9	13
1148	Changes to the statin prescribing policy in Belgium: potential impact in clinical and economic terms. 2012 , 12, 225-32	5
1147	Abdominal obesity and cardiovascular disease: is inflammation the missing link?. 2012 , 28, 642-52	84
1146	The science of risk models. 2012 , 19, 7-13	10
1145	Investigation on cardiovascular risk prediction using genetic information. 2012 , 16, 795-808	18

1144	Exercise blood pressure and the risk of future hypertension. 2012 , 26, 691-5	33
1143	Cardiovascular screening in general practice in a low SES area. 2012 , 13, 117	5
1142	Health-related quality of life in diabetic people with different vascular risk. 2012 , 12, 812	21
1141	The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. 2012 , 14, R117	43
1140	Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. 2012 , 14, R46	106
1139	Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnesic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. 2012 , 4, 51	18
1138	Socioeconomic inequalities in the prevalence of nine established cardiovascular risk factors in a southern European population. 2012 , 7, e37158	25
1137	Women up, men down: the clinical impact of replacing the Framingham Risk Score with the Reynolds Risk Score in the United States population. 2012 , 7, e44347	14
1136	Blood cholesterol level and risk of stroke in community-based or worksite cohort studies: a review of Japanese cohort studies in the past 20 years. 2012 , 61, 79-88	16
1135	Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study. 2012 , 8, 177-86	10
1134	European guidance on management of dyslipidaemias. 2012 , 7, 242-243	
1133	Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. 2012 , 4, 1-11	16
1132	Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. 2012 , 4, 135-43	5
1131	VIP in construction: systematic development and evaluation of a multifaceted health programme aiming to improve physical activity levels and dietary patterns among construction workers. 2012 , 12, 89	21
1130	Measures of interobserver agreement and reliability, 2nd edition. 2012 , 11, 347-347	
1129	Arterial hypertension in degenerative non-severe aortic stenosis. 2012 , 7, 95-99	
1128	Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. 2012 , 21, 1027-35	21
1127	Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid. 2012 , 21, 463-9	1

1126	A review on metaanalysis of biomarkers: promises and pitfalls. 2012 , 58, 1192-204	12
1125	Does Cardiovascular Ultrasound Have a Role in Assessment of Cardiovascular Risk in Asymptomatic Persons?. 2012 , 6, 164-175	
1124	Sexual dysfunction in rheumatoid arthritis patients: arthritis and beyond. 2012 , 31, 601-6	52
1123	Managing cardiovascular risk in patients with chronic inflammatory diseases. 2012 , 31, 585-94	16
1122	Coronary artery calcification score and carotid intima-media thickness in patients with hemophilia. 2012 , 10, 23-9	36
1121	Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic load. 2012 , 10, 20-2	11
1120	Family history of diabetes and effectiveness of lifestyle counselling on the cardio-metabolic risk profile in individuals at high risk of Type 2 diabetes: 1-year follow-up of the FIN-D2D project. 2012 , 29, 207-11	12
1119	Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study. 2012 , 18, 159-68	27
1118	Added value of CAC in risk stratification for cardiovascular events: a systematic review. 2012 , 42, 110-6	31
1117	Dissociation of blood pressure and resistance artery structure: potential clinical implications. 2012 , 110, 73-9	7
1116	New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. 2012 , 66, 622-30	16
1115	Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. 2012 , 9, 54-67	45
1114	[Cardiovascular disease based on gender: myths and evidence]. 2012 , 212, 81-3	0
1113	The antihypertensive treatment effect on left ventricular diastolic function is reflected in exercise electrocardiogram. 2012 , 45, 28-35	2
1112	Coronary heart disease diagnosis by artificial neural networks including genetic polymorphisms and clinical parameters. 2012 , 59, 190-4	50
1111	Cocoa intake and arterial stiffness in subjects with cardiovascular risk factors. 2012 , 11, 8	10
1110	The prevalence and management of cardiovascular risk factors in immigrant groups in Switzerland. 2012 , 57, 63-77	6
1109	[Assessment of elderly intensive care patients]. 2012 , 107, 29-31	0

1108	Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. 2012 , 31, 35-9	25
1107	Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores. 2013 , 27, 1566-70	17
1106	A computer tool for cardiovascular risk estimation according to Framingham and SCORE equations. 2013 , 19, 277-84	4
1105	Motivational interviewing and problem solving treatment to reduce type 2 diabetes and cardiovascular disease risk in real life: a randomized controlled trial. 2013 , 10, 47	51
1104	Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). 2013 , 14, 22	31
1103	Predictive models for type 2 diabetes onset in middle-aged subjects with the metabolic syndrome. 2013 , 5, 36	8
1102	Updated fracture incidence rates for the Italian version of FRAX [®] . 2013 , 24, 859-66	28
1101	Adherence to preventive statin therapy according to socioeconomic position. 2013 , 69, 1553-63	51
1100	Cardiovascular Evaluation of Master Athletes and Middle-aged/Senior Individuals Engaged in Leisure-time Sport Activities. 2013 , 5, 33-42	
1099	Metabolic syndrome, adiponectin, and cardiovascular risk in Spain (the Segovia study): impact of consensus societies criteria. 2013 , 11, 309-18	15
1098	Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: a randomized controlled trial. 2013 , 14, 45	12
1097	Cardiovascular risk estimation in women with a history of hypertensive pregnancy disorders at term: a longitudinal follow-up study. 2013 , 13, 126	48
1096	Assessment of total cardiovascular risk using WHO/ISH risk prediction charts in three low and middle income countries in Asia. 2013 , 13, 539	56
1095	Smoking cessation and the risk of cardiovascular disease outcomes predicted from established risk scores: results of the Cardiovascular Risk Assessment among Smokers in Primary Care in Europe (CV-ASPIRE) study. 2013 , 13, 362	22
1094	Cost-effectiveness of cardiovascular risk management by practice nurses in primary care. 2013 , 13, 148	5
1093	Similar decline in mortality rate of older persons with and without type 2 diabetes between 1993 and 2004 the Icelandic population-based Reykjavik and AGES-Reykjavik cohort studies. 2013 , 13, 36	15
1092	Impact of effectiveness information format on patient choice of therapy and satisfaction with decisions about chronic disease medication: the "Influence of intervention Methodologies on Patient Choice of Therapy (IMPACT)" cluster-randomised trial in general practice. 2013 , 13, 76	7
1091	Blood glucose may be an alternative to cholesterol in CVD risk prediction charts. 2013 , 12, 24	5

1090	Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. 2013 , 36, 3498-502	31
1089	OPTImal CARDiac REhabilitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a randomised, controlled trial to investigate the benefits of expanded educational and behavioural intervention programs. 2013 , 21, 324-30	19
1088	Prediction and classification of cardiovascular disease risk in older adults with diabetes. 2013 , 56, 275-83	22
1087	Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. 2013 , 56, 92-100	33
1086	Subclinical cardiovascular disease assessment in persons with diabetes. 2013 , 15, 358	6
1085	Arterial Stiffness and Cardiovascular Events in Hypertensives. 2013 , 7, 238-243	
1084	A multicenter evaluation of the appropriate use of single-photon emission tomography myocardial perfusion imaging in Greece. 2013 , 20, 275-83	13
1083	Better risk assessment with glycated hemoglobin instead of cholesterol in CVD risk prediction charts. 2013 , 28, 551-5	8
1082	Functional consequences of platelet binding to T lymphocytes in inflammation. 2013 , 94, 521-9	42
1081	High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. 2013 , 168, 5126-34	176
1080	Gender aspects in patients with angina and unobstructed coronary arteries. 2013 , 8, 25-31	4
1079	[Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. Author's reply]. 2013 , 31, 269	
1078	Characterization of lipid profile in primary health care users in Portugal. 2013 , 32, 987-996	6
1077	[Characterization of lipid profile in primary health care users in Portugal]. 2013 , 32, 987-96	10
1076	Metabolic syndrome in the prevention of cardiovascular diseases and diabetes--still a matter of debate?. 2013 , 67, 518-21	22
1075	Risk-adjusted versus overall blood pressure control rate for identifying the need for intensified cardiovascular risk reduction: lessons from a cross-sectional study. 2013 , 20, 972-9	3
1074	Diagnóstico de aterosclerosis en prevención primaria. 2013 , 11, 2420-2423	
1073	Cardiovascular risk in rheumatoid arthritis: how to lower the risk?. 2013 , 231, 163-72	48

1072	Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome--results from the countrywide TARGET study. 2013 , 168, 922-7	26
1071	Arterial stiffness parameters: how do they differ?. 2013 , 231, 359-64	31
1070	Pulse wave velocity, pulse pressure and number of carotid or femoral plaques improve prediction of cardiovascular death in a population at low risk. 2013 , 27, 529-34	22
1069	Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study. 2013 , 15, R128	17
1068	SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. 2013 , 15, R91	33
1067	Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. 2013 , 13, 130	29
1066	Increased urinary IgM excretion in patients with chest pain due to coronary artery disease. 2013 , 13, 72	12
1065	Which patient and treatment factors are related to successful cardiovascular risk score reduction in general practice? Results from a randomized controlled trial. 2013 , 14, 123	2
1064	The "Health Coaching" programme: a new patient-centred and visually supported approach for health behaviour change in primary care. 2013 , 14, 100	36
1063	Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. 2013 , 11, 170	29
1062	Effectiveness and tolerability of a trandolapril-based antihypertensive treatment regimen over 12 months in actual clinical care across Canada. 2013 , 33, 535-43	
1061	Screening results for subclinical coronary artery calcification in asymptomatic individuals in relation to a detailed parental history of premature coronary heart disease. 2013 , 28, 301-10	4
1060	The utilization of carotid artery imaging beyond metabolic scores and high-sensitivity CRP in screening intermediate-to-high Framingham risk of asymptomatic Taiwanese population. 2013 , 29, 765-75	3
1059	Evaluation of the performance of existing non-laboratory based cardiovascular risk assessment algorithms. 2013 , 13, 123	8
1058	Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach. 2013 , 13, 146	14
1057	How does gender influence the recognition of cardiovascular risk and adherence to self-care recommendations?: A study in Polish primary care. 2013 , 14, 165	12
1056	Management of women with systemic lupus erythematosus. 2013 , 75, 207-14	9
1055	The determinants of cost-effectiveness potential: an historical perspective on lipid-lowering therapies. 2013 , 31, 445-54	3

1054	Nurse management of cardiovascular risk factors in rheumatoid arthritis. 2013 , 22, 813-7	5
1053	Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. 2013 , 29, 589-96	7
1052	Longitudinal analysis of cardiovascular risk parameters in women with a history of hypertensive pregnancy disorders: the Doetinchem Cohort Study. 2013 , 120, 1333-9	13
1051	Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. 2013 , 31, 172-80	32
1050	A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea. 2013 , 45, 855-62	6
1049	. 2013 , 25, 2356-2366	32
1048	Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. 2013 , 74, 25-30	33
1047	Initial Evaluation and Approach to the Patient with Hypertension. 2013 , 463-473	
1046	Prediction of Global Cardiovascular Risk in Hypertension. 2013 , 144-150	
1045	European and British Guidelines on Hypertension. 2013 , 433-440	
1044	Is there a role for thoracic aortic calcium to fine-tune cardiovascular risk prediction?. 2013 , 29, 217-9	8
1043	Non-invasive assessments reveal that more than half of randomly selected middle-aged individuals have evidence of subclinical atherosclerosis: a DanRisk substudy. 2013 , 29, 301-8	15
1042	Cardiovascular disease: Prevention and treatment in renal transplant recipients. 2013 , 2, 184-196	
1041	Impaired glucose homeostasis in non-diabetic Greek hypertensives with diabetes family history. Effect of the obesity status. 2013 , 7, 294-304	2
1040	Tendencia de la mortalidad por enfermedades cardiovasculares en Andalucía y España entre 1990 y 2010. 2013 , 48, 31-37	6
1039	[Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease prevention]. 2013 , 25, 92-7	1
1038	Association between hematocrit in late adolescence and subsequent myocardial infarction in Swedish men. 2013 , 168, 3588-93	16
1037	Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study. 2013 , 106, 93-102	18

1036	Benefit of adding lifestyle-related risk factors for prediction of cardiovascular death among cardiac patients. 2013 , 163, 196-200	9
1035	[Vascular risk in outpatient from Internal Medicine departments. MICARE Study]. 2013 , 140, 246-54	7
1034	Evaluation of framingham and systematic coronary risk evaluation scores by coronary computed tomographic angiography in asymptomatic adults. 2013 , 111, 700-4	10
1033	Inflammation in young adulthood is associated with myocardial infarction later in life. 2013 , 165, 164-9	16
1032	[Metabolic Syndrome and Bipolar Affective Disorder: A Review of the Literature]. 2013 , 42, 283-91	4
1031	The role of regret minimisation in lifestyle choices affecting the risk of coronary heart disease. 2013 , 32, 253-60	28
1030	Long-term effect of persistent smoking on the prognosis of Chinese male patients after percutaneous coronary intervention with drug-eluting stent implantation. 2013 , 62, 283-8	11
1029	Cardiovascular risk profile and cognitive function in young, middle-aged, and elderly subjects. 2013 , 44, 1543-9	49
1028	Cardiovascular risk profile of mothers of a Portuguese birth cohort: a survey 4 years after delivery. 2013 , 57, 494-9	2
1027	Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. 2013 , 164, 70-6	30
1026	Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. 2013 , 147, 187-192	24
1025	A qualitative participatory study to identify experiences of coronary heart disease patients to support the development of online self-management services. 2013 , 82, 1183-94	24
1024	Early detection and invasive passivation of future culprit lesions: a future potential or an unrealistic pursuit of chimeras?. 2013 , 165, 869-881.e4	18
1023	Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. 2013 , 167, 2904-11	98
1022	[Relevance of diabetes in high cardiovascular risk hypertensive patients]. 2013 , 141, 287-91	1
1021	[Estimation of the "vascular age" based on body mass index in a population in primary prevention. Association with subclinical carotid atherosclerosis]. 2013 , 140, 255-9	4
1020	Galectin-3: relation to infarct scar and left ventricular function after myocardial infarction. 2013 , 163, 335-337	25
1019	Risk estimation scores do not mean everything: what about plaque burden and prognosis?. 2013 , 111, 1374-5	

1018	Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus. 2013 , 39, 389-96	19
1017	Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography. 2013 , 111, 851-6	19
1016	The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. 2013 , 15, 306	40
1015	Genetics and Cardiovascular Risk Prediction: A Step Toward Personalized Medicine?. 2013 , 7, 33-45	1
1014	Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET [®] (the STRONG DUET study). 2013 , 30, 60-70	5
1013	Risk prediction in stable angina pectoris. 2013 , 43, 141-51	6
1012	Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either . 2013 , 228, 265-9	19
1011	ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. 2013 , 27, 492-6	11
1010	Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment. 2013 , 8, 69-79	7
1009	Epidemiology of the Metabolic Syndrome. 2013 , 7-16	4
1008	Scaling up chronic disease prevention interventions in lower- and middle-income countries. 2013 , 34, 317-35	43
1007	Can we really predict risk of cancer?. 2013 , 37, 349-52	18
1006	Personalized cardiovascular medicine: concepts and methodological considerations. 2013 , 10, 308-16	23
1005	Sudden Death in Athletes. 2013 , 363-380	
1004	Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. 2013 , 109, 60-7	64
1003	Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease. 2013 , 112, 27-33	23
1002	Multivariable Evaluation of Candidates for Cardiovascular Disease. 2013 , 1-17	
1001	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. 2013 , 22, 193-278	286

1000	Cardiovascular risk and atherosclerosis prevention. 2013 , 22, 16-8		42
999	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	34 ⁰⁰
998	Assessing improvement in disease prediction using net reclassification improvement: impact of risk cut-offs and number of risk categories. 2013 , 28, 25-33		22
997	A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality. 2013 , 20, 827-36		14
996	The effects of a lifestyle intervention on leisure-time sedentary behaviors in adults at risk: the Hoorn Prevention Study, a randomized controlled trial. 2013 , 57, 351-6		23
995	Cardiovascular Disease Risk Prediction - Integration into Clinical Practice. 2013 , 7, 346-353		2
994	Clinical management of coronary heart disease in hypertension : practical recommendations from the Italian Society of Hypertension (SIIA). 2013 , 20, 129-34		5
993	Metabolic syndrome model definitions predicting type 2 diabetes and cardiovascular disease. 2013 , 36, 362-8		41
992	Design and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension. 2013 , 27, 210-5		6
991	Cardiovascular disease risk scores in identifying future frailty: the Whitehall II prospective cohort study. 2013 , 99, 737-42		44
990	Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. 2013 , 99, 1421-30		80
989	Stroke and coronary heart disease: predictive power of standard risk factors into old age--long-term cumulative risk study among men in Gothenburg, Sweden. <i>European Heart Journal</i> , 2013 , 34, 1068-74	9.5	13
988	Improved peri-operative risk stratification in non-cardiac surgery: going beyond established clinical scores. <i>European Heart Journal</i> , 2013 , 34, 796-8	9.5	3
987	Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. 2013 , 28, 2805-15		14
986	Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>European Heart Journal</i> , 2013 , 34, 451-61	9.5	34
985	ESC core curriculum for the general cardiologist (2013). <i>European Heart Journal</i> , 2013 , 34, 2381-411	9.5	56
984	Hypertension guidelines: more challenges highlighted by Europe. 2013 , 62, 660-5		19
983	Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. <i>European Heart Journal</i> , 2013 , 34, 2368-80	9.5	178

982	Clinical scores for predicting recurrence after transient ischemic attack or stroke: how good are they?. 2013 , 44, 1198-203	12
981	From guidelines to clinical practice: cardiovascular risk management in inflammatory arthritis patients. 2013 , 18, 424-8	7
980	Utility of established cardiovascular disease risk score models for the 10-year prediction of disease outcomes in women. 2013 , 11, 425-35	8
979	Carotid Artery Intima Media Thickness and HsCRP; Predictors for Atherosclerosis in Prediabetic Patients?. 2013 , 29, 495-9	8
978	Association of cardiovascular risk using non-linear heart rate variability measures with the framingham risk score in a rural population. 2013 , 4, 186	23
977	Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients. 2013 , 2013, 389031	8
976	Metabolic syndrome in schizophrenia. 2013 , 35, 227-40	53
975	Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. 2013 , 65, 1675-83	19
974	Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people. 2013 , 36 Suppl 2, S292-300	4
973	Online risk engines and scoring tools in endocrinology. 2013 , 17, S601-7	2
972	Relation between pulmonary function and 10-year risk for cardiovascular disease among healthy men and women in Italy: the Moli-sani Project. 2013 , 20, 862-71	18
971	Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. 2013 , 72, 1968-74	48
970	A new, accurate predictive model for incident hypertension. 2013 , 31, 2142-50; discussion 2150	19
969	Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. 2013 , 10, 99-114	5
968	Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. 2013 , 5, 166-81	33
967	Improving assessment of cardiovascular disease risk by using family history: an integrative literature review. 2013 , 28, E18-27	17
966	Clinical profile of Spanish postmenopausal women with a diagnosis of osteoporosis and risk factors for endometrial pathology, breast cancer, and cardiovascular disease. 2013 , 20, 852-9	4
965	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 , 31, 1281-357	3363

964	Age and gender differences of endothelial function in 4739 healthy adults: the HUNT3 Fitness Study. 2013 , 20, 531-40	70
963	A program of 3 physical therapy modalities improves peripheral arterial disease in diabetes type 2 patients: a randomized controlled trial. 2013 , 28, 74-82	11
962	Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. 2013 , 72, 1764-70	101
961	Pharmacotherapeutic Follow-up and Pharmacogenetics of CYP2C9 and CYP3A4 in Antihypertensive Therapy: A Pilot Study in a Community Pharmacy. 2013 , 47, 489-494	1
960	Global Cardiovascular Therapy. 2013 , 75-82	
959	Physical fitness and risk for heart failure and coronary artery disease. 2013 , 6, 627-34	100
958	Association of type D personality with unhealthy lifestyle, and estimated risk of coronary events in the general Icelandic population. 2013 , 20, 322-30	48
957	One year follow-up of patients with screen-detected metabolic syndrome in primary care: an observational study. 2013 , 30, 40-7	4
956	Predicting onset of major depression in general practice attendees in Europe: extending the application of the predictD risk algorithm from 12 to 24 months. 2013 , 43, 1929-39	14
955	Public health significance of four cardiovascular risk factors assessed 25 years ago in a low prevalence country. 2013 , 20, 151-60	4
954	Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. 2013 , 28, 554-60	38
953	Differences in predicted cardiovascular risk in Sinhalese and Tamils in Sri Lanka compared with Sri Lankans in Norway. 2013 , 25, 452-62	2
952	Cholesteryl ester transfer protein in patients with rheumatoid arthritis. 2013 , 40, 1040-7	13
951	Peripheral arterial disease in the Middle East: Underestimated predictor of worse outcome. 2013 , 2013, 98-113	4
950	Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigation-The POWER Survey. 2013 , 2013, 165789	2
949	Assessment of cardiovascular disease risk in South asian populations. 2013 , 2013, 786801	28
948	Combining personality traits with traditional risk factors for coronary stenosis: an artificial neural networks solution in patients with computed tomography detected coronary artery disease. 2013 , 2013, 814967	7
947	Long-term prediction of major coronary or ischaemic stroke event in a low-incidence Southern European population: model development and evaluation of clinical utility. 2013 , 3, e003630	4

946	Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. 2013 , 99, 866-72	103
945	Intersubject variability of blood analysis reference values: assessment of age and locality influence by means of a linear discriminant analysis model. 2013 , 27, 237-44	1
944	Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. 2013 , 65, 526-33	25
943	A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. 2013 , 32, 3158-80	110
942	Development of metabolic syndrome components in adults with a healthy obese phenotype: a 3-year follow-up. 2013 , 21, 1025-30	19
941	Economic evaluation of telmisartan, valsartan and losartan in combination with hydrochlorothiazide for treatment of mild-to-moderate hypertension in Greece: a cost-utility analysis. 2013 , 4, 81-88	2
940	Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. 2013 , 52, 45-52	121
939	Conventional and unconventional cardiovascular risk factors in men with erectile dysfunction. 2013 , 10, 305-8	4
938	Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. 2013 , 120, 924-31	84
937	Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?. 2013 , 15, 742-7	18
936	Evaluating cardiovascular risk using the tone-entropy algorithm. 2013 , 2013, 6139-41	
935	Vascular risk calculators: essential but flawed clinical tools?. 2013 , 127, 1929-31	9
934	Dietary information improves cardiovascular disease risk prediction models. 2013 , 67, 25-30	24
933	Novel and established anthropometric measures and the prediction of incident cardiovascular disease: a cohort study. 2013 , 37, 1579-85	34
932	Social factors and coping status in asymptomatic middle-aged Danes: association to coronary artery calcification. 2013 , 41, 737-43	5
931	Walking impairment questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status. 2013 , 6, 255-61	16
930	Arterial stiffness from monitoring of timing of korotkoff sounds predicts the occurrence of cardiovascular events independently of left ventricular mass in hypertensive patients. 2013 , 62, 161-7	14
929	Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. 2013 , 36, 3388-95	37

928	Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. 2013 , 72, 1771-6	43
927	Do obesity and parental history of myocardial infarction improve cardiovascular risk prediction?. 2013 , 20, 793-9	5
926	Is serum urate causally associated with incident cardiovascular disease?. 2013 , 52, 135-42	13
925	Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. 2013 , 39, 306-18	626
924	Arterial stiffness changes in patients with cardiovascular risk factors but normal carotid intima-media thickness. 2013 , 14, 622-8	13
923	Small artery structure during antihypertensive therapy is an independent predictor of cardiovascular events in essential hypertension. 2013 , 31, 791-7	56
922	Coronary artery calcification and ECG pattern of left ventricular hypertrophy or strain identify different healthy individuals at risk. 2013 , 31, 595-600; discussion 600	5
921	The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. 2013 , 95, 142-7	26
920	Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?. 2013 , 3, 367-378	4
919	Improved cardiovascular risk prediction using nonparametric regression and electronic health record data. 2013 , 51, 251-8	43
918	Prevalence of metabolically discordant phenotypes in a mediterranean population-The IMAP study. 2013 , 19, 758-68	4
917	Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immunocomplex production in patients with systemic sclerosis--a prospective case-series study. 2013 , 15, R105	31
916	Accuracy of anthropometric parameters in identification of high-risk patients predicted with cardiovascular risk models. 2013 , 346, 26-31	6
915	Classical and novel biomarkers for cardiovascular risk prediction in the United States. 2013 , 23, 158-62	43
914	Investigation on cardiovascular risk prediction using physiological parameters. 2013 , 2013, 272691	21
913	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. 2013 , 9, 788-95	19
912	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. 2013 , 109, 16-23	52
911	Proactive multifactorial intervention strategy reduces the risk of cardiovascular disease estimated with region-specific risk assessment models in Pacific Asian patients participating in the CRUCIAL trial. 2013 , 28, 1741-8	3

910	Population specific and up to date cardiovascular risk charts can be efficiently obtained with record linkage of routine and observational data. 2013 , 8, e56149	1
909	Excess Cardiovascular Risk Burden in Jamaican Women Does Not Influence Predicted 10-Year CVD Risk Profiles of Jamaica Adults: An Analysis of the 2007/08 Jamaica Health and Lifestyle Survey. 2013 , 8, e66625	19
908	Framingham risk score for prediction of cardiovascular diseases: a population-based study from southern Europe. 2013 , 8, e73529	29
907	Identification of cardiovascular risk components in urban Chinese with metabolic syndrome and application to coronary heart disease prediction: a longitudinal study. 2013 , 8, e84204	8
906	Hypertensive Patients and Their Management in Dentistry. 2013 , 2013, 1-8	8
905	Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. 2013 , 60, 1-14	45
904	Improving prediction algorithms for cardiometabolic risk in children and adolescents. 2013 , 2013, 684782	15
903	Carotid intima-media thickness and plaque in apparently healthy Japanese individuals with an estimated 10-year absolute risk of CAD death according to the Japan Atherosclerosis Society (JAS) guidelines 2012: the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). 2013 , 20, 755-66	35
902	Predictive value of adiponectin in patients with multivessel coronary atherosclerosis detected on computed tomography angiography. 2013 , 20, 767-76	16
901	Intercorrelations of lipoprotein subfractions and their covariation with lifestyle factors in healthy men. 2014 , 54, 174-80	8
900	Does inclusion of education and marital status improve SCORE performance in central and eastern Europe and former soviet union? findings from MONICA and HAPIEE cohorts. 2014 , 9, e94344	3
899	Association between 9p21 genomic markers and ischemic stroke risk: evidence based on 21 studies. 2014 , 9, e90255	16
898	Genetic risk score of NOS gene variants associated with myocardial infarction correlates with coronary incidence across Europe. 2014 , 9, e96504	9
897	Validity of cardiovascular risk prediction models in kidney transplant recipients. 2014 , 2014, 750579	17
896	Pharmacists' Use of Screening Tools to Estimate Risk of CVD: A Review of the Literature. 2014 , 2, 27-39	4
895	Antihypertensive drug therapy: a review based on recent guidelines. 2014 , 57, 1034	0
894	Cardiovascular disease risk score prediction models for women and its applicability to Asians. 2014 , 6, 259-67	6
893	Combining cross-sectional data on prevalence with risk estimates from a prediction model. A novel method for estimating the attributable risk. 2014 , 53, 371-9	3

892	Comparative accuracy of different risk scores in assessing cardiovascular risk in Indians: a study in patients with first myocardial infarction. 2014 , 66, 580-6		34
891	Recalibration of the SCORE risk chart for the Russian population. 2014 , 29, 621-8		9
890	Validity of self-measured waist circumference in adults at risk of type 2 diabetes and cardiovascular disease. 2014 , 12, 170		10
889	Inclusion of hazardous drinking does not improve the SCORE performance in men from Central and Eastern Europe: the findings from the HAPIEE cohorts. 2014 , 14, 1187		2
888	Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study. 2014 , 14, 118		23
887	Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. 2014 , 129, 2539-2546		53
886	Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. <i>European Heart Journal</i> , 2014 , 35, 633-8	9.5	62
885	Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients. 2014 , 28, 663-9		13
884	Impact of β -thalassemia trait carrier state on cardiovascular risk factors and metabolic profile in patients with newly diagnosed hypertension. 2014 , 28, 328-32		9
883	Rheumatoid arthritis and cardiac disease. 2014 , 9, 457-473		
882	Pulse pressure and subclinical peripheral artery disease. 2014 , 28, 242-5		10
881	Consensus statement on management of dyslipidemia in Indian subjects. 2014 , 66 Suppl 3, S1-51		35
880	BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. 2014 , 29, 777-90		63
879	Ethical issues in cardiovascular risk management: Patients need nurses' support. 2014 , 21, 540-53		6
878	The accuracy of predicting cardiovascular death based on one compared to several albuminuria values. 2014 , 85, 1421-8		8
877	Effects of preventive acupuncture and moxibustion on fat accumulation, blood lipid, and uterus e 2 of menopause rats. 2014 , 2014, 621975		4
876	The contribution of educational class in improving accuracy of cardiovascular risk prediction across European regions: The MORGAM Project Cohort Component. 2014 , 100, 1179-87		15
875	The role of dietary patterns' assessment in the predictive ability of cardiovascular disease risk estimation models: a review. 2014 , 65, 3-8		11

874	Association of neighborhood characteristics with cardiovascular health in the multi-ethnic study of atherosclerosis. 2014 , 7, 524-31		93
873	A high-carbohydrate diet lowered blood pressure in healthy Chinese male adolescents. 2014 , 8, 132-7		7
872	Primary care-based, targeted screening programme to promote sustained weight management. 2014 , 32, 30-6		6
871	Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. 2014 , 349, g5992		142
870	Automatic Characterization of the Physiological Condition of the Carotid Artery in 2D Ultrasound Image Sequences Using Spatiotemporal and Spatospectral 2D Maps. 2014 , 2014, 876267		0
869	Predicted 10-year risk of cardiovascular disease is influenced by the risk equation adopted: a cross-sectional analysis. 2014 , 64, e634-40		8
868	Serum samples that have been stored long-term (>10 years) can be used as a suitable data source for developing cardiovascular risk prediction models in large observational rheumatoid arthritis cohorts. 2014 , 2014, 930925		5
867	Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women. 2014 , 36, 71-82		44
866	Medical decision making and the counting of uncertainty. 2014 , 129, 2500-2		4
865	Target organ damage and cardiovascular risk factors among subjects with previously undiagnosed hypertension. 2014 , 21, 980-8		13
864	Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. <i>European Heart Journal</i> , 2014 , 35, 299-306	9.5	17
863	SCORE performance in Central and Eastern Europe and former Soviet Union: MONICA and HAPIEE results. <i>European Heart Journal</i> , 2014 , 35, 571-7	9.5	23
862	Highly sensitive troponins knocking at the door of primary prevention. <i>European Heart Journal</i> , 2014 , 35, 268-70	9.5	9
861	Using the electrocardiogram as a crystal ball for cardiovascular and all-cause mortality. <i>European Heart Journal</i> , 2014 , 35, 1303-5	9.5	3
860	Deprivation and health risk indicators in full-time permanent workers. 2014 , 24, 585-94		2
859	Home blood pressure measurement as a screening tool for hypertension in a web-based worksite health promotion programme. 2014 , 24, 776-81		2
858	Anthropometric measurements of general and central obesity and the prediction of cardiovascular disease risk in women: a cross-sectional study. 2014 , 4, e004138		63
857	Effect of cardiovascular prevention strategies on incident coronary disease hospitalisation rates in Spain; an ecological time series analysis. 2014 , 4, e004257		5

856	Ethnicity and the association between anthropometric indices of obesity and cardiovascular risk in women: a cross-sectional study. 2014 , 4, e004702	19
855	Ambulatory blood pressure adds little to Framingham Risk Score for the primary prevention of cardiovascular disease in older men: secondary analysis of observational study data. 2014 , 4, e006044	8
854	Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. 2014 , 32, 681-92	18
853	Clinical prediction rules in practice: review of clinical guidelines and survey of GPs. 2014 , 64, e233-42	24
852	Risks in estimating risk. <i>European Heart Journal</i> , 2014 , 35, 537-9	9.5 6
851	Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction. 2014 , 4, e005991	20
850	Comparison of different cardiac risk scores for coronary artery disease in symptomatic women: do female-specific risk factors matter?. 2014 , 21, 1443-50	12
849	Metabolic syndrome and lifestyle modification. 2014 , 15, 317-27	35
848	Latent time-varying factors in longitudinal analysis: a linear mixed hidden Markov model for heart rates. 2014 , 33, 4116-34	14
847	Effect of a participant-driven health education programme in primary care for people with hyperglycaemia detected by screening: 3-year results from the Ready to Act randomized controlled trial (nested within the ADDITION-Denmark study). 2014 , 31, 976-86	9
846	Tobacco use habits among Swedish female youth athletes and the influence of the social environment. 2014 , 12, 219-25	7
845	Epicardial fat thickness is independently associated with psoriasis. 2014 , 228, 55-9	17
844	Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk. 2014 , 62, 213-21	18
843	The impact of modern noninvasive cardiac imaging on coronary intervention rates. 2014 , 27, 50-7	3
842	Meta-analysis and aggregation of multiple published prediction models. 2014 , 33, 2341-62	44
841	A randomized trial of everolimus and low-dose cyclosporine in renal transplantation: with or without steroids?. 2014 , 46, 3375-82	5
840	Examining the association between utilization management and downstream cardiovascular imaging. 2014 , 49, 1616-37	2
839	Pre-operative co-morbidity and postoperative survival in the elderly: beyond one lunar orbit. 2014 , 69 Suppl 1, 17-25	17

838	Predicting major outcomes in type 1 diabetes: a model development and validation study. 2014 , 57, 2304-14	31
837	PCSK9 antibodies for the treatment of hypercholesterolemia. 2014 , 6, 5517-33	17
836	Model for assessing cardiovascular risk in a Korean population. 2014 , 7, 944-51	33
835	Cardiovascular Disease Risk Assessment: a Review of Risk Factor-based Algorithms and Assessments of Vascular Health. 2014 , 8, 1	
834	The role of aspirin in the prevention of cardiovascular disease. 2014 , 12, 147-54	102
833	Risk predictive modelling for diabetes and cardiovascular disease. 2014 , 51, 1-12	18
832	Do other cardiovascular risk factors influence the impact of age on the association between blood pressure and mortality? The MORGAM Project. 2014 , 32, 1025-32; discussion 1033	6
831	Validaci3n de los modelos de predicci3n de Framingham y PROCAM como estimadores del riesgo cardiovascular en una poblaci3n colombiana. 2014 , 21, 202-212	8
830	Association between albuminuria, atherosclerotic plaques, elevated pulse wave velocity, age, risk category and prognosis in apparently healthy individuals. 2014 , 32, 1034-41; discussion 1041	8
829	Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. 2014 , 25, 413-7	2
828	Country of birth modifies the associations of body mass and hemoglobin A1c with office blood pressure in Middle Eastern immigrants and native Swedes. 2014 , 32, 2362-70; discussion 2370	14
827	The use of overnight pulse wave analysis for recognition of cardiovascular risk factors and risk: a multicentric evaluation. 2014 , 32, 276-85	12
826	A simple nonexercise model of cardiorespiratory fitness predicts long-term mortality. 2014 , 46, 1159-65	83
825	Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. 2014 , 21, 310-20	51
824	Lifestyle-based prediction model for the prevention of CVD: the Healthy Heart Score. 2014 , 3, e000954	66
823	Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. 2014 , 32, 2411-21; discussion 2421	34
822	Cardiovascular-risk prediction and type of event. 2014 , 32, 473-4	0
821	Comparison of cardiovascular disease risk calculators. 2014 , 25, 254-65	29

820	Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension. 2014 , 32, 495-508	10
819	Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. 2014 , 21, 377-83	22
818	[Analysis of type 2 diabetes-induced late effects based on administrative data of social insurance in Austria and implications for the evaluation of the DMP diabetes mellitus]. 2014 , 164, 313-9	
817	Is representativeness the right question?. 2014 , 43, 631-2	7
816	Risk of Cardiovascular Disease among Diabetic Patients in Manipur, Northeast India. 2014 , 2014, 1-9	5
815	Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years. 2014 , 52, 121-7	3
814	Predicting return to work among sickness-certified patients in general practice: properties of two assessment tools. 2014 , 119, 268-77	3
813	Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group. 2021 , 60, 2207-2216	1
812	Riesgo cardiovascular en la poblaci3n anciana espa0la. Escala de riesgo EPICARDIAN. 2021 ,	
811	Polyphenol intake and cardiovascular risk in the PREDIMED-Plus trial. A comparison of different risk equations. 2021 ,	0
810	Approaches to antihypertensive therapy in patients predisposed to symptomatic hypotension and syncope. 2021 , 23, 207-218	
809	Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. 2021 , 224, 108726	1
808	Validation and comparison of 28 risk prediction models for coronary artery disease. 2021 ,	1
807	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. 2021 , 18, 271-279	4
806	Design of Long-Term Conditional Cash Transfer Program to Encourage Healthy Habits. 2021 , 30, 3987	0
805	Absolute mortality risk assessment of COVID-19 patients: the Khorshid COVID Cohort (KCC) study. 2021 , 21, 146	2
804	Lyell's syndrome provoked by external drug use. 2021 , 24, 25-34	
803	Association between change in cardiovascular risk scores and future cardiovascular disease: analyses of data from the Whitehall II longitudinal, prospective cohort study. 2021 , 3, e434-e444	3

802	Development of a life expectancy table for individuals with type 1 diabetes. 2021 , 64, 2228-2236	3
801	Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. 2021 , 32, 1188-1195	0
800	A pilot project to study troponin I in a representative sample of the region from the ESSE-RF study: distribution among population and associations with risk factors. 2021 , 20, 2940	5
799	Cardiorespiratory fitness and physical activity in people who have rheumatoid arthritis at an increased risk of cardiovascular disease: a cross-sectional study. 2021 , 41, 2177-2183	1
798	The analysis of high cardiovascular morbidity and mortality in the adult population as a medical and social problem and the search for ways to solve it. 2021 , 20, 58-64	
797	Ten-year risk of fatal cardiovascular disease and its association with metabolic risk factors among waste pickers in South Africa. 2021 , 21, 336	1
796	[Cancer and cardiovascular risk]. 2021 , 38, e1-e9	
795	QRISK3 Relation to Carotid Plaque is Higher than that of SCORE In Patients with Systemic Lupus Erythematosus. 2021 ,	1
794	Improvement in the Prediction of Coronary Heart Disease Risk by Using Artificial Neural Networks. 2021 , 30, 244-250	1
793	Prediction of presence and severity of coronary artery disease using prediction for atherosclerotic cardiovascular disease risk in China scoring system. 2021 , 9, 5453-5461	0
792	Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study. 2021 , 38, e14627	0
791	Standardized measurement of coronary inflammation using cardiovascular computed tomography: integration in clinical care as a prognostic medical device. 2021 , 117, 2677-2690	4
790	Non-fasting lipid profile for cardiovascular risk assessments using China ASCVD risk estimator and Europe SCORE risk charts in Chinese participants. 2021 , 11, 991-1001	1
789	A Body Shape Index (ABSI) and Hip Index (HI) Adjust Waist and Hip Circumferences for Body Mass Index, But Only ABSI Predicts High Cardiovascular Risk in the Spanish Caucasian Population. 2021 , 19, 352-357	2
788	Cardiovascular disease risk calculators to reflect the subclinical atherosclerosis of coronary artery in rheumatoid arthritis: a pilot study. 2021 , 5, 39	4
787	Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. 2021 , 14, 831-840	1
786	Left ventricular global longitudinal strain in low cardiac risk outpatients who recently recovered from coronavirus disease 2019. 2021 , 37, 2979-2989	2
785	Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients. 2021 ,	1

784	Change in cardiovascular risk assessment tool and updated Norwegian guidelines for cardiovascular disease in primary prevention increase the population proportion at risk: the Tromsø Study 2015-2016. 2021 , 8,	0
783	Cardiac remodeling induced by exercise in Caucasian male master athletes: a cross-sectional study. 2021 , 1	0
782	Effect of non-dipper pattern on echocardiographic myocardial work parameters in normotensive individuals. 2021 , 38, 1586-1595	0
781	Relationship of Pericardial Fat Tissue With Cardiovascular Risk Factors in Patients Without Cardiovascular Diseases. 2021 , 19, 524-530	0
780	Spouse's Cardiovascular Disease As a Risk Factor for Cardiovascular Disease in Middle-Aged Adults: A Matched-Pair Cohort Study. 2021 , 14, e007649	0
779	Prescription of Lipid-Lowering and Antihypertensive Drugs Following Pictorial Information About Subclinical Atherosclerosis: A Secondary Outcome of a Randomized Clinical Trial. 2021 , 4, e2121683	0
778	A Simple Model for Predicting 10-Year Cardiovascular Risk in Middle-Aged to Older Chinese: Guangzhou Biobank Cohort Study. 2021 , 1	0
777	Prediction of first cardiovascular disease event in 2.9 million individuals using Danish administrative healthcare data: a nationwide, registry-based derivation and validation study. 2021 , 1,	2
776	Estimation of 10-Year Risk of Death from Coronary Heart Disease, Stroke, and Cardiovascular Disease in a Pooled Analysis of Japanese Cohorts: EPOCH-JAPAN. 2021 , 28, 816-825	4
775	Predictive model and feature importance for early detection of type II diabetes mellitus. 2021 , 6,	3
774	Long-Term Prognostic Value of Stress CMR in Patients With Heart Failure and Preserved Ejection Fraction. 2021 , 14, 2319-2333	1
773	Arterial Stiffness in Type 1 Diabetes: The Case for the Arterial Wall Itself as a Target Organ. 2021 , 10,	0
772	Layer-specific global longitudinal strain and the risk of heart failure and cardiovascular mortality in the general population: the Copenhagen City Heart Study. 2021 , 23, 1819-1827	3
771	A review of risk prediction models in cardiovascular disease: conventional approach vs. artificial intelligent approach. 2021 , 207, 106190	8
770	Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. 2021 ,	10
769	The International Database of Central Arterial Properties for Risk Stratification: Research Objectives and Baseline Characteristics of Participants. 2021 ,	3
768	Estimation of vascular risk: Time and place matter. 2021 , 221, 596-597	
767	Ingesta de polifenoles y riesgo cardiovascular en el ensayo PREDIMED-Plus. Una comparación de diferentes ecuaciones de riesgo. 2021 ,	0

766	Risk prediction models for atherosclerotic cardiovascular disease: A systematic assessment with particular reference to Qatar. 2021 , 2021, 42	
765	Coronary artery disease burden in women poorly explained by traditional risk factors: Sex disaggregated analyses from the BioHEART-CT study. 2021 , 333, 100-107	0
764	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. 2021 , e3494	6
763	Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. 2021 , 144, 916-929	17
762	Risk Prediction of Cardiovascular Events by Exploration of Molecular Data with Explainable Artificial Intelligence. 2021 , 22,	4
761	Imaging-guided evaluation of subclinical atherosclerosis to enhance cardiovascular risk prediction in asymptomatic low-to-intermediate risk individuals: A systematic review. 2021 , 153, 106819	0
760	Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals. 2021 ,	1
759	Long-term prognostic value of ischaemia and cardiovascular magnetic resonance-related revascularization for stable coronary disease, irrespective of patient's sex: a large retrospective study. 2021 , 22, 1321-1331	1
758	Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk. 2021 , 1	0
757	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. 2021 , 10,	1
756	Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. 2021 , 8,	3
755	Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer. 2021 , 23, 91	
754	Socioeconomic factors and the onset of peripheral artery disease in older adults. 2021 , 50, 341-347	0
753	Cardiovascular risk and mortality prediction in patients suspected of sleep apnea: a model based on an artificial intelligence system. 2021 , 42,	2
752	Exercise, Physical Activity and Cardiometabolic Health: Pathophysiologic Insights. 2021 ,	0
751	Score2: A New Updated Algorithm to Predict Cardiovascular Disease Risk in Europe. 2021 ,	
750	Contribution of cardio-ankle vascular index to prediction of cardiovascular events in the adult urban population: data from the ESSE-RF study (Tomsk). 2021 , 20, 2967	0
749	Pilot project to study the association of troponin I with cardiovascular events in the population of Russian region. 2021 , 20, 2980	4

748	Chronic kidney disease measures for cardiovascular risk prediction. 2021 , 335, 110-118	3
747	Cardiovascular risk in the elderly population of Spain. The EPICARDIAN risk score. 2021 , 222, 13-13	
746	Planning the Follow-Up of Patients with Stable Chronic Coronary Artery Disease. 2021 , 11,	0
745	Developing Non-Laboratory Cardiovascular Risk Assessment Charts and Validating Laboratory and Non-Laboratory-Based Models. 2021 , 16, 58	0
744	Managing cardiovascular risk in people living with HIV in Asia - where are we now?. 2021 ,	
743	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. 2021 , 78, 983-995	13
742	Residential greenness and atherosclerotic cardiovascular disease risk in a rural Chinese adult population. 2021 , 222, 112458	3
741	Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. 2021 , 334, 66-75	1
740	Comparison of Different Cardiovascular Risk Score and Pulse Wave Velocity-Based Methods for Vascular Age Calculation. 2021 , 30, 1744-1751	0
739	Estimation of immediate and 7-day clinical prognostic indicators for ewe and lamb survival in the UK following vaginal delivery and caesarean section at a single veterinary practice. 2021 , 204, 106511	1
738	Preventive Cardiology. 2022 , 341-375	
737	Upper limbs skin microvascular characteristics in healthy men of working age. 2021 , 24, 60	1
736	Electronic Medical Records Data Analysis Technologies and Services for the Cardiovascular Diseases Risk Prediction. 2021 , 513-524	
735	[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines]. 2021 , 38, 21-43	1
734	The cardiovascular burden of light smoking. 2021 , 6, e48-e56	0
733	Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension. 2021 , 11, 1001	8
732	Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes. 2021 , 21, 14	5
731	Serum lipid abnormalities in migraine: A meta-analysis of observational studies. 2021 , 61, 44-59	6

730	Adaptive Patient Education Framework Featuring Personalized Cardiovascular Risk Management Interventions. 2006 , 264-268	3
729	Forecasting Life Expectancy and Mortality in Sweden â Some Comments on Methodological Problems and Potential Approaches. 2019 , 261-269	0
728	Arterial Aging: The Role of Hormonal and Metabolic Status and Telomere Biology. 2019 , 329-348	3
727	The Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women. 2018 , 215-238	1
726	Role of physician gender in drug therapy. 2012 , 183-208	6
725	Clinical Manifestations of Atherosclerosis. 2012 , 39-58	1
724	NHG-Standaard Cardiovasculair risicomanagement. 2011 , 361-408	1
723	Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry. 2017 , 20, 635	1
722	Primary and Secondary Prevention of Coronary Heart Disease. 2012 , 1010-1035	4
721	Maladies cardiovasculaires et activit� physique et sportive. 2016 , 195-233	0
720	[Validation of the SCORE index and SCORE for old people in the Castilla y L�n cardiovascular disease risk cohort]. 2019 , 36, 184-192	4
719	Cardiovascular Risk and Known Coronary Artery Disease Are Associated With Colorectal Adenoma and Advanced Neoplasia. 2017 , 69, 2348-2350	9
718	Rendimiento de las funciones de riesgo cardiovascular propuestas para Espa� en la poblaci� extreme� de la cohorte HERMEX. 2019 , 54, 173-182	0
717	Chronic hepatitis C infection: An independent risk factor for subclinical atheromatosis. 2019 , 219, 293-302	4
716	Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidaemia influenced the management of dyslipidaemia? The MEJORALO-CV Project. 2020 , 220, 282-289	0
715	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. 2020 , 50, 1333-1338	13
714	Risque cardiovasculaire dans la population adulte de Roumanie â Donn�es de lâ�tude SEPHAR III. 2017 , 201, 1395-1408	1
713	Feasibility of a cardiovascular cohort in a Sub-Saharan Africa community: preliminary report of the pilot project TAHES (Tanv�Health Study) in Benin. 2017 , 10, 1270528	3

712	Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. 2020 , 13, 605-613	2
711	Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. 2020 ,	5
710	Predicting cardiovascular disease risk across the atherosclerotic disease continuum. 2020 ,	1
709	Is exercise testing useful to improve the prediction of coronary events in asymptomatic subjects?. 2006 , 13, 37-44	10
708	The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. 2021 , 33, 211-218	3
707	Blood pressure management in hypertensive patients with syncope: how to balance hypotensive and cardiovascular risk. 2020 , 38, 2356-2362	4
706	Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis. 2020 , 12, 1759720X20982837	4
705	How well do anthropometric indices correlate with cardiovascular risk factors? A cross-sectional study in Croati. 2012 , 18, PH6-11	7
704	Cardiovascular risk assessment in South and Middle-East Asians living in the Western countries. 2020 , 36, 1719-1725	4
703	Guideline-Driven Assessment of Cardiovascular Disease and Related Risks After Spinal Cord Injury. 2009 , 14, 32-45	9
702	A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. 2011 , 6, e20416	37
701	Development and validation of a risk model for prediction of hazardous alcohol consumption in general practice attendees: the predictAL study. 2011 , 6, e22175	3
700	Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. 2012 , 7, e33084	21
699	Comparison of clinical and parasitological data from controlled human malaria infection trials. 2012 , 7, e38434	60
698	An equation to estimate the concentration of serum apolipoprotein B. 2012 , 7, e51607	9
697	Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study. 2013 , 8, e67611	41
696	Cardiovascular health and cognitive function: the Maine-Syracuse Longitudinal Study. 2014 , 9, e89317	64
695	Cardiovascular risk factors have larger impact on endothelial function in self-reported healthy women than men in the HUNT3 Fitness study. 2014 , 9, e101371	17

694	Predicting the onset of anxiety syndromes at 12 months in primary care attendees. The predictA-Spain study. 2014 , 9, e106370	9
693	Profile of individuals who are metabolically healthy obese using different definition criteria. A population-based analysis in the Spanish population. 2014 , 9, e106641	26
692	Weak prediction power of the Framingham Risk Score for coronary artery disease in nonagenarians. 2014 , 9, e113044	2
691	Tailoring the implementation of new biomarkers based on their added predictive value in subgroups of individuals. 2015 , 10, e0114020	4
690	On cross-sectional associations of leukocyte telomere length with cardiac systolic, diastolic and vascular function: the Asklepios study. 2014 , 9, e115071	15
689	Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. 2015 , 10, e0115270	21
688	Leukocyte subtype counts and its association with vascular structure and function in adults with intermediate cardiovascular risk. MARK study. 2015 , 10, e0119963	8
687	Trends in Cardiovascular Disease Risk Factor Prevalence and Estimated 10-Year Cardiovascular Risk Scores in a Large Untreated French Urban Population: The CARVAR 92 Study. 2015 , 10, e0124817	11
686	Diet Quality Scores and Prediction of All-Cause, Cardiovascular and Cancer Mortality in a Pan-European Cohort Study. 2016 , 11, e0159025	58
685	A Comparison of Different Algorithms for the Assessment of Cardiovascular Risk in Patients at Waiting List for Kidney Transplantation. 2016 , 11, e0161927	7
684	Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study. 2017 , 12, e0170778	10
683	Glycemic markers and relation with arterial stiffness in Caucasian subjects of the MARK study. 2017 , 12, e0175982	19
682	Why do authors derive new cardiovascular clinical prediction rules in the presence of existing rules? A mixed methods study. 2017 , 12, e0179102	4
681	PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region. 2017 , 12, e0189389	14
680	Predicted 10-year risk of cardiovascular mortality in the 40 to 69 year old general population without cardiovascular diseases in Germany. 2018 , 13, e0190441	12
679	Association between the retinal vascular network and retinal nerve fiber layer in the elderly: The Montrachet study. 2020 , 15, e0241055	3
678	Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease. 2017 , 44, 239-244	2
677	C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies. 2017 , 9, 891-899	11

676	Emerging Strategies for the Management of Atherogenic Dyslipidaemia. 2020 , 15, 1-3	5
675	Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science. 2020 , 15, e56	6
674	[Trends and current questions of cardiovascular prevention in primary health care]. 2012 , 153, 1536-46	2
673	Health Risk Appraisal Model for Assessing Hypertension by Changing Health Risk Factors. 2015 , 35, 131-156	2
672	Arterial hypertension in adults. Clinical guidelines 2020. 2020 , 25, 3786	155
671	Blood pressure control in primary care patients with arterial hypertension: analysing the Hypertension Register data. 2012 , 11, 4-11	7
670	RUSSIAN EXPERT SYSTEM ORISKON – ASSESSMENT OF THE MAJOR NON-COMMUNICABLE DISEASE RISK. 2013 , 12, 51-55	4
669	CENTRALISED SURVEY ON THE UNDERTREATMENT OF THE HYPERCHOLESTEROLEMIA IN RUSSIA (CEPHEUS). 2013 , 12, 67-74	4
668	Evaluation of cardiovascular risk factors for medical workers of an urban multidisciplinary hospital. 2019 , 18, 39-46	3
667	The potential of cardiovascular diseases – prevention according to the results of dispensary examinations of the adult population. 2019 , 18, 69-76	11
666	Integrated assessment of the potential for cardiovascular prevention according to the screening results and its prognostic significance. 2020 , 19, 2547	3
665	Biomarkers in predicting cardiovascular risk: new prospects of troponin I. 2020 , 19, 2584	4
664	Constru e valida de um manual informativo sobre o banho no leito. 2013 , 26, 554-560	8
663	Noninvasive detection of coronary artery disease -- challenges for prevention of disease and clinical events. 2005 , 60, 415-28	6
662	Costs and Cost-Effectiveness of Interventions and Policies to Prevent and Treat Cardiovascular and Respiratory Diseases. 2017 , 349-367	6
661	Impact of diet, physical activity, lipid status and glycoregulation in estimation of score (systematic coronary risk evaluation) for ten years in postmenopausal women. 2007 , 7, 197-204	3
660	. 2019 , 59, 45-53	10
659	[Epidemiology of Arterial Hypertension in Russian Federation - Importance of Choice of Criteria of Diagnosis]. 2019 , 59, 5-11	23

658	Prediction of the risk of mortality using risk score in patients with coronary heart disease. 2016 , 7, 81680-81690	
657	The prevalence of risk factors of cardiovascular diseases in persons with arterial hypertension exposed to occupational stress. 2017 , 95, 535-544	3
656	Follow-up of a cardiovascular prevention campaign. 2011 , 19, 190-6	3
655	Overview of Risk-Estimation Tools for Primary Prevention of Cardiovascular Diseases in European Populations. 2015 , 23, 91-9	4
654	Determinants of healthy ageing and its relation to 10-year cardiovascular disease incidence: the ATTICA study. 2018 , 26, 3-9	5
653	The "Five Risks algorithm": an easy tool for cardiovascular risk estimation. 2009 , 17, 133-8	1
652	Cardiovascular risk assessment and management in developing countries. 2005 , 1, 15-8	24
651	Methodological issues in cardiovascular epidemiology: the risk of determining absolute risk through statistical models. 2006 , 2, 309-15	9
650	Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population. 2008 , 4, 177-87	23
649	Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. 2008 , 4, 199-211	47
648	Should Cushing's Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?. 2020 , 18, 12-24	2
647	Cardiovascular Risk Assessment in People Living With HIV: A Systematic Review and Meta-Analysis of Real-Life Data. 2020 , 18, 5-18	9
646	Management of Measurable Variable Cardiovascular Disease' Risk Factors. 2018 , 14, 153-163	69
645	Artificial neural networks versus multiple logistic regression to predict 30-day mortality after operations for type a ascending aortic dissection. 2009 , 3, 81-95	10
644	New insights into the management of hypertension and cardiovascular risk with Angiotensin receptor blockers: observational studies help us?. 2014 , 8, 35-42	1
643	Cardiovascular Risk Assessment and Effects on Behavior in Switzerland The Swiss Heart Foundation HerzCheck(®)/Cardio-Test(®). 2015 , 9, 35-9	2
642	Accurate Prediction of Coronary Heart Disease for Patients With Hypertension From Electronic Health Records With Big Data and Machine-Learning Methods: Model Development and Performance Evaluation. 2020 , 8, e17257	13
641	Influence of admission plasma glucose level on short- and long-term prognosis in patients with ST-segment elevation myocardial infarction. 2010 , 67, 291-5	5

640	Global perspective on carotid intima-media thickness and plaque: should the current measurement guidelines be revisited?. 2019 , 38, 451-465	29
639	Integration of estimated glomerular filtration rate biomarker in image-based cardiovascular disease/stroke risk calculator: a south Asian-Indian diabetes cohort with moderate chronic kidney disease. 2020 , 39, 290-306	12
638	Beyond the cardiovascular risk charts: the new way of hybrid profiles. 2016 , 17, 851-854	2
637	Primary prevention strategy for cardiovascular disease in Lithuania. 2019 , 25, 14-39	4
636	Subclinical vessel lesion in normotensive patients with abdominal obesity: focus on arterial stiffness. 2013 , 10, 46-52	3
635	Prevalence trends in lifestyle-related risk factors. 2015 , 112, 185-92	32
634	An evidence-based approach to the use of telehealth in long-term health conditions: development of an intervention and evaluation through pragmatic randomised controlled trials in patients with depression or raised cardiovascular risk. 2017 , 5, 1-468	2
633	Using nationwide "Big data" from linked electronic health records to help improve outcomes in cardiovascular diseases: 33 studies using methods from epidemiology, informatics, economics and social science in the Clinical disease research using Linked Bespoke studies and Electronic health Records (CALIBER) programme. 2017 , 5, 1-336	10
632	The Potential Benefit of Monitoring Oxidative Stress and Inflammation in the Prevention of Non-Communicable Diseases (NCDs). 2020 , 10,	15
631	GPS' familiarity with and use of cardiovascular clinical prediction rules: a UK survey study. 2020 , 4,	1
630	Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?. 2012 , 18, 3492-501	49
629	How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?. 2016 , 22, 8103-11	18
628	Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea. 2020 , 35, 636-646	3
627	Artificial Neural Network as a Clinical Decision-Supporting Tool to Predict Cardiovascular Disease. 2009 , 4, 36-46	22
626	Application of Probabilistic Techniques for the Development of a Prognosis Model of Stroke Using Epidemiological Studies. 2013 , 5, 34-58	2
625	Age- and Gender-Normalized Coronary Incidence and Mortality Risks in Primary and Secondary Prevention. 2012 , 3, 193-204	3
624	[Inflammation and C-reactive protein in cardiovascular disease]. 2009 , 129, 1221-4	4
623	[The blood pressure level in a Norwegian population--the significance of inheritance and lifestyle]. 2011 , 131, 1185-9	4

622	Changes in myocardial infarction mortality. 2011 , 131, 468-70	4
621	Key Points of the 2019 Japanese Society of Hypertension Guidelines for the Management of Hypertension. 2019 , 49, 1123-1135	4
620	Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit. 2014 , 56, 371-6	10
619	Physical Activity Level Improves the Predictive Accuracy of Cardiovascular Disease Risk Score: The ATTICA Study (2002-2012). 2016 , 7, 52	4
618	Awareness and use of cardiovascular risk scores by family physicians in southeastern Ontario. 2013 , 03, 487-490	3
617	Lifestyle, Biological Risk Markers, Morbidity and Mortality in a Cohort of Men 33 - 42 Years Old at Baseline, after 24-Year Follow-Up of a Primary Health Care Intervention. 2015 , 05, 92-102	3
616	Relationship between cardiovascular risk as predicted by established risk scores and coronary artery plaque composition as detected by virtual histology intravascular ultrasound analysis: the PREDICT pilot study. 2008 , 3, 482-9	4
615	Cardiovascular disease risk assessment among patients attending two cardiac clinics in the Ashanti Region of Ghana. 2020 , 54, 140-145	1
614	A managed clinical network for cardiac services: set-up, operation and impact on patient care. 2005 , 5, e10	18
613	Nice new hypertension guidelines. 2012 , 2, 45	1
612	Prehypertension in dyslipidemic individuals; relationship to metabolic parameters and intima-media thickness. 2013 , 157, 41-9	6
611	Vulnerable atherosclerotic plaque - a review of current concepts and advanced imaging. 2018 , 162, 10-17	16
610	Early renal failure as a cardiovascular disease: Focus on lipoprotein(a) and prothrombotic state. 2015 , 4, 374-8	6
609	How does the risk of cardiovascular death and cardiovascular risk factor profiles differ between socioeconomic classes in Poland: A country in transition. 2019 , 26, 493-502	1
608	The 30-year cardiovascular risk profile of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia: the Bellville, South Africa pilot study. 2012 , 23, 5-11	38
607	Risk factor paradox in the occurrence of cardiac arrest in acute coronary syndrome patients. 2016 , 28, 405-412	2
606	Cardiovascular risk 10 years after liver transplant. 2014 , 12, 55-61	2
605	Diagnostic inertia in dyslipidaemia: results of a preventative programme in Spain. 2015 , 3, e1109	2

604	A method to construct a points system to predict cardiovascular disease considering repeated measures of risk factors. 2016 , 4, e1673	6
603	The association between serum lipids and risk of premature mortality in Latin America: a systematic review of population-based prospective cohort studies. 2019 , 7, e7856	0
602	Diabetes screening: a pending issue in hypertense/obese patients. 2015 , 3, e914	2
601	Correction of carbohydrate metabolism by means of physical therapy of patients with metabolic syndrome. 2021 , 7, 54-66	
600	Proteomics-Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality. 2021 , 78, 1621-1631	4
599	Updating the VIVOPTIM Program for the Assessment of Cardiovascular Risk. 2021 , 17, 675-678	
598	New opportunities for biomarkers in cardiovascular risk stratification. Resolution of Advisory board. 2021 , 26, 4700	
597	A newly developed and externally validated non-clinical score accurately predicts 10-year cardiovascular disease risk in the general adult population. 2021 , 11, 19609	2
596	Assessment of plasma ceramides as predictor for subclinical atherosclerosis. 2021 ,	1
595	Clinical Significance of Carotid Intima-Media Complex and Carotid Plaque Assessment by Ultrasound for the Prediction of Adverse Cardiovascular Events in Primary and Secondary Care Patients. 2021 , 10,	4
594	Association of iron deficiency with incident cardiovascular diseases and mortality in the general population. 2021 , 8, 4584	2
593	Rheumatoid cachexia in early rheumatoid arthritis: prevalence and associated variables. 2021 , 1-7	1
592	Ischemic Heart Disease and Rheumatoid Arthritis-Two Conditions, the Same Background. 2021 , 11,	1
591	Increasing the medico-economic efficiency of preventive counseling for patients with arterial hypertension and behavioral risk factors for non-communicable diseases. 2021 , 14, 324-333	
590	Health Promoting Behaviors and Risk of Cardiovascular Events among Patients with Cardiovascular Diseases. 2021 , 9, 135-142	2
589	Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic Disease (CORDIS) Study Group. 2021 ,	1
588	Decennial and Lifetime CV Risk Estimations Using JBS3 and ACC/AHA ASCVD Calculators in Kerala Based Indian Sub-Ethnics. 2022 , 413-423	
587	Physical Activity and Cardiorespiratory Fitness: Vital Signs for Cardiovascular Risk Assessment. 2021 , 23, 172	0

- 586 A modern approach to dyslipidemia. **2021**, 10
- 585 Cardiovascular risk score associations with frailty in men and women with or at risk for HIV.. **2022**, 36, 237-347 0
- 584 Cardiovascular risk profile and clinical characteristics of diabetic patients: a cross-sectional study in China. **2021**,
- 583 Sortilin as a marker of atherosclerosis: biological and pathophysiological aspects. **2021**, 27, 402-408
- 582 DNA methylation signatures of incident coronary heart disease: findings from epigenome-wide association studies. **2021**, 13, 186 2
- 581 La presi3n arterial ambulatoria, en comparaci3n con la medida cl3nica, mejora notablemente la estratificaci3n del riesgo cardiovascular de Framingham. **2021**, 74, 953-961 4
- 580 Cardiovascular Risk Calculators and their Applicability to South Asians. **2021**, 17, e100120186497
- 579 Cardiale aandoeningen. **2001**, 412-447
- 578 State-of-the-Art Diagnostic Testing in Women. **2004**, 173-194
- 577 Le risque cardio-vasculaire. **2004**, 188, 401-414
- 576 The Concept of Total Risk. **2005**, 219-229
- 575 Special Applications: Screening Apparently Healthy Individuals. **2006**, 351-386
- 574 Treatment With Drugs to Lower Blood Pressure and Blood Cholesterol Based on an Individual's Absolute Cardiovascular Risk. **2006**, 2006, 35-37
- 573 Coronary risk prediction for those with and without diabetes. **2006**, 13, 30-6 1
- 572 Women and Coronary Heart Disease. **2006**, 689-720
- 571 Prediction of Global Cardiovascular Risk in Hypertension. **2007**, 190-198
- 570 The 2003 Guidelines for the Management of Hypertension of the European Society of Hypertension and European Society of Cardiology. **2007**, 1177-1184
- 569 Prevention Guidelines: Management of the Coronary Patient. **2007**, 26-29

568 Cardiovascular Complications of Obesity and the Metabolic Syndrome. **2007**, 2693-2720

567 Incidence of certain risk factors for cardiovascular diseases in persons with high risk for occurrence of fatal cardiovascular events in the next 10 years. **2007**, 38, 53-58

566 Coronary Risk Factors: An Overview. **2007**, 2609-2630

565 Jak \acute{c} e optimizov \acute{a} t \acute{e} b \acute{i} frekvence?. **2007**, 49, 163-165

564 Processes and outcomes for acute myocardial infarction patients. **2007**, 20, 346-357

563 National and international recommendations for the management of hyperlipidaemia. **2007**, 292-309

562 Angina, its diagnosis and treatment.. **2007**, 49, 334-340

561 2 Preventie en risicofactoren. **2008**, 17-22

560 Es lohnt sich, gesund zu leben: Evidenzbasierte Empfehlungen zur Pr \ddot{u} vention von Krankheiten. **2008**, 15-26

559 Coronary Heart Disease. **2008**, 16-25

558 Biochemical Aspects, Laboratory Diagnosis and Follow-Up of High Blood Cholesterol: NCEP ATP III Guidelines. **2008**, 27, 64-85

557 [Digital risk analysis of cardiovascular diseases: new opportunities for the patients. Cardiovascular prevention program in the praxis]. **2008**, 149, 677-84

556 The impact of the metabolic syndrome on cardiovascular risk and disease in rheumatoid arthritis. **2008**, 3, 335-349

555 Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze: konsensus rossiyskikh kardiologov i ginekologov. **2008**, 5, 26-39

554 Digitalised Risk Analysis of Cardiovascular Diseases: New Possibility to Make Patients Motivated. Use of the Cardiovascular Prevention (CARMEN) Programme in the Practice. **2008**, 2, 407-416

553 Risk Factors and Event Rates in Patients With Atherothrombotic Disease in Germany: Results of the REACH Registry. **2008**, 105, 769-75

552 R \acute{e} ffences bibliographiques. **2008**, 151-171

551 DRUG DEVELOPMENT. **2009**, 15-28

- 550 NHG-Standaard Cardiovasculair risicomanagement. **2009**, 106-152 2
- 549 Hypertension. **2009**, 437-464
- 548 Prevention of Cardiovascular Disease. **2009**, 403-436
- 547 Diabetes, Pre-diabetes and Cardiovascular Diseases. **2010**, 35-52
- 546 A nutritional strategy for reducing disease and obesity risks. **2010**, 698, 68-73
- 545 Angina Pectoris. **2010**, 121-135
- 544 Diabetes Mellitus Type 2 and Cardiovascular Disease. **2010**, 137-150
- 543 3 Hypertensie in de praktijk. **2010**, 88-108
- 542 Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!. **2010**, 2,
- 541 Evidence-based data on Simvastatin: A 15-year experience. **2010**, 16, 238-249
- 540 Arteriële Hypertonie. **2011**, 251-265
- 539 Prediction of Cardiovascular Disease. **2011**, 33-45
- 538 The Use of a Cognitive Behavioral Program for Diabetes and Cardiovascular Risk Reduction. **2011**, 3361-3374
- 537 ACE-inhibitors and angiotensin receptor blockers. **2011**, 247-252
- 536 Diabetes, Pre-diabetes and Cardiovascular Diseases 2007. **2011**, 35-52
- 535 Preclinical markers of carotid atherosclerosis and cardiovascular risk assessed by the ESH/ESC scale (2003, 2007, 2009). **2011**, 10, 14-20 1
- 534 Empirical Evaluation of Ensemble Approach for Diagnostic Knowledge Management. **2011**, 20, 237-255 1
- 533 Assessment of Total Cardiovascular Risk in Hypertension: The Role of Subclinical Organ Damage. **2012**, 199-211

- 532 JUSTIFICACI3N DE LA IMPORTANCIA DE VALORAR EL RIESGO CARDIOVASCULAR EN PSORIASIS. **2012**, 1-27
- 531 Life expectancy and cause of death in men examined at medical check-ups in 1964. **2012**, 132, 30-5 1
- 530 RECOMENDACIONES EN PREVENCI3N DEL RIESGO VASCULAR. **2012**, 29-61
- 529 Arterial Stiffness as an Early Marker of Organ Damage. **2012**, 171-179
- 528 Subclinical atherosclerosis diagnostics as a component of a modern strategy for cardiovascular risk stratification. **2012**, 11, 76-84 4
- 527 Risk scoring for the primary prevention of cardiovascular disease. 1
- 526 Subclinical atherosclerosis as a risk factor of cardiovascular events. **2012**, 11, 82-86 17
- 525 PROGNOSTIC EFFECT OF BLOCKADE OF THE RIGHT BUNDLE BRANCH BLOCK PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. **2012**, 20, 94
- 524 THE PROGNOSTIC IMPORTANCE OF INFRINGEMENTS OF THE RHYTHM AND CONDUCTIVITY AT SICK OF THE MYOCARDIAL INFARCTION. **2012**, 20, 138
- 523 Genetic Influences on Blood Lipids and Cardiovascular Disease Risk. **2013**, 519-540
- 522 Risk Assessment Using Two Different Diagnostic Tools: Metabolic Syndrome and Cardiovascular Risk Score (SCORE)âData from a Weight Reduction Intervention Study. **2013**, 04, 1028-1036 1
- 521 Lifestyle Strategies for Risk Factor Reduction, Prevention and Treatment of Coronary Artery Disease. **2013**, 19-34
- 520 ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HYPERTENSION: PERSPECTIVES FOR CLINICAL USE. **2013**, 19, 117-124 2
- 519 ASSESSMENT OF TOTAL CARDIOVASCULAR RISK AS A PART OF REPEATED MEDICAL EXAMINATION OF EMPLOYEES OF A LARGE INDUSTRIAL ENTERPRISE. **2013**, 12, 43-49 1
- 518 Cardiovascular risk in obese patients with chronic periodontitis: a clinical controlled study. **2013**, 42, 188-195 3
- 517 CIRCADIAN BLOOD PRESSURE PROFILE IN YOUNG SUBJECTS WITH PRE-HYPERTENSION. **2013**, 19, 263-269 6
- 516 Predictive Value of Arterial Stiffness for Cardiovascular Events. **2014**, 257-266
- 515 Cardiovascular Risk in Young Workers with Left Bundle Branch Block. **2014**, 04, 270-274 1

- 514 The Role of CT Angiography of Coronaries in Early Diagnosis of Coronary Artery Plaques in Albanian People with No History of Cardiovascular Disease in Correlation with Traditional Risk Factors. **2014**, 26, 163-7
- 513 Epidemiology of Atherosclerotic Vascular Disease. **2014**, 1-21
- 512 Obesity and Cancer: Clinical Epidemiology. **2014**, 583-594
- 511 Opportunities of statusmetriya in evaluation of 10-year risk atherosclerosis clinical manifestations development. **2014**, 5, 16-19
- 510 Priority Areas for CVD Research. **2015**, 289-299
- 509 Myocardial infarction after carotid endarterectomy. **2015**, 8, 14
- 508 [Identification of circulatory diseases and their risk during medical examination of an adult population: methodological aspects]. **2015**, 87, 31-37 10
- 507 Integral assessment of coronary heart disease risk in the epidemiological studies (ESSE-RF in the Kemerovo Region). Communication 1: Age and sex determinants. **2015**, 18, 34 3
- 506 Epidemiology of Atherosclerotic Vascular Diseases. **2015**, 1499-1516
- 505 Raised Blood Cholesterol: Preventable Risk Factor for Cardiovascular Disease. **2015**, 69-79
- 504 [Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Part II]. **2015**, 115, 94-99
- 503 The unity of approaches to preventing coronary heart disease and cerebrovascular diseases. **2015**, 18, 24 1
- 502 EXERCISE TESTS IN CARDIOLOGY: PAST, PRESENT AND FUTURE. PART II. **2015**, 14, 82-88
- 501 Clinical Cardiovascular Proteomics. **2016**, 389-414
- 500 Rehabilitation Therapy in Patients with Heart Failure. **2016**, 603-626
- 499 Épidémiologie des facteurs de risque de l'athérosclérose. **2016**, 181-187
- 498 Impact of Co-morbidites, Physiological Status and Age on Survival. **2016**, 49-68
- 497 Interdisciplinary Approach to Cardiovascular Diseases for Research and Everyday Clinical Practice Purposes. **2016**, 339-371

496	[Results of circulatory disease detection during prophylactic medical examination of the adult population: the first two years' experience]. 2016 , 88, 46-52	7
495	Detection of early stages of atherosclerosis. 2016 , 18, 9-13	
494	Which Measures of Health Status Assessment are the Most Significant in Organized Cohorts with Low Current Cardiovascular Risk? The Screening Study of Penitentiary Staff in Saratov Region, Russia. 2016 , 48, 42-52	
493	Lipertance - a novel agent in comprehensive prevention of cardiovascular events. 2016 , 13, 200-202	
492	The hunt for fatal myocardial infarction biomarkers: predictive circulating microRNAs. 2016 , 4, S1	
491	Use Case IV: Imaging Biomarkers in Thorax and Heart. 2017 , 253-258	
490	OBSOLETE: Cardiovascular Disease Prevention. 2017 ,	
489	The value of population-based programs within «Healthy Heart Day» moves to identify hypertension and major risk factors for cardiovascular diseases. 2017 , 20, 17	2
488	Algorithm for predicting CHD death risk in Turkish adults: conventional factors contribute only moderately in women. 2017 , 17, 436-444	1
487	Diabetes Mellitus Type 2 and Cardiovascular Disease. 2017 , 153-168	
486	Towards Pervasive Predictive Analytics in Interactive Prevention and Rehabilitation for Older People. 2017 , 1-11	
485	Level of FABP3, FABP4, Nt-proBNP and Total Cardiovascular Risk in the Population of Central Kazakhstan. 2017 , 5, 33-36	
484	The prevalence of factors of cardiovascular and metabolic risks according data of health centers. 2017 , 23, 4-10	1
483	Combination of susceptibility gene and traditional risk factors might enhance the performance of coronary heart disease screening strategy. 2017 , 8, 69005-69011	
482	Treatment of patients with high cardiovascular risk: a modern view on combined therapy. 2017 , 14, 12-16	0
481	[Is stress cardiovascular magnetic resonance really useful to detect ischemia and predict events in patients with different cardiovascular risk profile?]. 2017 , 87, 116-123	
480	Risk factors for cardiovascular diseases in the descendants of patients after early myocardial infarction. 2017 , 63, 398-402	2
479	. 2017 , 106, 921-926	0

- 478 Peripheral arterial disease and cardiovascular risk. The importance of Doppler in multi-pathological population. **2017**, 2, 026-033
- 477 Relations Between Diabetes, Kidney Disease and Metabolic Syndrome: Dangerous Liaisons. **2017**, 24, 355-362
- 476 INNOVATION TECHNOLOGY OF SUBCLINICAL ATHEROSCLEROSIS VERIFICATION. **2017**, 2, 28-35 1
- 475 PRECLINICAL ATHEROSCLEROSIS AND MODERN METHODS OF ITS DIAGNOSIS. **2017**, 19, 9-16
- 474 Les anti-inflammatoires non stéroïdiens. **2018**, 619-636
- 473 Prevalence of cardiovascular risk factors among teachers of Saint Petersburg universities. **2018**, 21, 42
- 472 Biomarkers: Population Screening and Risk-Stratification. **2018**, 323-333
- 471 Traitement des dyslipidémies. **2018**, 123-139.e1
- 470 Comment on: Clinical Validity, Understandability, and Actionability of Online Cardiovascular Disease Risk Calculators: Systematic Review. **2018**, 20, e10093 2
- 469 CATESTATIN AS A NOVEL MARKER OF CARDIOVASCULAR RISK IN SYSTEMIC HYPERTENSION. **2018**, 111-116
- 468 PROGNOSTIC SIGNIFICANCE OF ENDOTHELIAL DYSFUNCTION MARKERS IN ARTERIAL HYPERTENSION. **2018**, 7-13 4
- 467 ACCORDING TO THE MATERIALS OF THE 2015/2016 NEW EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) GUIDELINES FOR REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY ARTHRITIS: GENERAL CHARACTERIZATION AND DISCUSSION PROBLEMS. **2018**, 51, 373-378 1
- 466 Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. **2018**, 11, 378-387 2
- 465 SCORE Kardiyovaskler Risk Puanlama Sistemi ile Non-dipper Hipertansiyon Arasındaki İlişki. 379-386
- 464 Total cardiovascular risk among native population of Kyrgyzstan with diabetes mellitus type 2 and impaired glucose tolerance in high- and low-altitude regions. 3, 3
- 463 Interdisciplinary Approach to Cardiovascular Diseases for Research and Everyday Clinical Practice Purposes. **2019**, 139-171 1
- 462 Diabetes and Cardiovascular Disease. **2019**, 709-730
- 461 Development and validation of a next-gen health stratification engine to determine risk for multiple cardiovascular diseases. 0

460 Improving the Quality of Life of Patients with Arterial Hypertension in Diabetes Mellitus. **2019**, 9, 110-114

459 Prediction performance of a cardiovascular risk assessment tool using Stanford EHR data repository.

458 Disease overarching mechanisms that explain and predict outcome of patients with high cardiovascular risk: rationale and design of the Berlin Long-term Observation of Vascular Events (BeLOVE) study. 1

457 Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations). **2019**, 57, 255-264 2

456 Two-channel portable fluorescence meter for risk stratification of cardiovascular diseases. **2019**,

455 Sympathetic nervous system and cardiovascular risk in mitral valve prolapse. **2019**, 19, 51-57 1

454 [The Method of Assessment of the Population Risk of Cardiovascular Diseases: Rationale and Examples of Application]. **2019**, 59, 44-51

453 Role of miRNAs induced by oxidized low-density lipoproteins in coronary artery disease: the REGICOR Study.

452 Use of polygenic risk scores and other molecular markers to enhance cardiovascular risk prediction: prospective cohort study and modelling analysis.

451 [Age characteristics of risk cardiovascular complications in women with left breast cancer with preserved ejection fraction at the stage of chemotherapy and radiotherapy]. **2019**, 59, 23-30

450 Approaches to Primary Prevention of Cardiovascular Diseases in Dyslipidemia. **2019**, 34-40

449 [Cardiovascular risk tables. Present and future]. **2019**, 36, 173-175

448 Cardiovascular risk factors in patients with calcium pyrophosphate crystal deposition disease. **2019**, 57, 545-552 6

447 Reclassification by applying the Framingham equation 30 years to subjects with intermediate cardiovascular risk. MARK study. **2019**, 153, 351-356

446 Early cognitive dysfunction as a marker for the poor course of multiple sclerosis: a prospective 12-year follow-up. **2019**, 11, 47-51 1

445 Effects of aged garlic extract on arterial elasticity in a placebo-controlled clinical trial using EndoPAT[®] technology. **2020**, 19, 1490-1499 1

444 Significance of General Laboratory Examination in the Diagnosis of Secondary Hypertension. **2020**, 29-64

443 Ejercicio en prevenci3n primaria de enfermedad cardiovascular y c3ncer. **2019**, 26, 44-51

442	Blood Pressure Variability in Pregnancy: an Opportunity to Develop Improved Prognostic and Risk Assessment Tools. 2020 , 22, 10	1
441	CARDIOVASCULAR RISK ASSESSMENT IN MEN AGED 18-29. 2020 , 18, 253-257	
440	Association of Cardiovascular Events and Blood Pressure and Serum Lipoprotein Indicators Based on Functional Data Analysis as a Personalized Approach to the Diagnosis. 2020 , 278-293	1
439	Proteinuria from an internist's point of view. 2020 , 66, e55-e57	1
438	Adherence to cardiovascular prevention principles in subjects at high risk. 2020 , 66, e5-e12	
437	Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. 2020 , 35, 367-376	1
436	Polymorphism rs2762939 of CYP24A1 enzyme and coronary artery disease: angiographic results from a large prospective cohort of patients. 2020 , 31, 366-371	0
435	Limited Utility of Cardiovascular Risk Scores for People Living with HIV in Malawi.	0
434	Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study. 2021 , 1	3
433	The Acceptance and Use of the e-Health Instrument 'The Personal Health Check' in Four Dutch Municipalities: Lessons Learned. 2021 , 1	
432	The 10-year incidence of hypertension across blood pressure categories in a population-based cohort in southwestern Sweden. 2021 , 21, 523	1
431	Comparison of risk assessment tools for cardiovascular diseases: results of an Iranian cohort study. 2021 , 200, 116-123	
430	Distributions and burden of coronary calcium in asymptomatic Saudi patients referred to computed tomography. 2021 , 37, 100902	
429	Gender differences in left ventricular hypertrophy regression after renal denervation in patients with resistant hypertension. 2020 , 34, 128-135	
428	Risk Assessment in CVD. 2020 , 33-60	
427	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. 2020 , 42, e35-e40	1
426	Use of cardiovascular imaging in risk restratification of the diabetic patient. 2021 , 28, 122-133	1
425	HIV and Dyslipidemia. 2021 , 431-466	

424	Cardiovascular Risk Assessment: From Global Risk Scoring to Risk Enhancing Factors. 2021 , 35-59	
423	Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. 2020 , 42, e41-e48	2
422	Global brain glucose uptake on 18F-FDG-PET/CT is influenced by chronic cardiovascular risk. 2021 , 42, 444-450	0
421	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. 2020 , 42, e25-e29	
420	Cardiovascular Risk in Adults and its Association with Health Services Utilization. ENSANUT 2018-2019. 2020 , 10, 809-824	
419	Acute-Phase Stroke Outcome and Lipids.. 2021 , 55, 538-544	1
418	THE IMPACT OF OCCUPATIONAL AND LIFESTYLE FACTORS ON STATE OF ARTERIAL VESSELS IN COPPER INDUSTRY WORKERS. 2020 , 99, 45-50	1
417	Strategic directions for non-communicable disease prevention and control in the framework of international activities of the FSBI «National medical research center for therapy and preventive medicine» under the Ministry of Health of the Russian Federation. 2020 , 23, 7	1
416	What is the best Cardiovascular Risk Score for the Brazilian Population?. 2020 , 33, 627-628	
415	COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN AND RED BLOOD CELLS DISTRIBUTION WIDTH LEVELS IN SUBGROUPS DEPENDING ON THE SEVERITY OF HYPERLIPIDEMIA ACCORDING TO LABORATORY REGISTRY DATA. 2020 , 241-245	
414	Development and validation of a nomogram to predict coronary heart disease in patients with rheumatoid arthritis in northern China. 2020 , 12, 3190-3204	2
413	Cardiovascular Disease Risk Factors among Copper Industry Workers of the Sverdlovsk Region. 2020 , 33-37	
412	Risk factors for cardiovascular disease in ethnic Europeans and Koreans living in the Primorsky Krai. 2020 , 19, 40-47	3
411	The estimation scale of the daily pedometry of senior students. 2020 , 24, 100-108	
410	Higher Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients Without Methotrexate Treatment. 2021 , 12, 703279	
409	Physical fitness and cardiovascular risk factors in the novel diabetes subgroups. 2021 ,	0
408	Increased isoDGR motifs in plasma fibronectin are associated with atherosclerosis through facilitation of vascular fibrosis.	
407	Reliability between Cardiovascular Risk Assessment Tools: A Pilot Study. 2020 ,	

406	The Burden of Smoking on Cardiovascular Disease. 2007 , 227-234	
405	Pharmacotherapy in Prevention and Rehabilitation. 2007 , 439-453	0
404	Cardiac Rehabilitation: Canada. 2007 , 37-40	
403	Die Heinz Nixdorf Recall Studie – Risikofaktoren, koronarer Kalk und Lebensstil. 2008 , 521-538	
402	Nuclear Cardiology in Women. 2009 , 287-297	
401	Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis. 2020 , 9,	
400	Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care setting.	1
399	Adherence to statin therapy in patients with high and very high cardiovascular risk in real clinical practice. 2020 , 11, 38-48	1
398	The Use of SCORE and GRACE Risk Tools to Assess the Length of Stay in a Cardiac Intensive Care Unit. 2021 , 1101-1111	
397	Identification of Clinically Relevant Rules: An Interpretable Approach for CVD Risk Assessment. 2021 , 644-654	
396	Estimation of the cardiovascular risk using world health organization/international society of hypertension risk prediction charts in Central Vietnam. 2020 , 15, e0242666	0
395	Assessment of cardiovascular risk in Kyrgyz Republic. 4,	
394	The association between GP organisational factors and the effectiveness of a prevention programme for cardiometabolic diseases: a prospective intervention study. 2020 , 4,	
393	[Vascular age in a sample of general population of the sanitary area of Toledo (Spain). RICARTO study]. 2021 , 157, 513-523	
392	Cardiology. 2004 , 54, 695-702	2
391	The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. 2005 , 55, 838-45	87
390	Comprehensive cardiovascular risk management--what does it mean in practice?. 2007 , 3, 587-603	11
389	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. 2007 , 3, 711-9	2

388	Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. 2007 , 3, 491-502	49
387	Multivariate risk assessment and risk score cards in hypertension. 2007 , 3, 313-20	3
386	Cardiovascular high-risk patients--treat to protect, but whom?. 2008 , 10 Suppl, S2	2
385	Rationale for multiple risk intervention: the need to move from theory to practice. 2007 , 3, 985-97	11
384	The independent relationship between triglycerides and coronary heart disease. 2009 , 5, 89-95	45
383	Causal beliefs and perceptions of risk for diabetes and cardiovascular disease, The Netherlands, 2007. 2011 , 8, A130	17
382	K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome. 2006 , 1, 169-80	
381	Genome-wide association studies in myocardial infarction and coronary artery disease. 2010 , 5, 116-21	1
380	Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. 2013 , 138, 461-91	13
379	Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: a case study. 2008 , 19, 97-101	5
378	An evaluation of coronary atherosclerosis using coronary CT in subjects with asymptomatic carotid lesions. 2014 , 10, 22-8	2
377	New cardiovascular risk factors and their use for an accurate cardiovascular risk assessment in hypertensive patients. 2014 , 9, 127-34	3
376	Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis?. 2014 , 7, 461-7	3
375	Dispersion of ventricular repolarization in relation to cardiovascular risk factors in hypertension. 2014 , 7, 545-50	4
374	Utility of different cardiovascular disease prediction models in rheumatoid arthritis. 2014 , 7, 588-94	3
373	Trends in the Risk for Cardiovascular Disease among Adults with Diabetes in Oman. 2015 , 15, e39-45	3
372	Prediction of risk of cardiovascular events in patients with mild to moderate coronary artery lesions using naïve Bayesian networks. 2016 , 13, 899-905	1
371	Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. 2018 , 2,	18

- 370 A Comparison of Patient History- and EKG-based Cardiac Risk Scores. **2019**, 2019, 82-91
- 369 10-year risk of cardiovascular disease and body mass index in association with the obesity paradox. **2020**, 16, 16-23 1
- 368 Estimation of the 10-Year Risk of Cardiovascular Diseases: Using the SCORE, WHO/ISH, and Framingham Models in the Shahrekord Cohort Study in Southwestern Iran. **2020**, 15, 105-112 1
- 367 Cardiovascular risk and aging: the need for a more comprehensive understanding. **2021**, 18, 462-478 2
- 366 How Do We Measure Stress as a Risk Factor?. **2021**, 16, 3-5
- 365 Cardiovascular event risk estimation among residents of a rural setting in Bayelsa state, Nigeria. **2021**, 11, 300-315
- 364 Understanding the association between endothelial dysfunction and left ventricle diastolic dysfunction in development of coronary artery disease and heart failure. **2021**, 92, e2021204
- 363 Occupational class differences in ankle-brachial index and pulse wave velocity measurements to detect subclinical vascular disease. **2021**, 112, 268-278
- 362 Association between estimated glomerular filtration rate and 10-year atherosclerotic cardiovascular disease risk among community residents in Shanghai, China.. **2021**, 1
- 361 Can machine learning bring cardiovascular risk assessment to the next level?. 0
- 360 Machine Learning to Predict Long-Term Cardiac-Relative Prognosis in Patients With Extra-Cardiac Vascular Disease.. **2021**, 8, 771504
- 359 Outcomes in patients with a first episode of chest pain undergoing early coronary CT imaging. **2021**, 0
- 358 Actionable absolute risk prediction of atherosclerotic cardiovascular disease: a behavior-management approach based on data from 464,547 UK Biobank participants.
- 357 Behandlung der arteriellen Hypertonie in der Hausarztpraxis. **2021**, 02, 327-338
- 356 Nailfold videocapillaroscopy identifies microvascular pathologies in psoriasis vulgaris: Results of a prospective controlled study. **2021**, 19, 1736-1744 3
- 355 Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). **2021**, 16, e0259372 0
- 354 Gender Differences in the Diagnosis of Dyslipidemia: ESCARVAL-GENERO. **2021**, 18, 2
- 353 Statin Therapy in Very Old Patients: Lights and Shadows.. **2021**, 8, 779044 2

352	Prediction of Cardiovascular Parameters With Supervised Machine Learning From Singapore "I" Vessel Assessment and OCT-Angiography: A Pilot Study. 2021 , 10, 20	3
351	Influence of physical activity, the Mediterranean diet and sociodemographic variables on the values of different cardiovascular risk scales. 2021 , 1-11	
350	Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients. 2021 , 1	0
349	It's Time to Add Electrocardiography and Echocardiography to CVD Risk Prediction Models: Results from a Prospective Cohort Study. 2021 , 14, 4657-4671	0
348	The COVID-19 pandemic and temporal change in metabolic risk factors for cardiovascular disease: a natural experiment within the HELIUS study.	
347	Vascular age in a sample of general population of the sanitary area of Toledo (Spain). RICARTO study. 2021 , 157, 513-523	
346	Cost-Effectiveness of Portable Electrocardiogram for Screening Cardiovascular Diseases at a Primary Health Center in Ahmedabad District, India.. 2021 , 9, 753443	0
345	Web-Based Decision Support System for Coronary Heart Disease Diagnosis.. 2021 , 1338, 31-38	
344	Prediabetes as a risk factor for major adverse cardiovascular events. 2021 , 53, 2090-2098	1
343	Glycosylation and Cardiovascular Diseases. 2021 , 1325, 307-319	1
342	Understanding the bias in machine learning systems for cardiovascular disease risk assessment: The first of its kind review.. 2022 , 142, 105204	8
341	Impact of a Patient's Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making.. 2021 , e017605	
340	Using clinical prediction models to personalise lifestyle interventions for cardiovascular disease prevention: A systematic literature review.. 2022 , 25, 101672	
339	Estimation of the 10-Year Risk of Cardiovascular Diseases: Using the SCORE, WHO/ISH, and Framingham Models in the Shahrekord Cohort Study in Southwestern Iran. 2020 , 15, 105-112	1
338	An explainable XGBoost-based approach towards assessing the risk of cardiovascular disease in patients with Type 2 Diabetes Mellitus. 2020 ,	4
337	Coronary atherosclerotic burden in veteran male recreational athletes with low to intermediate cardiovascular risk. 2020 , 39, 587-594	
336	Performance of Cardiovascular Risk Equations versus Vascular Ultrasound in Systemic Lupus Erythematosus in a Black African Population. 2021 , 11, 523-532	
335	Preventing unnecessary imaging in patients suspect of coronary artery disease through machine learning of electronic health records.	2

- 334 New evidences on the association between HDL-C and cardiovascular risk: a never ending research story.. **2022**, 0
- 333 Cardiorespiratory fitness and mortality from all causes, cardiovascular disease and cancer: dose-response meta-analysis of cohort studies.. **2022**, 1
- 332 Comments on the section "Cardiovascular risk estimation" in the 2021 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice. **2022**, 21, 3171 3
- 331 Models for risk assessment and stratification. **2022**, 119-150
- 330 Predicting Coupled Herbs for the Treatment of Hypertension Complicated with Coronary Heart Disease in Real-World Data Based on a Complex Network and Machine Learning.. **2022**, 2022, 8285111 0
- 329 Cardiovascular Risk Models in Chronic Kidney Disease: A Systematic Review and External Validation of Models. 3
- 328 Cardiovascular risk assessment tools in Asia.. **2022**, 1
- 327 Cardiovascular risk prediction equations underestimate risk in people living with HIV: Comparison and cut-point redefinition for 19 cardiovascular risk equations.. **2022**, 3
- 326 Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction.. **2022**, 12, 1033 3
- 325 Prediction and risk stratification from hospital discharge records based on Hierarchical sLDA.. **2022**, 22, 14
- 324 Prevalence of cardiovascular risk factors in superior vestibular neuritis: A cross-sectional study following STROBE guidelines.. **2022**, 1
- 323 The Association of Dietary Intake with Arterial Stiffness and Vascular Ageing in a Population with Intermediate Cardiovascular Risk-A MARK Study.. **2022**, 14, 0
- 322 Effectiveness of Lifestyle Modification vs. Therapeutic, Preventative Strategies for Reducing Cardiovascular Risk in Primary Prevention-A Cohort Study.. **2022**, 11, 0
- 321 A machine learning framework for risk prediction of multi-label cardiovascular events based on focused carotid plaque B-Mode ultrasound: A Canadian study.. **2021**, 140, 105102 2
- 320 The CLL-IPI applied in Binet A CLL: a nation-wide cohort study.. **2022**, 1
- 319 Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings.. **2022**, 65, 644 1
- 318 Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology.. **2022**, 37, 61-72
- 317 Prediction of Cardiovascular and All-Cause Mortality After Myocardial Infarction in US Veterans.. **2022**, 1

316	Association of Retinal Age Gap with Arterial Stiffness and Incident Cardiovascular Disease.	0
315	SEA 2022 Standards for Global Control of Cardiovascular Risk.. 2022,	0
314	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. 16,	0
313	Contemporary Review of Risk Scores in Prediction of Coronary and Cardiovascular Deaths.. 2022, 24, 7	
312	Rheumatoid arthritis patients "al nostro cuore".. 2021,	0
311	Neural network-based integration of polygenic and clinical information: development and validation of a prediction model for 10-year risk of major adverse cardiac events in the UK Biobank cohort.. 2022, 4, e84-e94	2
310	Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial. 2022,	0
309	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. 2022,	6
308	Simple cardiovascular risk stratification by replacing total serum cholesterol with anthropometric measures: The MORGAM prospective cohort project.. 2022, 26, 101700	0
307	Actionable absolute risk prediction of atherosclerotic cardiovascular disease based on the UK Biobank.. 2022, 17, e0263940	
306	Electrocardiogram-Based Heart Age Estimation by a Deep Learning Model Provides More Information on the Incidence of Cardiovascular Disorders.. 2022, 9, 754909	3
305	A short history of the European Association of Preventive Cardiology (EAPC).. 2022,	0
304	Ideal cardiovascular health duration and risk of chronic kidney disease and cardiovascular disease.. 2021,	0
303	Gene expression profiling of coronary artery disease and its relation with different severities. 2018, 97, 853-867	1
302	Cardiovascular risk associated with co-morbid insomnia and sleep apnoea (COMISA) in type 2 diabetics.. 2022, 15, 184-194	0
301	Conceptual design of the dual X-ray absorptiometry health informatics prediction system for osteoporosis care.. 2022, 28, 14604582211066465	0
300	Chronic inflammatory diseases, subclinical atherosclerosis, and cardiovascular diseases: Design, objectives, and baseline characteristics of a prospective case-cohort study - ELSA-Brasil.. 2022, 77, 100013	1
299	Simulating Delay in Seeking Treatment for Stroke Due to COVID-19 Concerns with a Hybrid Agent-Based and Equation-Based Model. 2022, 379-391	

298	Cardiac computed tomographic angiography after abnormal ischemia test as a gatekeeper to invasive coronary angiography.. 2022 , 1	1
297	Supervised and unsupervised learning to define the cardiovascular risk of patients according to an extracellular vesicle molecular signature.. 2022 ,	3
296	Development and validation of a cardiovascular diseases risk prediction model for Chinese males (CVDMMCM).	
295	Age Specific Models to Capture the Change in Risk Factor Contribution by Age to Short Term Primary Ischemic Stroke Risk.. 2022 , 13, 803749	1
294	Cardiovascular disease risk in rheumatoid arthritis.. 2022 , 31, 190-192	
293	Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older.. 2021 , CIRCGEN121003429	0
292	Kidney function and the risk of sudden cardiac death in the general population.	
291	Correlation between Coronary Artery Calcium- and Different Cardiovascular Risk Score-Based Methods for the Estimation of Vascular Age in Caucasian Patients.. 2022 , 11,	
290	High cardiovascular risk in older patients with opioid use disorder: Differences with the general population.. 2022 ,	
289	Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?. 2022 , 12, e057476	
288	[Arterial Hypertension].. 2022 , 147, 414-428	0
287	The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.. 2022 ,	
286	Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease.. 2022 , 17, e0265050	0
285	Circulating MicroRNAs as Novel Biomarkers in Risk Assessment and Prognosis of Coronary Artery Disease.. 2022 , 17, e06	4
284	Cardiovascular Risk Perception and Knowledge among Italian Women: Lessons from IGENDA Protocol.. 2022 , 11,	2
283	Blood Pressure Hyperreactivity to Standing: a Predictor of Adverse Outcome in Young Hypertensive Patients.. 2022 , HYPERTENSIONAHA12118579	0
282	Noninvasive Voice Biomarker Is Associated With Incident Coronary Artery Disease Events at Follow-up.. 2022 ,	2
281	[Mortality, cardiovascular risk, and health status in a male cohort initiated in 1968. The Manresa study].. 2022 ,	0

280	A Powerful Paradigm for Cardiovascular Risk Stratification Using Multiclass, Multi-Label, and Ensemble-Based Machine Learning Paradigms: A Narrative Review.. 2022 , 12,	3
279	Cardiovascular risk assessment with carotid ultrasound in rheumatoid arthritis.. 2022 ,	3
278	L'essentiel des recommandations 2021 de la Société européenne de cardiologie pour la prévention cardiovasculaire. Que faut-il retenir?. 2022 ,	
277	Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.. 2022 ,	1
276	Methodological conduct of prognostic prediction models developed using machine learning in oncology: a systematic review.. 2022 , 22, 101	0
275	Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies.. 2022 , 1	2
274	Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling.. 2022 , 12, e058215	1
273	Comparison of American and European Guidelines for Primary Prevention of Cardiovascular Disease: JACC Guideline Comparison.. 2022 , 79, 1304-1313	1
272	Association of epicardial adipose tissue with different stages of coronary artery disease: A cross-sectional UK Biobank cardiovascular magnetic resonance imaging substudy.. 2022 , 40, 101006	0
271	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement.. 2022 , 10, 100335	3
270	Nonlaboratory-based risk assessment model for coronary heart disease screening: Model development and validation.. 2022 , 162, 104746	0
269	Evaluation of Cardiovascular Diseases Risk in the Iranian Population. 2021 , 1,	
268	Mikrovaskuläre Pathologien bei Patienten mit Psoriasis vulgaris mittels Nagelfalzkapillarmikroskopie identifiziert: Ergebnisse einer prospektiven kontrollierten Studie. 2021 , 19, 1736-1745	
267	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis.. 2021 , 11,	0
266	Absolute Cardiovascular Disease Risk Assessed in Old Age Predicts Disability and Mortality: A Retrospective Cohort Study of Community-Dwelling Older Adults.. 2021 , 10, e022004	1
265	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases.. 2021 , 14, 6893-6906	1
264	Neuroimaging cerebrovascular biomarkers in Parkinson's disease. 2021 , 19714009211059118	
263	Anthropometric measures and biomarkers for cardiovascular disease risk factors: evidence from a study of Polish adults participating in the cardiovascular disease prevention program (CHUK). 2022 , 84, 431-441	

- 262 Decreased retinal vascular complexity is an early biomarker of MI supported by a shared genetic control.
- 261 The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients.. **2022**, 8, e1272 1
- 260 Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. **2021**,
- 259 Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.. **2021**, 8, 1
- 258 Workplace Interventions Aimed to Reduce the Risk of Cardiovascular Disease: A Systematic Review. **2021**, 17-29
- 257 Grounding of Pilots: Medical Reasons and Recommendations for Prevention.. **2021**, 92, 950-955 0
- 256 Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. **2021**, 1
- 255 SCORE2 SCORE in patients with systemic lupus erythematosus.. **2022**, 14, 1759720X221092373
- 254 Cardiovascular risk prevention in clinical medicine: current guidelines in the United States and in Europe. **2022**, 471-490
- 253 Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events.. **2022**, 54, 1036-1046 1
- 252 Scoring systems of metabolic syndrome and prediction of cardiovascular events: A population based cohort study.. **2022**,
- 251 Associations of genetic and infectious risk factors with coronary heart disease.
- 250 Validation of the 30-Year Framingham Risk Score in a German Population-Based Cohort.. **2022**, 12,
- 249 Effectiveness of Statins for Primary Prevention of Cardiovascular Disease in Low- and Medium-Risk Males: A Causal Inference Approach with Observational Data. **2022**, 12, 658 0
- 248 Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.. **2022**, 1-10 0
- 247 Could Artificial Intelligence/Machine Learning and Inclusion of Diet-Gut Microbiome Interactions Improve Disease Risk Prediction? Case Study: Coronary Artery Disease.. **2022**, 13, 627892 0
- 246 Quantifying Societal Burden of Radiation-Induced Cardiovascular Events in Breast Cancer Survivors.. **2022**, 12, 869529
- 245 MicroRNA-134-5p and the Extent of Arterial Occlusive Disease Are Associated with Risk of Future Adverse Cardiac and Cerebral Events in Diabetic Patients Undergoing Carotid Artery Stenting for Symptomatic Carotid Artery Disease.. **2022**, 27, 0

244 Data_Sheet_1.PDF. **2020**,

243 Table_1.DOCX. **2020**,

242 table_1.docx. **2018**,

241 Absolute cardiovascular risk scores and medication use in rural India: a cross-sectional study.. **2022**, 12, e054617

240 The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases. **2021**, 18, 816-824

239 Artificial Intelligence- and Radiomics-Based Evaluation of Carotid Artery Disease. **2022**, 513-523

238 Dietary Acid Load but Not Mediterranean Diet Adherence Score Is Associated With Metabolic and Cardiovascular Health State: A Population Observational Study From Northern Italy.. **2022**, 9, 828587 3

237 Ethnic differences in cardiovascular risk: examining differential exposure and susceptibility to risk factors.. **2022**, 20, 149 1

236 2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. **2022**, 21, 3235 11

235 Undertreatment or Overtreatment With Statins: Where Are We?. **2022**, 9, 808712 1

234 Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis.. **2022**, 12, 7498 1

233 NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes.. **2022**, 14, 64 0

232 Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. **2022**, 9, 0

231 . **2022**,

230 Derivation, internal validation, and recalibration of a cardiovascular risk score for Latin America and the Caribbean (Glorisk-LAC): A pooled analysis of cohort studies. **2022**, 9, 100258

229 Objectively Assessed Cardiorespiratory Fitness and All-Cause Mortality Risk: An Updated Meta-analysis of 37 Cohort Studies Involving 2,258,029 Participants.. **2022**, 4

228 Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care.. **2022**, 17, e0266816 0

227 Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.. **2022**, 1 3

226	How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients With and Without Previous Cardiovascular Disease?. 2022 , 1	2
225	Prognostic Value of Stress CMR in Symptomatic Patients With Coronary Stenosis on CCTA. 2022 ,	0
224	The Association Between the Frequency of Annual Health Checks Participation and the Control of Cardiovascular Risk Factors. 2022 , 9,	
223	Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. 2022 , 48, 101435	0
222	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society.. 2022 , 163, 1-14	4
221	Performance Analysis of Cardiovascular Diseases Using Machine Learning. 2022 , 188-197	
220	Cardiac troponin T and NT-proBNP for detecting myocardial ischemia in suspected chronic coronary syndrome.. 2022 ,	0
219	Cardiovascular Risk Stratification in Diabetic Retinopathy via Atherosclerotic Pathway in COVID-19/non-COVID-19 Frameworks using Artificial Intelligence Paradigm: A Narrative Review. 2022 , 12, 1234	1
218	Shared-care survivorship program for testicular cancer patients: safe and feasible.. 2022 , 7, 100488	
217	Toepassing van carotis intimamediadikte- en plaquemetingen bij preventief medisch onderzoek. 2009 , 17, 185-190	1
216	An Ensemble Learning Method for Constructing Prediction Model of Cardiovascular Diseases Recurrence. 2022 , 208-220	
215	Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.. 2022 , 22, 342	0
214	The Management of Cardiovascular Disease Risk in Patients with Rheumatoid Arthritis.. 2022 ,	
213	Cardiovascular Diseases and Periodontitis. 2022 , 261-280	1
212	Cardiovascular Risk Assessment in Metabolic Syndrome and Diabetes. 2022 , 89-105	
211	European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease. 2022 , 35-58	
210	The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents. 2022 , 23, 5617	0
209	Cardiovascular Risk Assessment by SCORE2 Predicts Risk for Colorectal Neoplasia and Tumor-Related Mortality. 2022 , 12, 848	0

- 208 Cardiovascular Disease Risk Modeling for Astronauts: Making the Leap From Earth to Space. **2022**, 9, 0
- 207 Occupational and Leisure Physical Activity on Cardiovascular Risk and Body Composition Among Courier Workers. 109980042211055
- 206 Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). **2022**, 27, 5006 1
- 205 Relation between periodontitis and risk of cardiovascular disease: Insights from The Tromsø Study. 0
- 204 Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study. **2022**, 9, 1
- 203 Lipidome- and genome-wide study to understand sex differences in circulatory lipids.
- 202 Marital Status and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals.
- 201 Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study. **2022**, 2022, 1-9
- 200 Artificial Intelligence in Predicting Systemic Parameters and Diseases From Ophthalmic Imaging. 4, 0
- 199 Improving Cardiovascular Outcomes: The Era of Personalized Therapy in Atherosclerosis. **2022**, 11, 3077
- 198 Developing Clinical Prediction Models Using Primary Care Electronic Health Record Data: The Impact of Data Preparation Choices on Model Performance. **2022**, 2,
- 197 Les outils d'estimation du risque cardiovasculaire, le Score2 de l'ESC. **2022**, 2022, 35-42
- 196 Association of blood lipids with coronary artery plaque among Saudi patients referred to computed tomography. **2022**, 22,
- 195 Polygenic Risk Score Improves the Accuracy of a Clinical Risk Score for Coronary Artery Disease.
- 194 Gender gap in annual preventive care services in France. **2022**, 49, 101469 0
- 193 Intelligent digitalization of cardiovascular risks. **2022**, 77-94
- 192 Choroidal thickness and granulocyte colony-stimulating factor in tears improve the prediction model for coronary artery disease. **2022**, 21,
- 191 Heterogeneity in coronary heart disease risk. **2022**, 12, 0

- 190 Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health. 4
- 189 2022 Taiwan lipid guidelines for primary prevention. **2022**, 1
- 188 Machine Learning Coronary Artery Disease Prediction Based on Imaging and Non-Imaging Data. **2022**, 12, 1466
- 187 Beneficial effects of RAS blockers in prediabetics with a hypertension-An observational cohort study. **2022**, 9, 65-73
- 186 A novel method for vascular age estimation via pressure pulse wave of radial artery. **2022**, 78, 103904
- 185 Cardio-metabolic risk modeling and assessment through sensor-based measurements. **2022**, 165, 104823
- 184 Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease. **2022**, 11, 100363
- 183 SEA 2022 standards for the comprehensive control of cardiovascular risk. **2022**, 34, 130-179
- 182 The profile of HDL-C subfractions and their association with cardiovascular risk in the Hungarian general and Roma populations. **2022**, 12, 1
- 181 The power and wisdom of prevention. Cardiovascular risk, new challenge, and approach to PLWH. **2022**, 64, 291-299
- 180 The experience of the decision-making algorithm of primary healthcare for the elderly patients with cardiovascular diseases. **2022**, 11, 85-97 1
- 179 An independent external validation of the QRISK3 cardiovascular risk prediction model applied to UK Biobank participants.
- 178 Light intensity physical activity is beneficially associated with brain volume in older adults with high cardiovascular risk. 9,
- 177 Pre-screening to guide coronary artery calcium scoring for early identification of high-risk individuals in the general population. 0
- 176 Development and Validation of a Personalized, Sex-Specific Prediction Algorithm of Severe Atheromatosis in Middle-Aged Asymptomatic Individuals: The ILERVAS Study. 9,
- 175 Utilidad de una aplicaci3n web interactiva en la mejora del control de los factores de riesgo cardiovascular. Proyecto Control-RCV. **2022**,
- 174 Machine-Learning Score Using Stress CMR for Death Prediction in Patients With Suspected or Known CAD. **2022**, 0
- 173 The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?. 0

- 172 [[Artículo traducido]]Realizaci3n del examen de calcio en los pacientes con psoriasis severa: evaluaci3n del riesgo y potencial de reclasificaci3n en una poblaci3n de riesgo cardiovascular bajo. **2022,**
- 171 Approach to Patients with Obesity and Other Cardiovascular Risk Factors in Primary Care Using the Delphi Methodology. **2022,** 11, 4130
- 170 Assessment of Cardiovascular Disease Risk. **2022,** ○
- 169 Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: A Population-Based Study. **2004,** 13, 1646-1650 44
- 168 Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine. **2022,** 12, 1180 ○
- 167 Socioeconomic Deprivation: An Important, Largely Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease. **2022,** 146, 240-248 1
- 166 The association between essential trace element mixture and atherosclerotic cardiovascular disease risk among Chinese community-dwelling older adults.
- 165 Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. ○
- 164 Risk of bias of prognostic models developed using machine learning: a systematic review in oncology. **2022,** 6, ○
- 163 The Impact of 51 Risk Factors on Life Expectancy in Canada: Findings from a New Risk Prediction Model Based on Data from the Global Burden of Disease Study. **2022,** 19, 8958
- 162 Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. **2022,** 59, 1369-1381
- 161 Association of Retinal Age Gap With Arterial Stiffness and Incident Cardiovascular Disease. 2
- 160 An evolutionary machine learning algorithm for cardiovascular disease risk prediction. **2022,** 17, e0271723 ○
- 159 Impact of outcome definitions on cardiovascular risk prediction in a contemporary primary prevention population.
- 158 Associations between dairy fat intake, milk-derived free fatty acids, and cardiometabolic risk in Dutch adults. 1
- 157 Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation. 1
- 156 Risk assessment of interstate pipelines using a fuzzy-clustering approach. **2022,** 12,
- 155 Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons. ○

- 154 Association of physical activity with vascular aging in a population with intermediate cardiovascular risk, analysis by sex: MARK study. **2022**, 13, ○
- 153 Comparing Atrial-Fibrillation Validated Rapid Scoring Systems in the Long-Term Mortality Prediction in Patients Referred for Elective Coronary Angiography: A Subanalysis of the BiaÅstok Coronary Project. **2022**, 19, 10419
- 152 Higher Arm Versus Lower Arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-Analysis of Individual Participant Data From the INTERPRESS-IPD Collaboration.
- 151 Exercise intervention on cardiorespiratory fitness in rheumatoid arthritis patients with high cardiovascular disease risk: a single-arm pilot study. ○
- 150 The comparison of cardiovascular disease risk prediction scores and evaluation of subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study.
- 149 Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines. **2022**, ○
- 148 CohenâKappa Coefficient as a Measure to Assess Classification Improvement following the Addition of a New Marker to a Regression Model. **2022**, 19, 10213 1
- 147 Comparison between Carotid Distensibility-Based Vascular Age and Risk-Based Vascular Age in Middle-Aged Population Free of Cardiovascular Disease. **2022**, 11, 4931
- 146 Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study. **2022**, 50, 10-16
- 145 GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis. **2022**, 12, 100373 2
- 144 Interplay between Artificial Intelligence and Biomechanics Modeling in the Cardiovascular Disease Prediction. **2022**, 10, 2157 ○
- 143 Acceptability of predictive testing for ischemic heart disease in those with a family history and the impact of results on behavioural intention and behaviour change: a systematic review. **2022**, 22, ○
- 142 Recalibrating 10-Year Risk Models Using Population-Based Data. **2022**, 80, 1343-1345 ○
- 141 Deep learning artificial intelligence framework for multiclass coronary artery disease prediction using combination of conventional risk factors, carotid ultrasound, and intraplaque neovascularization. **2022**, 150, 106018 ○
- 140 High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study. **2022**, 14, 1759720X2211224 ○
- 139 M-mode Carotid Artery Image Classification and Risk Analysis Based on Machine Learning and Deep Learning Techniques. **2022**, 675-689 ○
- 138 Assessment of metabolic disorders and cardiovascular risk in males with urolithiasis. **2022**, 25, 33 ○
- 137 Hederagenin Exerts Potential Antilipemic Effect via p38MAPK Pathway in Oleic Acid-induced HepG2 cells and in Hyperlipidemic Rats. **2022**, 94, ○

136	Association between Multiple Health Indicators and Carotid Artery Intima-Media Thickness in a Healthy and Active Elderly Population.	0
135	Arterielle Hypertonie â€”Eine Bbersicht ff.den fztlichen Alltag. 2022 , 9, 207-221	0
134	Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines. 2022 , 43, 3302-3311	2
133	Atherogenic indices: usefulness as predictors of cardiovascular disease. 2022 , 34, 269-270	0
132	Prevalence and Clinical Impact of Electrocardiographic Abnormalities in Patients with Chronic Kidney Disease. 2022 , 11, 5414	0
131	Risk prediction in theory and practice.	0
130	SCORE 2: een nieuw model om het risico op cardiovasculaire ziekten in te schatten.	0
129	Estratificaci3n de riesgo cardiovascular: conceptos, an3lisis cr3tico, desaf3os e historia de su desarrollo en Chile. 2022 , 33, 534-544	0
128	Individual risk prediction: Comparing random forests with Cox proportional-hazards model by a simulation study.	0
127	A retrospective study on the association between urine metanephrines and cardiometabolic risk in patients with nonfunctioning adrenal incidentaloma. 2022 , 12,	0
126	Prognostic Value of Ankle-Brachial Index in Prediction of Cardiovascular Events in an Asian Population with Multiple Atherosclerotic Risk Factors. 000331972211247	0
125	Gu3a pr3ctica sobre el diagn3stico y tratamiento de la hipertensi3n arterial en Espa3a, 2022. Sociedad Espa3ola de Hipertensi3n - Liga Espa3ola para la Lucha contra la Hipertensi3n Arterial (SEH-LELHA). 2022 ,	1
124	MonEco: a Novel Health Monitoring Ecosystem to Predict Respiratory and Cardiovascular Disorders. 2022 ,	0
123	Pr3valence des facteurs de risque cardiovasculaire dans la n3vrite vestibulaire sup3rieure : analyse transversale suivant la m3thode STROBE. 2022 , 139, 193-197	0
122	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Russian translation.	0
121	Association of cardio-metabolic risk factors with elevated basal heart rate in South African Asian Indians. 2022 , 47,	0
120	Association of sarcopenia with ideal cardiovascular health metrics among US adults: a cross-sectional study of NHANES data from 2011 to 2018. 2022 , 12, e061789	0
119	3ndices aterog3nicos: utilidad como predictores en enfermedad cardiovascular. 2022 , 34, 269-270	0

- 118 Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations. **2022**, 146, 868-877 2
- 117 Extracellular vesicles number and cell subtype may be influenced by diabetes mellitus and metformin in patients at high cardiovascular risk. **2022**, 0
- 116 Lipidome- and Genome-Wide Study to Understand Sex Differences in Circulatory Lipids. **2022**, 11, 0
- 115 Cholesterol: how to measure and how to treat. **2022**, 33, 402-410 0
- 114 Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis. 9, 0
- 113 Association between hypercholesterolemia and mortality risk among patients referred for cardiac imaging test: Evidence of a "cholesterol paradox"? **2022**, 0
- 112 Performance of the SCORE and Globorisk cardiovascular risk prediction models among patients seen in Dutch general practice: a prospective cohort study. BJGP.2021.0726 0
- 111 IMPROVING CARDIOVASCULAR DISEASE RISK PREDICTION WITH MACHINE LEARNING USING MENTAL HEALTH DATA: A PROSPECTIVE UK BIOBANK STUDY. 0
- 110 A Framework for Interfacing and Partnering with Environmental Justice Communities as a Prelude to Human Health and Hazard Identification in the Vulnerable Census Tracts of Columbus, Ohio. **2022**, 19, 13846 0
- 109 Crosstalk between high-density lipoproteins and endothelial cells in health and disease: Insights into sex-dependent modulation. 9, 0
- 108 Development and Validation of a Coronary Heart Disease Risk Prediction Model in Snorers with Hypertension: A Retrospective Observed Study. Volume 15, 1999-2009 0
- 107 Higher Potassium Intake and Lower Sodium Intake May Help in Reducing CVD Risk by Lowering Salt Sensitivity of Blood Pressure in the Han Chinese Population. **2022**, 14, 4436 0
- 106 Cholesterol and Hypertension Treatment Improve Coronary Risk Prediction but Not Time-Dependent Covariates or Competing Risks. Volume 14, 1145-1154 0
- 105 Cardiovascular mortality risk prediction using objectively measured physical activity phenotypes in NHANES 2003-2006. **2022**, 164, 107303 0
- 104 Ankle Brachial Index is a strong predictor of mortality in hypertensive patients: results of a five-years follow-up study. 0
- 103 Development and validation of a 1-km cardio-trekking test to estimate cardiorespiratory fitness in healthy adults. **2022**, 30, 102039 0
- 102 Protecting the Heart in Cancer Patients: The Role of Cardio-Oncology. 47-52 0
- 101 Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease. **2022**, 20, 0

100	A review of risk concepts and models for predicting the risk of primary stroke. 16,	1
99	The association between the body height and cardiovascular diseases: a retrospective analysis of 657,310 outpatients in Germany. 2022 , 27,	0
98	Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. e070918	0
97	Performance and validation of the Healthy Heart Score Model for predicting 12-year cardiovascular mortality in a nationwide Mediterranean population. 2022 ,	0
96	The predictive effect of direct-indirect bilirubin ratio on clinical events in acute coronary syndrome: results from an observational cohort study in north China. 2022 , 22,	0
95	Machine learning outperforms traditional logistic regression and offers new possibilities for cardiovascular risk prediction: A study involving 143,043 Chinese patients with hypertension. 9,	0
94	Polygenic risk score and age: an extra help in the cardiovascular prevention of the young?. 2022 , 24, 1181-1185	0
93	Impact of Health and Social Factors on the Cardiometabolic Risk in People with Food Insecurity: A Systematic Review. 2022 , 19, 14447	0
92	Serum Uric Acid Significantly Improves the Accuracy of Cardiovascular Risk Score Models.	0
91	Prognostic value of syntax score, intravascular ultrasound and near-infrared spectroscopy to identify low-risk patients with coronary artery disease 5-year results from the ATHEROREMO and IBIS-3 cohorts. 2022 , 17, e0275592	0
90	Deep Learning Improves Prediction of Cardiovascular Disease-Related Mortality and Admission in Patients with Hypertension: Analysis of the Korean National Health Information Database. 2022 , 11, 6677	1
89	Development and validation of a cardiovascular diseases risk prediction model for Chinese males (CVDMCM). 9,	0
88	Relationship between sexual differences and cardiovascular risk factors in the prevalence of asymptomatic coronary disease. 2022 ,	0
87	Evaluation of available risk scores to predict multiple cardiovascular complications for patients with type 2 diabetes mellitus using electronic health records. 2023 , 3, 100087	0
86	Ten-Year Evolution of Statin Eligibility and Use in a Population-Based Cohort. 2023 , 187, 138-147	0
85	Temporal Trends in Low-Dose Aspirin Use (from the CoLaus PsyCoLaus Study). 2023 , 190, 61-66	0
84	VideoCAD: An Uncertainty-Driven Neural Network for Coronary Artery Disease Screening from Facial Videos. 2022 , 1-1	0
83	A deep survival learning approach for cardiovascular risk estimation in patients with sleep apnea. 2022 , 1-1	0

- 82 PREMATURE AGING AND CARDIOVASCULAR DISEASES RELATED TO HIV INFECTION. **2021**, 80, 342-348 ○
- 81 Laboratory-based and office-based Globorisk scores to predict 10-year risk of cardiovascular diseases among Iranians: results from the Fasa PERSIAN cohort. **2022**, 22, ○
- 80 De Gentse wieg in de Belgische cardiovasculaire epidemiologie van vandaag. ○
- 79 High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention. 9, 1
- 78 Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia. **2022**, ○
- 77 Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review. **2022**, 19, 15981 ○
- 76 Cardiovascular risk assessment with carotid ultrasound in rheumatoid arthritis. **2022**, 159, 470-474 ○
- 75 New Way to â€œSCOREâ€Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines. **2022**, 24, 1679-1684 ○
- 74 Using Artificial Intelligence to Analyse the Retinal Vascular Network: The Future of Cardiovascular Risk Assessment Based on Oculomics? A Narrative Review. ○
- 73 Explainable machine learning framework for predicting long-term cardiovascular disease risk among adolescents. **2022**, 12, ○
- 72 Prediction abilities of SCORE2 risk algorithms for incident dementia and all-cause mortality: results from the UK Biobank cohort study. ○
- 71 Vascular age acquired from the pulse signal: A new index to screen early vascular aging. **2022**, 151, 106355 ○
- 70 Subendocardial Viability Ratio Predictive Value for Cardiovascular Risk in Hypertensive Patients. **2023**, 59, 24 2
- 69 Multivariate Sequential Analytics for Cardiovascular Disease Event Prediction. **2022**, 61, e149-e171 ○
- 68 Aortic Distensibility Measured by Automated Analysis of Magnetic Resonance Imaging Predicts Adverse Cardiovascular Events in UK Biobank. **2022**, 11, 1
- 67 Effectiveness and feasibility of cardiovascular disease personalised prevention on high polygenic risk score subjects: a randomised controlled pilot study. ○
- 66 The Relationship of Kidney Function, Cardiovascular Morbidity, and All-Cause Mortality: a Prospective Primary Care Cohort Study. ○
- 65 Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002â€2012). **2022**, 21, ○

64	Association between 10-Year Atherosclerotic Cardiovascular Disease Risk and Estimated Glomerular Filtration Rate in Chinese People with Normal to Slightly Reduced Kidney Function: A Cross-Sectional Study. 2022 , 19, 16300	○
63	Relevance of circulating markers of endothelial activation for cardiovascular risk assessment in rheumatoid arthritis: A narrative review. 2022 , 121264	○
62	Correlation between the level of evidence and the class of recommendations concerning the pharmacological aspects of the Guidelines of the European Society of Cardiology. 2022 ,	○
61	Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. 2022 , 4, e873-e883	○
60	Impact of high prebiotic and probiotic dietary education in the SARS-CoV-2 era: improved cardio-metabolic profile in schizophrenia spectrum disorders. 2022 , 22,	○
59	Utility of SCORE2 risk algorithm for predicting life course accelerated frailty and physical function decline.	○
58	The association between spontaneous preterm birth and maternal hypertension in the fifth decade of life: a retrospective case-control study.	○
57	Gender gaps in type 1 diabetes care.	○
56	Cardiovasculaire epidemiologie: een terugblik.	○
55	A real opportunity to modify cardiovascular risk through primary care and prevention: A pilot study. 10,	○
54	Application of Deep Convolutional Neural Networks MobileNetV2 and Xception for Detecting Cardiac Arrhythmia. 2023 , 581-589	○
53	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1. 2023 , 1-65	○
52	Metabolic and nutritional biomarkers in adults consuming lacto-ovo vegetarian, vegan and omnivorous diets in Spain. A cross-sectional study.	1
51	IgG N-Glycosylation Cardiovascular Age Tracks Cardiovascular Risk Beyond Calendar Age. 2023 ,	1
50	The contribution of smoking to differences in cardiovascular disease incidence between men and women across six ethnic groups in Amsterdam, the Netherlands: The HELIUS study. 2023 , 31, 102105	○
49	Liver Transplantation for NAFLD: indications and post-transplant management.	○
48	Epidemiologisches Wissen, persönliche Erfahrungen und Entscheidungsfindung - Überlegungen zum Konzept der Elternteil-Patienten-Beziehung. 2023 , 125-138	○
47	Toward a Predict and Prevent Approach in Obstructive Airway Diseases. 2023 ,	○

- 46 Determining the Proportionality of Ischemic Stroke Risk Factors to Age. **2023**, 10, 42 ○
- 45 Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. **2022**, 42, 519-530 ○
- 44 Clove oil. **2023**, 325-344 ○
- 43 Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations. **2023**, 9, e002767 ○
- 42 Socioeconomic and Behavioral Determinants of Cardiovascular Risk in Russia: A Structural Equation Modeling Approach. Volume 16, 585-605 ○
- 41 Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. **2023**, 28, 969 1
- 40 Extensive deep learning model to enhance electrocardiogram application via latent cardiovascular feature extraction from identity identification. **2023**, 231, 107359 ○
- 39 A prediction model for the impact of environmental and genetic factors on cardiovascular events: development in a salt substitutes population. **2023**, 21, ○
- 38 The oft-overlooked cardiovascular complications of inflammatory bowel disease. **2023**, 19, 375-391 ○
- 37 A Bayesian network model for predicting cardiovascular risk. **2023**, 231, 107405 ○
- 36 L'aspirine a-t-elle une place dans la prévention cardiovasculaire primaire par la polypill? Étude de simulation sur une population virtuelle réaliste. **2023**, ○
- 35 Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve. **2023**, 10, 74 ○
- 34 Prevalence of prediabetes and undiagnosed diabetes in a large urban middle-aged population: the CARVAR 92 cohort. **2023**, 22, ○
- 33 Associations of genetic and infectious risk factors with coronary heart disease. 12, ○
- 32 Comparison of different software for processing physical activity measurements with accelerometry. **2023**, 13, ○
- 31 Lifestyle intervention reduces risk score for cardiovascular mortality in company employees with pre-diabetes or diabetes mellitus – A secondary analysis of the PreFord randomized controlled trial with 3 years of follow-up. 14, ○
- 30 Rendimiento y validación del Test del Corazón Saludable para la predicción de mortalidad cardiovascular en población mediterránea a escala nacional. **2023**, ○
- 29 Identifying Plasma and Urinary Biomarkers of Fermented Food Intake and Their Associations with Cardiometabolic Health in a Dutch Observational Cohort. **2023**, 71, 4426-4439 ○

- 28 Advances in the Analysis of Electrocardiogram in Context of Mass Screening: Technological Trends and Application of AI Anomaly Detection. **2023**, 107-132 ○
- 27 The Relationship of Plasma Aterogenity Index and Mean Platelet Volume with the Risk of Development of 1-Year Total Major Adverse Cardiac Event in Patients with Non-ST Elevation Myocardial Infarction. ○
- 26 Behandlung und LDL-Cholesterin-Einstellung von Patienten mit hohem und sehr hohem kardiovaskulärem Risiko in Deutschland und im europäischen Vergleich â Daten des SANTORINI-Registers. ○
- 25 Machine-learning versus traditional approaches for atherosclerotic cardiovascular risk prognostication in primary prevention cohorts: a systematic review and meta-analysis. ○
- 24 Current Toolset in Predicting Acute Coronary Thrombotic Events: The âVulnerable Plaqueâ In a âVulnerable Patientâ Concept. **2023**, 13, 696 ○
- 23 Predicting risk on cardiovascular or cerebrovascular disease based on a physical activity cohort: Results from APAC study. **2023**, 4, ○
- 22 Association between preeclampsia in daughters and risk of cardiovascular disease in parents. **2023**, 38, 335-343 ○
- 21 Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE. **2023**, 10, e000864 ○
- 20 Validation of the general Framingham Risk Score (FRS), SCORE2, revised PCE and WHO CVD risk scores in an Asian population. **2023**, 100742 ○
- 19 Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis at Low Cardiovascular Risk. **2023**, 11, 974 ○
- 18 Prediction models for cardiovascular disease risk among people living with HIV: A systematic review and meta-analysis. 10, ○
- 17 Comparison of ct angiography and scoring systems for cardiovascular risk stratification in asymptomatic patients. **2023**, 16, 190 ○
- 16 Predictive value of cardiovascular risk scoring systems for the detection of myocardial injury following carbon monoxide intoxication. **2023**, 23, 30 ○
- 15 Depressive symptoms and mortality â Effect variation by body mass index: a prospective study in a primary care population. ○
- 14 Clinical evaluation of optical spectral transmission imaging for detection of disease activity in rheumatoid arthritis. 1-9 ○
- 13 Identification and Management of Atherosclerotic Cardiovascular Disease Risk in South Asian Populations in the U.S.. **2023**, 2, 100258 ○
- 12 Age-related variation in thyroid function â A narrative review highlighting important implications for research and clinical practice. **2023**, 16, ○
- 11 Preventive cardiology: Quo vadis?. **2023**, 69, 76-81 ○

- 10 Hyperuricemia may be associated with muscle wellness in older adults. ○
- 9 Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity. **2023**, 13, 531 ○
- 8 ~~Effect of...~~ **2016**, 35-41 ○
- 7 Cardiovascular risk factors in cancer survivors: The whole is greater than the sum of parts. ○
- 6 Presence of tophi and carotid plaque were risk factors of MACE in subclinical atherosclerosis patients with gout: a longitudinal cohort study. 14, ○
- 5 Cardiovascular disease incidence prediction by machine learning and statistical techniques: a 16-year cohort study from eastern Mediterranean region. **2023**, 23, ○
- 4 Effects of Auricular Point Acupressure with Lifestyle Interventions on Cerebrovascular Function among Adults with High Stroke Risk: A Randomized Controlled Study. **2023**, 2023, 1-8 ○
- 3 The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. ○
- 2 Renal hyperfiltration revisited—Role of the individual body surface area on mortality. **2023**, ○
- 1 Computational clustering reveals differentiated coronary artery calcium progression at prevalent levels of pulse wave velocity by classifying high-risk patients. 10, ○